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Principles of allogeneic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a successful treatment 
for patients suffering from a variety of hematological malignancies.1 Prior to SCT patients 
are treated with high dose chemotherapy combined with total body irradiation in order 
to eradicate malignant cells and to suppress the hematopoietic system of the patient to 
allow engraftment of donor hematopoietic cells. Initially the purpose of the SCT was to 
replace the lethally damaged patient hematopoietic cells by donor hematopoietic cells 
to reconstitute the hematopoietic system.2 In this view autologous stem cells or stem 
cell from a syngeneic twin were supposed to be the best source of hematopoietic stem 
cells, since allo-SCT was associated with immunological complications such as graft versus 
host disease (GVHD) or graft rejection. However, clinical studies demonstrated that the 
occurrence of GVHD was associated with a decreased likelihood of disease relapse after 
transplantation, resulting in a better overall survival.3 Donor derived T-cells appeared not 
only to be responsible for the detrimental GVHD but also for a reduced risk of disease 
relapse. Depletion of T-cells from the graft to prevent GVHD resulted in an increased 
risk of disease relapse illustrating that donor derived T-cells were capable of mediating 
a graft versus leukemia (GVL) effect.4-6 Since transplantation between homozygous twins 
did not result in a GVL-effect it was concluded that the presence of T-cells in the graft 
was not sufficient to mediate GVL-reactivity but that alloreactive T-cells were essential for 
the antitumor effect.7;8 Direct evidence that GVL-reactivity was mediated by donor derived 
T-cells was provided by the observation that donor lymphocyte infusion (DLI) could induce 
durable remissions in patients with persistent or relapsed leukemia. DLI as a treatment for 
recurrence of the malignant disease after allo-SCT has resulted in 20% to 90% complete 
remissions depending on the malignancy. In chronic myelogenous leukemia (CML) in 
chronic phase the best results were found. Although response rates in other hematological 
malignancies were much lower, evident clinical responses have been found in patients 
treated for relapsed acute myelogenous leukemia (AML), multiple myeloma (MM), chronic 
lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) and acute lymphoblastic 
leukemia (ALL).9-16
The potential advantage of allo-SCT over autologous SCT appears to be the possibility 
to exploit the immune system to eradicate residual malignant cells after transplantation. 
Following allo-SCT normal hematopoietic and immune cells are of donor origin, whereas 
residual leukemic cells are of patient origin. In this setting where the hematopoietic system 
is of donor origin, donor derived T-cells can be infused to eliminate residual patient normal 
hematopoietic cells and leukemic cells without a risk for rejection. In other words, allo-SCT 
provides a platform for adoptive immunotherapy with DLI to eradicate residual leukemic 
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cells. In this approach conditioning regimens prior to transplantation may not be aimed 
at fully eradicating malignant cells but can be limited to doses sufficient to permit donor 
stem cell engraftment. Therefore toxicity of the conditioning regimen prior to SCT can 
be reduced.17 However, the major complication following adoptive immunotherapy with 
DLI is GVHD. The main focus in hematopoietic SCT research is to develop strategies 
for immunotherapy of hematopoietic malignancies resulting in reduced GVHD while 
preserving GVL-reactivity. 
GVL-reactivity and GVHD following HLA-matched allo-SCT
Since alloreactive T-cells recognizing HLA-mismatched alleles are present in high frequencies 
in peripheral blood, HLA-mismatched SCT may result in strong allo-immunity.18 To reduce 
the risk of GVHD and allograft rejection, allo-SCT is preferably performed using an HLA-
matched donor.19;20 The optimal donor for an allo-SCT is a fully matched sibling of the 
patient. However, GVHD and GVL-reactivity coincide in the majority of patients following a 
fully HLA-matched allo-SCT with a T-cell repleted graft or after DLI. This illustrates that both 
GVL-reactivity and GVHD are triggered by genetic disparities other than HLA molecules. 
Single nucleotide polymorphisms present in the coding region of a gene may result in 
amino acid substitutions in a protein. In most cases this will not influence the biological 
activity of the protein, however processing of these polymorphic proteins may result 
in presentation of polymorphic peptides in the context of HLA-molecules. Differences 
between patient and donor in these polymorphic peptides presented on the cell-surface 
by HLA-class I or class II molecules are called minor histocompatibility antigens (MiHA) and 
may be recognized by CD8+ or CD4+ T-cells respectively. MiHA specific T-cell responses 
have been identified both in patients with selective beneficial GVL-reactivity as well as in 
patients suffering from GVHD.10;17;21 
MiHAs in GVL-reactivity and GVHD
Several studies have demonstrated the presence of both CD4+ and CD8+ MiHA specific 
T-cells in patients suffering from GVHD following HLA-identical SCT. However, MiHA 
specific CD4+ and CD8+ T-cells have also been isolated from patients with selective 
GVL-reactivity. The appearance of both MiHA specific CD4+ T-cells and CD8+ T-cells in 
patients following allo-SCT and DLI who showed long term complete remissions of 
their malignancies illustrated their clinical relevance for GVL-reactivity. Detailed studies 
analyzing kinetics of MiHA specific immune responses showed that the appearance of 
MiHA  specific T cells coincided with the disappearance of malignant cells from peripheral 
blood, further illustrating a GVL-effect of these T-cells.22-27 Clonal isolation of these MiHA 
specific CD4+ and CD8+ T-cells from patients responding to DLI after HLA-matched allo-




T-cell responses directed against MiHAs expressed on both hematopoietic cells 
and non-hematopoietic cells are likely to induce GVL-reactivity as well as GVHD. Since 
HLA-class I molecules are expressed on most nucleated cells, expression of HLA-class I 
restricted MiHAs on target cells is mainly determined by expression, translation and 
processing of genes encoding the MiHA in different target tissues. CD8+ T-cells recognizing 
broadly expressed MiHAs in the context of HLA-class I may mediate GVL-reactivity as well 
as cause damage in different organs resulting in profound GVHD. However, CD8+ T-cell 
responses directed to hematopoiesis restricted antigens may more selectively induce 
GVL-reactivity without GVHD.24;29-31 Not only differential expression of MiHAs but also 
differential expression of HLA-molecules may contribute to hematopoiesis restricted 
allogeneic T-cell responses. In contrast to ubiquitous expression of HLA-class I molecules, 
expression of HLA-class II molecules is mainly restricted to hematopoietic cells. In patients 
with HLA-class II positive hematological malignancies, an HLA-class II restricted MiHA 
specific immune response may therefore more selectively induce GVL-reactivity. Several 
HLA-class II restricted MiHAs encoded by broadly expressed genes have been identified 
from immune responses in patients without severe GVHD.28;32
Identification of MiHAs
To gain more insight into the biology of MiHA specific T-cell responses in GVHD and GVL-
reactivity, MiHAs have been molecularly characterized. Laborious techniques such as 
biochemical identification of peptides eluted from HLA-molecules and the use of cDNA 
libraries to express MiHAs in target cells were initially used to identify MiHA encoding gene 
transcripts. These strategies resulted in successful discovery of several MiHAs, however low 
efficiency of the techniques hampered identification of the majority of MiHAs recognized 
by T-cell clones.25-28;33-41 To better understand the development of GVL-reactivity and GVHD, 
characterization of large numbers of MiHAs is essential. High-throughput identification 
and expression analysis of MiHAs in patients with various clinical responses after allo-SCT 
may provide insight into differences and allow manipulation of the balance between GVL-
reactivity and GVHD. We developed an efficient strategy for MiHA identification using whole 
genome association scanning (WGAS). Multiple MiHA specific T-cell clones were isolated 
from clinical immune responses in patients who received an HLA-matched allograft 
followed by DLI. Using the WGAS-based strategy we identified multiple novel MiHAs.27 
This strategy may allow characterization of the biological relevance of immune responses 
directed against various MiHAs in different clinical immune responses. Analysis of different 
immune responses in patients after allo-SCT and DLI using the WGAS based strategy 
have demonstrated that immune responses with high amplitudo directed against broadly 
expressed antigens resulted in GVHD, whereas smaller immune responses directed 
against hematological restricted antigens resulted in more selective GVL-reactivity.42;43
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Balance between GVHD and GVL-reactivity
Before HLA-matched allo-SCT, donor derived T-cells most likely have not been exposed to 
patient specific antigens and must be primed by professional antigen presenting cells (APC) 
in order to exert an efficient anti-tumor reactivity.44-46 Residual patient derived dendritic 
cells, B-cells or macrophages which co-express the same antigens as patient leukemic 
cells can serve as APC for the induction of GVL-reactivity but also GVHD responses. 
Since APCs are hematopoietic cells, it may be expected that preferentially hematopoiesis 
specific antigens are presented, although also ubiquitously expressed antigens will be 
presented.22;23 In the early post-transplant period, residual patient derived APCs may 
directly prime donor T-cells resulting in GVL-reactivity if the antigens are co-expressed by 
patient leukemic cells.44;46 Leukemic cells themselves may also acquire an APC phenotype 
in vivo and function as APC to directly prime anti-leukemic T-cell responses.47-49 However, in 
the context of a pro-inflammatory environment as a consequence of tissue damage caused 
by conditioning regimens or ongoing infections, APCs may not only express endogenous 
antigens, but can cross-present antigens from different cell types as well, resulting in 
the induction or amplification of anti-host responses which may induce GVHD.50 Various 
conditions of the local microenvironment will determine whether T-cells are capable of 
recognizing different antigens and cause damage to target organs. This includes activation 
status of local environment, homing of T-cells and expression of adhesion molecules on 
target organs.21;51 In contrast to the early post-transplant period, late after transplantation 
patient APCs will gradually be replaced by APCs of donor origin. In the absence of pro-
inflammatory stimuli there might be a lower chance to develop a broad immune response 
with high amplitudo resulting in GVHD. In this period, leukemic cells may acquire an APC 
phenotype and directly trigger an immune response resulting in selective GVL-reactivity. 
However, if leukemic cells do not acquire an APC phenotype in this period, GVL-reactivity has 
to be induced by either limited number of residual patient APCs or by donor derived APCs 
cross-presenting patient derived antigens.50 Although mice studies have demonstrated 
that this indirect antigen presentation does occur, the question remains how effective this 
is in humans.10;17;50;52 The efficacy of DLI in this period may therefore either depend on the 
presence of residual patient APCs and their activation status or on the capacity of leukemic 
cells to acquire an APC phenotype.
Traditionally CD8+ T-cells are considered to be the primary effector cells in GVL-
reactivity, whereas CD4+ T-cells are known to be required as helper cells for the induction 
and maintenance of CD8+ T-cell mediated immunity.53 However, CD4+ T-cells with direct 
cytolytic activity against leukemic cells have also been isolated from patients with GVL-
responses.23;28;32;54;55 These data suggested that CD4+ T-cells may also serve as effector cells 
in GVL-reactivity. Since constitutive expression of HLA-class II molecules is predominantly 
restricted to hematopoietic cells, CD4+ T-cells may more selectively mediate GVL-reactivity. 
Indeed several clinical studies have shown that depletion of CD8+ T-cells from the graft or 
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DLI indeed resulted in a reduced incidence and severity of GVHD without compromising 
GVL-reactivity.56;57 However, HLA-class II expression on non-hematopoietic cells can be 
upregulated after exposure to pro-inflammatory cytokines. An HLA-class II restricted 
immune response may therefore also result in GVHD if HLA-class II molecules on non-
hematopoietic tissues are upregulated. 
Unrelated donor stem cell transplantation
Allo-SCT is preferably performed using an HLA-matched donor to reduce the risk of GVHD 
and allograft rejection. The optimal donor for allo-SCT is a fully matched sibling of the 
patient. However, identical sibling donors are only available in about 30% of the patients.20 
In the absence of a family donor a good alternative is a matched unrelated donor (URD). 
In a recent large study it was shown that the highest survival in URD-transplantation was 
associated with high resolution DNA matching for HLA-A, -B, -C, and -DRB1. However, a 
perfectly matched donor is frequently not found. A single mismatch at one of these loci 
(7/8 match) was associated with lower survival, lower disease free survival, higher treatment 
related mortality and more acute GVHD (aGVHD) compared to 8/8 HLA matched pairs. This 
applied both high resolution (allele) and low resolution (antigen) mismatches. Remarkably, 
no differences for relapse and engraftment were found. Single mismatches at HLA-B or -C 
appeared to be better tolerated than mismatches for HLA-A or -DRB1. Mismatching for an 
additional allele was associated with even lower survival. A single HLA-DQB1 mismatch was 
not associated with adverse outcome. However, an HLA-DQB1 mismatch in a 7/8 matched 
pair was associated with a small but not statistically significant adverse effect on survival. 
Mismatching for HLA-DPB1 was not associated with a difference in survival.19;20;58
In URD-SCT preferably a fully matched donor for HLA-A, -B, -C, -DRB1 and HLA-DQB1 
is used (10/10 match). However, in the absence of a full match, a donor matched at 9/10 
alleles may be selected. A single mismatch at HLA-DQB1 may be preferred over another 
locus mismatch, since mismatching for a single HLA-DQB1 was not associated with 
adverse outcome, whereas a mismatch for HLA-A, -B, -C or -DRB1 resulted in lower overall 
survival.19 Since mismatching for HLA-DPB1 did not result in a difference in transplant 
outcome in most studies, HLA-DPB1 is not taken into consideration in donor selection in 
most centers. Although the role of HLA-DP in GVL-reactivity and GVHD has been unclear 
for a long time, several studies have now demonstrated that HLA-DP does function as a 
classical transplantation antigen.19;59;60 
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The role of HLA-DPB1 in allo-SCT
HLA-DP is the sixth classic HLA-molecule. It consists of an alpha and a beta chain encoded 
by the HLA-DPA1 and HLA-DPB1 genes respectively. The genes are located centromeric 
to HLA-DR and HLA-DQ in the class II region of chromosome 6p21.3. HLA-DP shares 
structural similarities with the HLA-DR and HLA–DQ. For the HLA-DP alpha chain 34 alleles 
are known, whereas for the highly polymorphic beta chain 155 alleles are know to date.62 
Population studies have shown strong linkage disequilibrium between HLA-DPA1 and 
HLA-DPB1, but weak disequilibrium between HLA-DP and the other HLA-class II loci.63;64 
This may result from a recombination ‘hotspot’ in chromosome 6 between HLA-DPA1 and 
HLA-DQB1 genes. In sibling donors HLA-DPB1 mismatch has been reported up to 10.9%.65 
In HLA-A, -B, -C, -DRB1 and HLA-DQB1 matched URD hematopoietic SCT 70-89% HLA-
DPB1 mismatch rates are reported.60;66-70 
The relevance of matching for HLA-DPB1 in URD-SCT has been inconclusive for a long 
time. Several clinical studies failed to show a statistical significant difference in the incidence 
of severe GVHD  or patient survival between HLA-DPB1 matched and mismatched patient-
donor pairs.71;72 As a result, HLA-DPB1 has not been taken into consideration in donor 
selection. Large clinical studies performed between 1999 and 2008 provided evidence 
for an immunogenic role of HLA-DPB1 in allo-SCT. In T-cell repleted allo-SCT mismatching 
for HLA-DPB1 was associated with an increased risk of severe GVHD and a decreased 
risk of disease relapse.19;60;68;73;74 The overall effect on survival of patients who received 
an HLA-DPB1 matched or mismatched graft did not statistically differ, possibly due to a 
balanced effect of an increased risk of GVHD and reduced relapse rate. In contrast, in T-cell 
depleted allo-SCT mismatching for HLA-DPB1 was not associated with an increased risk 
of GVHD, whereas a significant decreased risk of disease relapse was still observed. This 
was particularly evident in patients transplanted for ALL, where HLA-DPB1 mismatched 
transplantation resulted in a significantly better overall survival.59
Further support that HLA-DPB1 mismatched transplantation can result in strong 
T-cell responses in vivo was provided by several studies demonstrating CD4+ T-cell 
responses directed against mismatched HLA-DPB1 molecules. HLA-DP specific CD4+ 
T-cells were isolated from skin biopsies in patients who developed GVHD following HLA-
DPB1 mismatched SCT.75;76 HLA-DP specific CD4+ T-cells were also isolated from an 
allograft rejection where patient and donor differed for a single HLA-DPB1 mismatch in 
the rejection direction.77 It was speculated that HLA-DP specific CD4+ T-cells might also be 
able to induce a selective GVL-effect in the context of a T-cell depleted allo-SCT. To exploit 
this concept, HLA-DP expression on leukemic blasts was analysed. HLA-DP expression was 
found on the vast majority of leukemic cells analyzed. However considerable variability 
was found and expression was lower on AML than on B-ALL or B-CLL cells. Most leukemic 
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blasts were also susceptible to direct lysis by allogeneic HLA-DP specific T-cells.61 However, 
thus far direct evidence that HLA-DP specific CD4+ T-cells were involved in GVL-reactivity 
had not been shown.
Permissive and non-permissive mismatches
Since different studies resulted in conflicting outcomes concerning the role of HLA-DPB1 
in allo-SCT, it was suggested that there might be a difference in immunogenicity between 
different HLA-DPB1 mismatches. In primary mixed lymphocyte reaction (MLR) a variety in 
response values to different HLA-DPB1 mismatches was found. This observation resulted 
in the hypothesis that not all HLA-DPB1 incompatibilities would elicit measurable T-cell 
responses in MLR. In vitro studies showed that specific amino acid sequence differences 
between donor and recipient were associated with high T-cell responses.78-80 From these 
studies it was suggested that patient and donor needed to be matched only for specific 
regions in the hypervariable regions of the HLA-DPB1 allele to prevent GVHD. In 2008 
a study was performed in which it was indeed shown that incompatibilities at distinct 
positions in the hypervariable regions of HLA-DPB1 were risk factors for developing acute 
GVHD. A specific amino acid mismatch at position 69 of the HLA-DPB1 molecules was 
associated with a higher rate of treatment related mortality.73 In two large studies around 
5 000 patients who underwent an allo-SCT through the Japan Marrow Donor Program 
were analyzed for specific mismatches associated with an increased risk of GVHD or a 
decreased risk of disease relapse. Two specific HLA-DPB1 mismatch combinations were 
found to be statistically significantly correlated with severe aGVHD and 6 different specific 
HLA-DPB1 mismatch combinations were associated with a decreased risk of disease 
relapse and a better overall survival.81;82 It was suggested that these observations should 
be taken into consideration in donor selection. 
The suggestion that matching at an epitope level might be clinically more relevant in 
terms of transplant outcome than matching at allele level was translated into a clinical 
algorithm by Zino et al.83 In this algorithm permissive and non-permissive mismatches were 
defined. HLA-DPB1 molecules were classified in different immunogenicity groups based on 
T-cell recognition patterns by HLA-DPB1*0901 specific CD4+ T-cell clones. Individuals were 
not supposed to elicit strong anti-HLA-DP responses to HLA-DPB1 molecules classified 
within the same immunogenicity group. This was based on the hypothesis that T-cells 
should not respond to foreign HLA-DPB1 molecules sharing specific amino acids with the 
‘self’ HLA-DPB1 allele. These mismatches were called permissive mismatches. In contrast, 
strong T-cell responses were expected to be generated in response to HLA-DPB1 molecules 
classified in higher immunogenic groups, representing non-permissive mismatches. 
Retrospective analysis of a patient cohort showed a significantly higher probability of 2-year 
survival in permissive compared to non-permissive mismatches. However, no significant 
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effect on aGVHD or disease relapse was observed in 10/10 matched patients.84;85 These 
different observations have not been confirmed in other studies.73;85
Mismatched HLA-DPB1 as a specific target for GVL-reactivity 
As discussed before, immune responses directed against hematopoiesis restricted 
antigens can be expected to result in selective GVL-reactivity, whereas immune responses 
directed against broadly expressed antigens may result in both GVL-reactivity and GVHD. 
We demonstrated in patients with selective GVL-reactivity low frequencies of MiHA specific 
T-cells, whereas in patients with both GVL-reactivity and GVHD higher frequencies of MiHA 
specific T-cells directed against multiple MiHAs were found.42;43 Since constitutive expression 
of HLA-class II molecules may be expected to be predominantly restricted to hematopoietic 
cells, an immune response directed against a single HLA-class II restricted antigen can be 
hypothesized to induce selective GVL-reactivity. In case of an immune response directed 
against an HLA-class II restricted MiHAs, a relatively restricted immune response inducing 
selective GVL-reactivity may be expected to occur. However, alloreactive T-cells recognizing 
mismatched HLA-molecules are present in high frequencies in peripheral blood.18 A single 
HLA-class-II locus mismatched SCT may therefore result in a broad allo-immune response, 
thereby increasing the risk for GVHD. Mismatching for HLA-DPB1 has indeed been shown 
to induce strong HLA-DPB1 specific CD4+ T-cell responses in vivo.75-77 In T-cell repleted SCT 
mismatching for HLA-DPB1 was associated with both a decreased risk of disease relapse 
and an increased risk in GVHD.19;60 In contrast, in T-cell depleted SCT, mismatching for 
HLA-DPB1 was associated with a decreased risk of disease relapse without an increased 
risk in GVHD.59 These data suggest that in HLA-DPB1 mismatched allo-SCT the transplant 
regimen used may be important for the balance of GVL-reactivity and GVHD.
HLA-class II expression can be upregulated on non-hematopoietic tissues by pro-
inflammatory cytokines released as a consequence of tissue damage caused by the 
conditioning regimen, ongoing infections, or other immune responses. In T-cell repleted 
SCT, infusion of T-cells derived from an HLA-DPB1 mismatched donor in an inflammatory 
environment may therefore result in a strong immune response resulting in GVHD. In 
contrast, HLA-DPB1 mismatched allo-SCT followed by donor derived T-cells at a later time 
point may more selectively induce GVL-reactivity when tissue damage is largely restored 
and HLA-class II expression may be anticipated to be restricted to hematopoietic cells. 
In HLA-DPB1 mismatched allo-SCT local circumstances in the host at the time of T-cell 
infusion may therefore determine whether GVL-reactivity develops in the presence or 
absence of GVHD. 
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Aim of this study
The overall survival between patients transplanted with an HLA-DPB1 matched or 
mismatched SCT did not statistically differ in most studies.19;60 However, it has been 
shown that HLA-DP can function as a classical transplantation antigen and can induce 
strong allo-immune responses in vivo.75;76;86;87 In T-cell repleted SCT mismatching for HLA-
DPB1 is associated with an increased risk of GVHD. In contrast, in T-cell depleted SCT 
no association with an increased risk of GVHD was found, whereas a decreased risk of 
disease relapse was still observed, suggesting that in T-cell depleted SCT mismatching 
for HLA-DPB1 may induce a selective GVL-effect.59 Furthermore, it has been suggested 
that specific HLA-DPB1 mismatches were associated with an increased risk of GVHD or 
treatment related mortality.73;81;83;84 Together these data suggest that different outcomes 
can be expected following HLA-DPB1 mismatched allo-SCT depending on the transplant 
regimen used and possibly also influenced by specific circumstances present in the host 
at the time of transplantation. 
The aim of this thesis is to investigate whether mismatching for HLA-DPB1 can result 
in selective GVL-reactivity without GVHD. Furthermore, we determined whether all HLA-
DPB1 mismatches can be expected to result in an allo-immune response in vivo. Finally, 
we investigated whether following HLA-DPB1 mismatched SCT HLA-DP specific immune 
responses are often induced and whether the occurrence of HLA-DP specific immune 
responses is associated with GVL-reactivity, GVHD or both.
To analyze whether HLA-DP specific CD4+ T could induce a specific GVL-effect without 
GVHD, we analyzed in chapter 2 the immune response in a patient transplanted with a 
10/10 matched, HLA-DPB1 mismatched SCT followed by DLI for relapsed chronic B-cell 
leukemia. In this patient a profound GVL-effect with minimal skin GVHD resulting in a 
persistent complete remission of the disease was observed. We analyzed the kinetics 
of the immune response and clonally isolated leukemia reactive T-cell clones from the 
peak of the immune response. The specificity of the immune response was unraveled. 
Furthermore, differential recognition patterns of HLA-DP specific CD4+ T-cells for various 
hematological malignant cells and non-hematopoietic cells were tested. 
Various studies have suggested that some HLA-DPB1 mismatches would result in 
stronger allo-reactivity than others. It has been suggested that matching at an epitope 
level would be clinically more relevant in terms of transplant outcome than matching 
at allele level.73;81;83;84 An algorithm defining permissive and non-permissive HLA-DPB1 
mismatches had been tested in a retrospective analysis of a patient cohort. Higher overall 
survival in patients transplanted with a permissive mismatch compared to non-permissive 
mismatches was found, however no significant effect on GVHD or disease relapse was 
observed.84 In other retrospective analyses other specific HLA-DPB1 mismatches were 
suggested to be associated with GVL-reactivity, GVHD or transplant related mortality.73;81;82 
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These different observations from various research groups were not consistent and have 
not been confirmed in other studies.85 
In chapter 3 we analyzed whether permissive HLA-DPB1 mismatches could result 
in HLA-DPB1 specific immune response in vivo. Two patients responding to DLI after 
HLA-A, -B, -C, -DRB1, -DQB1 matched, HLA-DPB1 mismatched SCT were analyzed for the 
presence of patient HLA-DPB1 specific CD4+ T-cells. The patients received a permissive 
or non-permissive HLA-DPB1 mismatched SCT followed by DLI. CD4+ T-cells were isolated 
from peripheral blood obtained during the clinical immune response to DLI, and tested 
for specific recognition of stimulator cells transduced with patient and not donor HLA-DP 
molecules.
To analyze whether different HLA-DPB1 mismatches would result in differential 
frequencies of immune responses, we analyzed in chapter 4 whether immunogenicity of 
HLA-DPB1 mismatches could be predicted based on the presence or absence of specific 
amino acid sequences. We developed a model to generate HLA-DPB1 responses in vitro 
and tested in total 48 different stimulator/responder combinations by stimulating CD4+ 
T-cells from 5 HLA-DPB1 homozygous individuals with the same APC transduced with 
different allo-HLA-DP molecules. Furthermore, we analyzed whether CD4+ T-cell clones 
with different HLA-DPB1 specificity showed similar cross-recognition patterns as previously 
demonstrated and we analyzed whether we could identify additional patterns in cross-
reactivity of HLA-DPB1 molecules by HLA-DPB1 specific CD4+ T-cells. 
To analyze whether HLA-DP specific immune responses are frequently induced after 
T-cell depleted HLA-DPB1 mismatched SCT and DLI we developed in chapter 5 a method to 
screen patients for the presence of HLA-DP specific CD4+ T-cells. We analyzed 24 patient-
donor combinations. Patients analyzed suffered from various B-cell malignancies, multiple 
myeloma and myeloid leukemias. Furthermore, we analyzed whether the presence of HLA-
DP specific CD4+ T-cells was associated with clinical outcome in terms of GVHD or GVL-
reactivity, and whether HLA-DP specific T-cell responses could be found after permissive 
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Mismatching for HLA-DPB1 in unrelated donor hematopoietic stem cell transplantation 
(URD-SCT) has been associated with a decreased risk of disease relapse, indicating that 
HLA-DP may represent a target for graft versus leukemia (GVL) reactivity in HLA-class II 
expressing hematological malignancies. To investigate whether HLA-DP specific T-cells 
could mediate GVL-reactivity following HLA-DPB1 mismatched URD-SCT and donor 
lymphocyte infusion (DLI), we analyzed the immune response in a patient with leukemic 
lymphoplasmacytic lymphoma responding to DLI without GVHD. The emergence of 
leukemia reactive CD4+ T-cells during the clinical immune response was demonstrated 
by IFN-γ ELISPOT analysis. Following clonal isolation of these leukemia reactive CD4+ 
T-cells, blocking studies, panel studies and retroviral transduction experiments of both 
mismatched HLA-DPB1 alleles identified HLA-DPB1*02:01 and HLA-DPB1*03:01 as the 
targets of this immune response. The HLA-DP specific CD4+ T-cell clones were capable of 
recognizing and lysing several HLA-DP expressing myeloid and lymphoid hematological 
malignant cells. Since HLA-DP expression is mainly restricted to hematopoietic cells, HLA-
DP may be used as a specific target for immunotherapy following T-cell depleted URD-SCT. 
Therefore, in patients with HLA-class II expressing hematological malignancies HLA-DPB1 
mismatched SCT may be preferable over fully matched SCT allowing DLI to induce a GVL-
effect.
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Introduction
The graft-versus-leukemia (GVL) reaction that can be observed after allogeneic 
hematopoietic stem cell transplantation (SCT) is a beneficial immune response resulting in 
the elimination of residual leukemic cells in the patient. Donor derived T-cells play a major 
role in GVL-reactivity and graft versus host disease (GVHD), since depletion of T-cells from 
stem cell grafts resulted in a higher risk of leukemic relapse and a decrease of GVHD.1;2 
T-cells present in the graft as well as T-cells administered by donor lymphocyte infusion 
(DLI) after transplantation can induce GVL-reactivity and GVHD.3;4 To minimize the risk for 
GVHD, patients are preferably transplanted with stem cells from an HLA identical sibling or 
an HLA-matched unrelated donor (URD).5  Following HLA identical SCT, GVL-reactivity and 
GVHD are likely to be caused by donor derived T-cells recognizing minor histocompatibility 
antigens (MiHA). T-cells recognizing broadly expressed MiHAs may play a role in both GVL-
reactivity and GVHD. In contrast, T-cells recognizing hematopoiesis restricted MiHAs may 
selectively mediate GVL-reactivity.6-9 
Alloreactive T-cells recognizing HLA-mismatched alleles are present in high 
frequencies in peripheral blood.10 An HLA-mismatched SCT may therefore result in a strong 
alloimmune response. Since HLA-class I molecules are ubiquitously expressed an HLA-
class I mismatched SCT may cause severe GVHD. In contrast to ubiquitous expression of 
HLA-class I molecules, constitutive expression of HLA-class II molecules is mainly restricted 
to hematopoietic cells. A single HLA-class II locus mismatched SCT might therefore be 
anticipated to induce selective GVL-reactivity without GVHD. However, HLA-class II 
expression can be upregulated on various tissues after exposure to pro-inflammatory 
cytokines.11;12 An anti-HLA-class II immune response following HLA-class II mismatched SCT 
may therefore also result in GVHD if HLA-class II molecules on non-hematopoietic tissues 
are upregulated as a consequence of the conditioning regimen or infections.13 The results 
obtained from clinical transplantation studies concerning the impact of mismatching for 
different HLA-alleles have led to the current standard that patient and donor are usually 
preferably matched for the HLA-class II alleles HLA-DR and HLA-DQ in addition to the HLA-
class I molecules.14;15 
The role of HLA-DP as a transplantation antigen is less clear. Clinical reports on the 
impact of matching for HLA-DP on transplant outcome and GVHD often showed conflicting 
results.16-20 A recent study, however, demonstrated that mismatching for HLA-DPB1 
in T-cell depleted URD-SCT was associated with a significant decreased risk of disease 
relapse, whereas no effect on the incidence of severe GVHD was observed. It has been 
suggested that in T-cell depleted SCT HLA-DP may represent a relatively specific target 
for a GVL-reactivity in patients with HLA-class II expressing hematological malignancies.21 
We hypothesize that administration of DLI several months after a T-cell depleted 
HLA-DPB1 mismatched SCT in the absence of an inflammatory environment, may cause 
a selective GVL-effect without risking severe GVHD. To investigate whether HLA-DP 
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specific T-cells could be demonstrated to be involved in GVL-reactivity following HLA-DPB1 
mismatched URD-SCT, we analyzed the immune response in a patient with a refractory 
leukemic lymphoplasmacytic lymphoma responding to DLI following T-cell depleted SCT. 
We isolated the leukemia reactive T-cell clones during the clinical immune response and 
identified HLA-DP specific CD4+ T-cells as the likely mediators of persistent complete 
remission of the disease in the absence of GVHD. 
Case report
A 55-year-old female patient with a leukemic lymphoplasmacytic lymphoma was referred 
to our center for URD-SCT. This chronic B cell leukemia was resistant to chemotherapy after 
receiving multiple courses of chlorambucil, cyclophosphamide, doxorubicin, vincristin and 
prednisone, and fludarabin. Following pre-treatment with rituximab, resulting in a partial 
response, the patient was transplanted with mobilized peripheral blood stem cells from 
a male HLA-matched unrelated donor. Patient and donor were fully matched for HLA-A, 
HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 but differed for both HLA-DPB1 alleles. The 
HLA-DPB1 alleles were molecularly typed HLA-DPB1*02:01,03:01 for the patient and HLA-
DPB1*04:02,05:01 for the donor. The non-myeloablative conditioning regimen consisted 
of fludarabin, anti-thymocyteglobulin and busulfan.22 The graft was depleted of T-cells by 
in vitro incubation with 20 mg Alemtuzumab (Campath-1H) in the bag. No post-transplant 
GVHD prophylaxis was administered. Following transplantation rapid hematopoietic 
recovery occurred, and no GVHD developed. Chimerism analysis was performed on bone 
marrow samples by fluorescence in situ hybridization using X- and Y- chromosome specific 
probes as described previously.8 The malignant cells in bone marrow (BM) and peripheral 
blood (PB) were identified as CD19+ and CD20 low B-cells by flowcytometry. One month 
after SCT persistent disease was observed with 7% malignant cells in BM. Chimerism 
studies showed 73% donor cells in BM. Five months after SCT the number of malignant 
cells gradually increased, and therefore a single dose of DLI containing 2.5*106 T-cells / 
kg body weight was administered 7 months after SCT. After an initial further rise of the 
malignant cells to 58% in BM, the percentage leukemic cells started to decline from 6 
weeks after DLI. Five month after DLI, complete remission and conversion to full donor 
chimerism was observed (Figure 1). During this clinical response transient minimal GVHD 
of the skin and mouth grade 1 developed, which was treated with topical corticosteroids. 
At present, 3 years later, the patient is in complete remission and good clinical condition 
without GVHD.
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Materials and methods
Cell collection and preparation
After informed consent, PB and BM samples were obtained from the patient, the unrelated 
stem cell donor as well as from other patients and healthy donors. Mononuclear cells (MNC) 
were isolated by Ficoll-Isopaque separation and cryopreserved. Stable EBV-transformed 
B cell lines (EBV-LCL) were generated using standard procedures. Fibroblasts (FBs) were 
cultured from skin biopsies in DMEM with low glucose (BioWhittaker, Verviers, Belgium) 
and 10% fetal bovine serum (FBS, BioWhittaker). Renal cell carcinoma cell lines (RCC 02.20 
and 91.04) and breast cancer cell lines (BCC MDA 231 and BT 549) were kindly provided by 
Dr. E. Verdegaal of the department of Clinical Oncology in the LUMC. 
Flowcytometry
The monoclonal antibodies (moAb) anti-CD4 fluorescein isothiocyanate (FITC), anti-CD3 
phycoerythrin (PE) and anti-CD19 allophycocyanin (APC) were obtained from Becton 
Dickinson (BD, San Jose, USA). Anti-CD8 FITC moAb was purchased from Caltag (Burlingame, 
USA). Anti-HLA-DP PE-labeled moAbs were obtained from Leinco Technologies (St. Louis, 
Missouri, USA), and anti-NGFR-PE was derived from Pharmingen (San Diego, USA). 
Flowcytometric analysis was performed on a BD flowcytometer.  
Figure 1. Clinical immune response to DLI following HLA-DPB1 mismatched URD-SCT. Percentage 
of malignant cells (—♦—) and percentage of donor chimerism (--■--) in BM after SCT. Arrow indicates DLI 
infusion. From 6 weeks after DLI the percentage malignant cells in BM started to decline. At the same 
time a rise in percentage donor chimerism was observed. Five months after DLI complete remission 
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Characterization of the anti-leukemic immune response by ELISPOT analysis
To determine the potential contribution of CD4+ T-cells and CD8+ T-cells to the clinical 
immune response following DLI, IFN-γ production of CD4+ and CD8+ T-cells in response 
to malignant cells from the patient was determined by ELISPOT analysis. PB-MNC obtained 
from the patient before DLI and at various time points during the clinical response were 
monocyte depleted using magnetic CD14 beads (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. Next, CD4+ T-cells were isolated 
from the CD14 negative fraction using CD4 multisort isolation beads (Miltenyi Biotec GmBH). 
The CD4 positive fraction and the CD4 negative fraction, consisting of mainly CD8+ T-cells, 
were used in an IFN-γ ELISPOT (MabTech, Nacka Strand, Sweden) analysis according to 
the manufacturer’s instructions. Briefly, 96-well nitrocellulose plates precoated with anti-
IFN-γ antibodies (Mab-1 D1K) were seeded with 1x105 T-cells and 0.5 x105 leukemic cells 
in IMDM (BioWhittaker) supplemented with 10% human serum and 20 IU IL2/ml (Chiron, 
Amsterdam, The Netherlands), and incubated overnight at 37ºC. Cytokine secretion was 
detected by addition of a biotinylated anti-IFN-γ antibody (7-B6-1 biotin) for 2 hours at 
room temperature (RT). Following incubation with streptavidin (Extravidin-ALP E2636, 
Sigma, St Louis, USA) for 1 hour, substrate reagent (BCIP/NIBT-ALP-substrate, Sigma) was 
added to allow spot formation. Spots were counted using an automatic ELISPOT reader. 
To analyze the specificity of the CD4+ T-cells responding to the leukemic cells, an 
ELISPOT assay was performed in the presence of anti-HLA-DP (B7.21) or anti-HLA-DQ 
(SPVL3) monoclonal antibodies (moAbs). Leukemic cells were pre-incubated with saturating 
concentrations of antibodies for 30 min at RT before seeding into the ELISPOT plates. 
Isolation of leukemia reactive T-cell clones
To allow further characterization of leukemia reactive T-cells, T-cells producing IFN-γ in 
response to stimulation with the leukemic cells were clonally isolated. PB-MNC or BM-
MNC were depleted of monocytes using CD14 beads and overnight incubated with equal 
numbers of irradiated (30Gy) BM derived leukemic cells harvested from the patient before 
transplantation. Cell suspensions were incubated at a final concentration of 2x106 cells/
ml in IMDM containing 10% human serum and 10 IU IL2/ml. After overnight stimulation, 
activated IFN-γ secreting T-cells were stained using the IFN-γ capture assay (Miltenyi 
Biotec GmbH) according to manufacturer’s instructions, and isolated by cell sorting as 
described previously.23 Briefly, cells were incubated with IFN-γ catch reagent (anti-CD45/
anti-IFN-γ-antibody) and cultured for 45 min at 37°C under continuous rotation. After 
incubation with IFN-γ-detection antibody (PE labeled) for 10 minutes, cells were stained 
with FITC-conjugated anti-CD4 or FITC-conjugated anti-CD8 moAbs. Cell suspensions 
were counterstained with propidium iodide (PI, Sigma, St Louis, USA) immediately prior to 
cell sorting to exclude dead cells. Viable (PI-negative), CD4 positive or CD8 positive, IFN-γ 
secreting lymphocytes were sorted single cell per well or 50 cells per well into U-bottom 
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microtiter plates (Greiner Bio-One, the Netherlands) containing 100 μl of feeder mixture 
consisting of culture medium, IL2 (120 IU/ml), phytohemagglutinin (PHA, 0.8 μg/ml, Murex 
Biotec Limited, Dartford, UK), and 50 Gy-irradiated allogeneic third-party PB-MNC (0.5x105/
ml). Proliferating T-cell clones were selected, and further expanded using non-specific 
stimulation and third party feeder cells. 
Characterization of T-cell clones
To analyze the specificity of the expanded T-cell clones, IFN-γ production in response to 
patient derived leukemic cells, donor EBV-LCL, a panel of unrelated EBV-LCL and various 
hematological malignant cells was tested. To determine IFN-γ production, 5 000 T-cells 
were cocultured with 30 000 stimulator cells in a final volume of 150 μl IMDM culture 
medium supplemented with 20 IU IL2/ml. After overnight incubation, supernatants 
were harvested, and IFN-γ production was measured by ELISA (CLB, Amsterdam, The 
Netherlands). Recognition of non-hematopoietic cells was analyzed using FBs, RCC and 
BCC as stimulator cells. Following cell culture for 6 days in the presence or absence of 
200 U/ml IFN-γ (Immukine, Boehringer Ingelheim bv, Alkmaar, The Netherlands), cells were 
thoroughly washed and 10 000 stimulator cells were cocultured with 5 000 T-cells in a final 
volume of 150 μl IMDM culture medium supplemented with 20 IU IL2/ml. IFN-γ production 
was measured by ELISA after overnight incubation.  
To determine the HLA-restriction molecules essential for recognition, blocking studies 
were performed using anti-HLA-class I (W6/32), anti-HLA-class II (PdV5.2), anti-HLA-DR 
(B8.11-2), anti-HLA-DP (B7.21) and anti-HLA-DQ (SPVL3) antibodies. Target cells were pre-
incubated with saturating concentrations of moAbs for 30 minutes at RT before addition 
of T-cells. After overnight incubation supernatants were harvested, and IFN-γ production 
by the T-cell clones was determined by ELISA. 
To determine the cytotoxic capacity of the isolated T-cell clones against leukemic 
cells, a CFSE (carboxyfluorescein diacetate succinimidyl ester; molecular Probes Europe, 
Leiden, The Netherlands) based cytotoxicity assay was performed as described before.24 
Briefly, 25 000 CFSE labeled leukemic cells from the patient or 15 000 CFSE labeled PB-
MNC from unrelated patients were incubated with 75 000 unlabeled T-cells for 24 hours. 
Cell suspensions were collected and stained with APC labeled antibodies specific for B 
cells (CD19) or myeloid cells (CD33 / CD34) to detect leukemic cells. To exclude dead cells 
from analysis 0.2 μg/ml PI was added immediately prior to measurement. Survival of CFSE 
labeled, marker positive target cells was analyzed on a flowcytometer. To allow quantitative 
analysis 10 000 Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, USA) were 
added to each sample and 2 000 microbeads were acquired. The percentage of lysis was 
calculated as follows: % lysis = 100 - ([absolute no. viable CFSE+ target cells exp]/[absolute 
no. viable CFSE+ target cells control]) x 100). T-cell clones showing more than 20% lysis of the 
leukemic cells were determined to be cytotoxic T-cell clones. 
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Chapter 2
Retroviral transduction of donor EBV-LCL with cDNA encoding patient HLA-DPB1
To confirm specific recognition of HLA-DPB1*02:01 and HLA-DPB1*03:01 by the isolated 
T-cell clones, donor EBV-LCL were retrovirally transduced with patient derived HLA-
DPB1 alleles. Total RNA from patient PB-MNC was extracted using Trizol (Invitrogen, 
Carlsbad, CA) and transcribed into cDNA by reverse transcriptase using  random oligo dT 
primers (Pharmacia, Uppsala, Sweden). HLA-DPB1 fragments were obtained by Reverse 
Transcription-Polymerase Chain Reaction (RT-PCR) and cloned into LZRS retroviral 
vectors containing the marker gene truncated nerve growth factor receptor (∆NGF-R). 
The identity of the PCR products was verified by sequence reactions. φ-NX-A packaging 
cells were transfected with these retroviral vectors using a calcium phosphate transfection 
method (Life Technologies, Gaithersburg, USA). Retroviral supernatants containing the 
HLA-DPB1*02:01 or HLA-DPB1*03:01 gene were harvested and used for transduction 
of donor-derived EBV-LCL using recombinant human fibronectin fragments CH-296 (Bio 
Whittaker) as described before.25 HLA-DPB1 transduced EBV-LCL were stained with PE-
conjugated anti-∆NGF-R moAbs and purified using anti-PE isolation beads (Miltenyi Biotec 
GmbH). 
T-cell receptor (TCR) – Vβ chain analysis
To determine whether T-cell clones with the same specificity were derived from the same 
clonal origin, TCR-Vβ chain analysis was performed. First, CD4+ T-cell clones were stained 
with specific antibodies against different TCR-Vβ chains using a TCR-Vβ repertoire kit 
(Beckman Coulter, Fullerton, USA) and analyzed by flowcytometry. T-cell clones expressing 
the same TCR-Vβ were further analyzed by PCR using TCR-Vβ specific upstream primers 
in combination with a downstream TCR-BC primer. TCR-Vβ  PCR products were purified 
with the Qiaquick PCR purification kit (Qiagen, Valencia, CA) and sequenced using the dye 
terminator cycle sequencing kit (ABI-PRISM; PerkinElmer, Foster City, CA), according to the 
manufacturer’s instructions to obtain a complete identification of the TCR-Vβ genes.
Results
Identification of leukemia reactive CD4+ T-cells during the clinical response to DLI
To determine which T-cells were involved in the anti-tumor response following DLI in the 
patient, IFN-γ production by CD4+ T-cells and CD8+ T-cells in response to stimulation with 
patient leukemic cells was determined using ELISPOT. PB samples obtained before DLI 
and at various intervals following DLI were analyzed. Specific production of IFN-γ by CD4+ 
T-cells but not CD8+ T-cells was observed during the clinical immune response to DLI from 
six weeks after DLI (Figure 2). The correlation between the kinetics of the anti-leukemic 
CD4+ T-cell response and the disappearance of leukemic cells resulting in persistent 
complete remission of the disease suggests that these CD4+ T-cells mediated the anti-
leukemic effect. 
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Figure 2. Determination of an anti-leukemic CD4+ T-cell response starting 6 weeks after DLI. 
Number of IFN-γ ELISPOTs produced by CD4+ T-cells (■) and CD8+ T-cells (□) before and after DLI in 
response to stimulation by leukemic cells from the patient. Leukemic cells as a percentage of PB-MNC 
is shown on the secondary axis (—♦—).
Isolation and characterization of leukemia reactive T-cells
To further characterize the anti-leukemic T-cell response, leukemia reactive T-cell clones 
were isolated from PB-MNC obtained 10 weeks post-DLI and from BM-MNC obtained 14 
weeks post-DLI. After overnight stimulation with patient leukemic cells, activated IFN-γ 
producing T-cells were isolated using cell sorting. The percentage of IFN-γ producing T-cells 
10 weeks and 14 weeks post-DLI was 0.2% and 0.7% respectively. Isolation and expansion 
of IFN-γ producing T-cells resulted in 24 CD4+ T-cell clones, 19 CD8+ T-cell clones and 6 
natural killer (NK) cell clones for further analysis. 
All clones were tested for recognition of patient malignant cells and donor derived EBV-
LCL as measured by IFN-γ production. All CD4+ T-cell clones showed specific production of 
IFN-γ (114-592 pg/ml) in response to patient malignant cells, but not to donor derived cells 
(Figure 3a). The CD8+ T-cell clones and NK-cell clones did not produce IFN-γ in response 
to patient leukemic cells, indicating that these clones were isolated probably due to 
spontaneous ex vivo production of IFN-γ or non-specific staining (data not shown).
To determine whether these CD4+ T-cell clones were capable of lysing the leukemic 
cells, a CFSE based cytotoxicity assay was performed. Of the 20 CD4+ T-cell clones tested, 
11 CD4+ T-cell clones (55%) showed specific lysis (20-84%) of the malignant CD19+ B cells 
(Figure 3b). Due to contamination, four CD4+ T-cell clones were lost before analysis. The 
isolated CD8+ T-cell clones and NK-cell clones did not show lysis of patient leukemic cells 
(data not shown). These results illustrate that leukemia reactive cytokine producing and 
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Figure 3. Reactivity of isolated CD4+ T-cell clones against patient malignant cells. Clones A - H 
represent CD4+ T-cell clones isolated from peripheral blood obtained 10 weeks after DLI. Clones J - Y 
were isolated from bone marrow obtained 14 weeks post DLI. (A) patient leukemic cells (■) and donor 
derived EBV-LCL (□) were tested for recognition by all isolated CD4+ T clones. Release of IFN-γ (pg/
ml) in 50 μl supernatant is shown. (B) Percentage lysis of patient malignant cells by the isolated CD4+ 
T-cell clones in a 24h CFSE based cytotoxicity assay. The experiment was performed in duplicate, mean 
percentage lysis of leukemic cells is shown. Clones E, R, X, Y could not be tested in the cytotoxicity assay 
due to contamination.
Identification of HLA-DPB1*02:01 and HLA-DPB1*03:01 as targets for leukemia 
reactive CD4+ T-cells
To determine the HLA restriction molecules essential for recognition by the isolated CD4+ 
T-cell clones, blocking studies were performed. Addition of HLA-class II moAbs reduced 
IFN-γ production by all isolated CD4+ T-cell clones. Pre-incubation of the leukemic cells with 
specific moAbs for the HLA-class II molecules resulted in abrogation of IFN-γ production by 
all CD4+ T-cell clones upon blocking with HLA-DP, but not with HLA-DR or HLA-DQ specific 
A
B
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moAbs, illustrating HLA-DP restricted recognition. The mean percentage of inhibition of 
IFN-γ production for all T-cell clones upon addition of HLA-class II moAbs was 53 +/- 28%. 
The mean percentage of inhibition of IFN-γ production upon addition of an HLA-DP specific 
moAb was 87 +/- 19%. A representative example of the inhibition of IFN-γ production upon 
addition of blocking moAbs is shown in figure 4a. 
To analyze whether the circulating CD4+ T-cells that responded ex vivo to the leukemic 
cells by production of IFN-γ as demonstrated in the ELISPOT analysis were all HLA-DP 
specific, the ELISPOT analysis was performed in the presence of blocking antibodies. 
Addition of HLA-DP specific moAbs to the leukemic cells completely abrogated production 
of IFN-γ ELISPOTs by the CD4+ T-cells isolated at the maximal anti-leukemic response 14 
weeks post-DLI (Figure 4b). These results indicate that the profound anti-tumor response 
















































Figure 4. HLA-DP restricted recognition of patient leukemic cells by CD4+ T-cell clones. (A) 
Representative example of HLA-DP restricted recognition of patient leukemic cells by the isolated CD4+ 
T-cell clones. IFN-γ release (pg/ml) of clone M in response to patient malignant cells in the absence or 
presence of various blocking antibodies is shown. (B) Production of IFN-γ ELISPOTs by CD4+ T-cells 
obtained 14 weeks after DLI in response to stimulation with malignant cells from the patient, in the 





To further identify the specificity of the HLA-DP restricted CD4+ T-cell clones, 
recognition of a panel of EBV-LCL was analyzed. Since patient and donor differed for both 
HLA-DPB1 alleles, the T-cell clones were likely to recognize allo-HLA-DPB1 of the patient. To 
analyze whether there was differential recognition of the patient derived HLA-DPB1*02:01 
and HLA-DPB1*03:01 alleles, a panel of EBV-LCL expressing either HLA-DPB1*02:01 
or HLA-DPB1*03:01 was tested for recognition. Of the 20 CD4+ T-cell clones tested, 17 
CD4+ T-cell clones recognized all EBV-LCL expressing HLA-DPB1*03:01 (n=7) but not EBV-
LCL expressing HLA-DPB1*02:01 (n=5). Three CD4+ T-cell clones recognized all EBV-LCL 
expressing HLA-DPB1*02:01 and not HLA-DPB1*03:01. EBV-LCL expressing the donor 
specific HLA-DPB1*04 allele (n=3) were not recognized by the T-cell clones. Representative 
examples of the recognition pattern of an HLA-DPB1*02:01 specific T-cell clone and an 
HLA-DPB1*03:01 specific T-cell clone are shown in figure 5a.
To confirm specific recognition of HLA-DPB1*02:01 and HLA-DPB1*03:01, donor 
EBV-LCL were retrovirally transduced with the patient derived HLA-DPB1*02:01 or HLA-
DPB1*03:01 genes. Transduction with HLA-DPB1*02:01 only induced recognition by 
the HLA-DPB1*02:01 specific T-cell clones, and not by HLA-DPB1*03:01 specific clones. 
Transduction with HLA-DPB1*03:01 resulted only in recognition by the HLA-DPB1*03:01 
specific clones. These experiments confirm specific recognition of HLA-DPB1*02:01 and 
HLA-DPB1*03:01 (Figure 5b).
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Figure 5. Differential recognition of HLA-DPB1*02:01 and HLA-DPB1*03:01 by the HLA-DP 
restricted T-cell clones. (A) Recognition of a panel of EBV-LCL expressing HLA-DPB1*02, HLA-DPB1*03 
or HLA-DPB1*04 by two representative T-cell clones. Two representative examples of each target are 
shown. White bars represent the recognition pattern of a T-cell clone (clone B) recognizing only EBV-
LCL expressing HLA-DPB1*02:01. Black bars represent the recognition pattern of a T-cell clone (clone 
A) recognizing only EBV-LCL expressing HLA-DPB1*03:01. In total 3 HLA-DPB1*02:01 restricted T-cell 
clones and 17 HLA-DPB1*03:01 restricted T-cell clones were identified. (B) Recognition of donor EBV-LCL 
upon retroviral transduction of patient HLA-DPB1*02:01 and HLA-DPB1*03:01 by HLA-DPB1*02:01(□) 
or HLA-DPB1*03:01 (■) specific T-cell clones.
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To analyze whether the recognition of HLA-DP by the T-cell clones was solely 
determined by the expression of HLA-DP or whether the T-cell clones recognized the 
allo-HLA-DP molecules in combination with a peptide only expressed by hematopoietic 
cells, we tested several HLA-DPB1*02 or HLA-DPB1*03 typed non-hematopoietic cell 
lines for recognition. Since constitutive expression of HLA-class II molecules was expected 
to be absent on non-hematopoietic cells two FBs, two RCC cell lines and two BCC cell lines 
were cultured for 6 days in the absence or presence of 200 U/ml IFN-γ to induce HLA-class 
II expression. As shown in figure 6a and 6b expression of HLA-DP was absent on resting 
FBs, both RCC cell lines and on BCC BT 549. BCC MDA 231 showed expression of HLA-DP 
without incubation with IFN-γ. Incubation with IFN-γ resulted in upregulated expression of 
HLA-DP for all cell lines analyzed. All non-hematopoietic cell populations were recognized 
by the specific T-cells clones if sufficient HLA-DP was expressed. (figure 6c and 6d) Specific 
recognition of HLA-DP was confirmed by blocking studies (data not shown). Since the T-cell 
clones recognized cells derived from various tissues, specific recognition by the T-cell 
clones was determined by the expression of allo-HLA-DP and not by the recognition of a 




T-cell clones with the same specificity are derived from different clonal origin
To analyze whether T-cell clones with the same specificity were derived from the same 
clonal origin, TCR-Vβ chain usage was determined. Different TCR-Vβ expression was found 
for all 3 T-cell clones specific for HLA-DPB1*02:01. Seven different TCR-Vβ chains were 
identified for the HLA-DPB1*03:01 specific T-cell clones, illustrating a polyclonal origin of 
this immune response. T-cell clones using the same TCR-Vβ, as determined by PCR and 
sequence reactions, were isolated at different time points following DLI, illustrating the 
persistence of this anti-HLA-DP immune response (data not shown).
HLA-DP as a specific target for immunotherapy
To investigate whether HLA-DP could more broadly be used as a target for cellular 
immunotherapy, the expression of HLA-DP on various leukemic cells was analyzed. B-ALL 





































































Figure 6. Expression of HLA-DP on non-hematopoietic cells of various origins and recognition by 
HLA-DP specific T-cells. Mean fluorescence intensity (MFI) of HLA-DP-PE staining on (A) HLA-DPB1*03 
typed EBV-LCL, fibroblasts (FBs) and renal cell carcinoma (RCC) cells and (B) HLA-DPB1*02 typed EBV-
LCL, FBs and breast cancer (BCC) cells. HLA-DP expression on FBs, RCC and BCC cells is shown after 
6 days culturing in the absence (□) or presence (■) of 200 U/ml IFN-γ. (C) IFN-γ release (pg/ml) of an 
HLA-DPB1*03 specific T-cell clone (clone J) in response to HLA-DPB1*03 stimulator cells cultured in the 
absence (□) or presence (■) of IFN -γ. (D) IFN-γ release (pg/ml) of an HLA-DPB1*02 specific T-cell clone 
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was variable in myeloid leukemias, including AML (n=3) and CML (n=4). Two T-ALL samples 
analyzed did not express HLA-DP (data not shown). 
To analyze whether various hematological malignant cells that expressed HLA-
DP (Figure 7a) could be recognized by the isolated HLA-DP specific T-cell clones, HLA-
DPB1*03:01 expressing ALL, CLL, AML and CML samples were tested for recognition and 
lysis by an HLA-DPB1*03:01 specific cytotoxic T-cell clone in an IFN-γ ELISA and cytotoxicity 
assay respectively. All samples tested were recognized comparable to the patient leukemic 
cells as measured by IFN-γ production (Figure 7b), and specific lysis (30-60%) of the 
malignant cell populations was observed (Figure 7c). HLA-DP restricted recognition and 
lysis was confirmed in blocking experiments (data not shown). These results indicate 
that various hematological malignancies with sufficient expression of HLA-DP may be 
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Figure 7. HLA-DP expression on various lymphoid and myeloid malignant cells and their 
recognition by an HLA-DPB1*03:01 restricted T-cell clone. PB-MNC from the patient analyzed in this 
study and from HLA-DP*0301 positive ALL, CLL, AML and CML patients were used in this experiment. 
(A) Expression of HLA-DP on malignant B-cells (CD19) or myeloid cells (CD33 / CD34). (B) Recognition of 
total PB-MNC by an HLA-DPB1*03:01 specific T-cell clone (clone A) as measured by IFN-γ production. 
(C) For the B cell malignancies lysis of the CD19 positive leukemic cells by an HLA-DPB1*03:01 specific 
cytotoxic CD4+ T-cell clone (clone A)  in a 24h CFSE based cytotoxicity assay is shown. For the myeloid 
malignancies lysis of the CD33 or CD34 malignant cells is shown. The experiment was performed in 







In this study we analyzed the immune response in a patient with a refractory chronic 
B cell leukemia responding to DLI after an HLA-DPB1 mismatched SCT. We observed a 
profound GVL-effect with minimal skin GVHD resulting in a persistent complete remission 
of the disease. Our results indicate that the GVL-effect was caused by a polyclonal 
immune response comprising both T helper and cytotoxic CD4+ T-cells directed against 
both mismatched HLA-DPB1 alleles. By ELISPOT analysis we identified the anti-leukemic 
response starting at 6 weeks after DLI. Since the emergence and kinetics of the leukemia-
reactive CD4+ T-cells corresponded to the disappearance of the malignant cells the HLA-
DP specific CD4+ T-cells were likely to mediate the anti-leukemic effect. 
Since we demonstrated using ex vivo ELISPOT analysis the presence of only CD4+ and 
not CD8+ leukemia reactive T-cells both in peripheral blood and bone marrow, our study 
indicates that HLA-DP specific CD4+ T-cells can elicit a profound anti-leukemic response 
in the absence of leukemia reactive CD8+ T-cells. Although CD4+ T-cells have mostly been 
studied in their role as helper cells for development of CD8+ T-cell immunity26;27, CD4+ 
T-cells with direct cytolytic activity have been isolated from patients with GVL responses 
after SCT, and have been suggested to play a direct role in anti-tumor immunity as effector 
cells.28-31 Some of the HLA-DP specific CD4+ T-cells that were isolated in this study were 
capable of direct lysis of leukemic cells indicating that CD4+ T helper cells and CD4+ 
cytotoxic T-cells are sufficient for a direct effector function in GVL-reactivity.
The expression of HLA-DP on normal peripheral blood cells is found most profoundly 
on B-cells.32 Similarly, high expression of HLA-DP is found on most B-ALL and CLL cells 
whereas myeloid leukemic cells show more variable expression of HLA-DP.33 Especially B 
cell malignancies may therefore be susceptible to an HLA-DP mediated GVL-effect. Indeed, 
the beneficial effect of mismatching for HLA-DPB1 in T-cell depleted URD-SCT on the risk 
of disease relapse has been reported to be present most pronounced in ALL as compared 
to AML and CML.21 In our study however, HLA-DP expressing myeloid leukemias were also 
demonstrated to be recognized and lysed by HLA-DP specific CD4+ T-cells, and therefore 
both B-cell malignancies and myeloid malignancies with sufficient HLA-DP expression may 
be susceptible to an HLA-DP mediated GVL-effect. As illustrated by the tumor cell lines, 
occasionally non-hematological tumor cells may also constitutively express HLA-DP and be 
therefore a target for HLA-DP specific immunotherapy. 
The conflicting results of clinical reports on the impact of mismatching for HLA-
DPB1 on GVHD may be explained by different transplantation regimens. HLA-DP reactive 
T-cells administered at the time of SCT may result in both GVHD and GVL-reactivity as 
a consequence of upregulated HLA-DP expression on non-hematopoietic cells caused 
by pro-inflammatory cytokines released as a consequence of tissue damage induced by 
the conditioning regimen or infections.11;12 T-cell depleted SCT followed by the infusion of 
donor T-cells at a later time point, however, may more selectively induce a GVL response 
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when tissue damage is largely restored, and the expression of HLA-DP is anticipated to be 
restricted to hematopoietic cells. In this study we showed that resting FBs and most other 
non-hematopoietic cell lines did not express HLA-DP and were therefore not recognized 
by the T-cell clones. However, long-term incubation of non-hematopoietic cells with high 
amounts of IFN-γ as a model to mimic an inflammatory environment, induced substantial 
upregulation of HLA-DP and thereby recognition by the T-cell clones. 
It has been suggested that not all HLA-DPB1 differences as defined by allele typing will 
be able to induce a T-cell response. Several groups have attempted to identify permissive 
and non-permissive HLA-DPB1 mismatch combinations to prevent GVHD based on the 
hypothesis that specific amino acid substitutions in the hypervariable region of the HLA-
DPB1 allele are essential for T-cell reactivity.34-37 Mixed lymphocyte reactions (MLR) showed 
that in 30% of HLA-DP mismatched pairs a negative MLR was observed and substantial 
differences in MLR reactivity between different HLA-DPB1 mismatched combinations were 
found. Strikingly, HLA-DPB1*03 and HLA-DPB1*02, which were the targets of the immune 
response in our patient, were found to be the most potent stimulators in a MLR.34 These 
studies suggest that only certain combinations of HLA-DP mismatches may be able to 
induce a potent T-cell reactivity, and further explain controversial observations described 
in different studies on the outcome of HLA-DPB1 mismatched SCT. 
In summary, our results illustrate that HLA-DP may represent a relatively specific target 
for GVL-reactivity. HLA-DPB1 mismatched SCT may be preferable over a fully matched SCT 
in HLA-class II expressing hematological malignancies, making use of HLA-DP as a target 
for immunotherapy. After T-cell depleted URD-SCT, the administration of donor T-cells 
may induce an allo-HLA-DP specific immune response resulting in a potent GVL-effect 
without the risk of severe GVHD. 
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Letter to the editor
Clinical studies have indicated that human leucocyte antigen (HLA)-DPB1 functions as a 
classical transplantation antigen in allogeneic stem cell transplantation (SCT). Mismatching 
for HLA-DPB1 was associated with an increased risk of graft versus host disease (GVHD) 
but also a decreased risk of disease relapse.1;2 However, some studies showed that specific 
HLA-DPB1 mismatches were associated with poor clinical outcome.3 It was suggested that 
this unfavorable effect was caused by differences in immunogenicity between HLA-DPB1 
alleles. An algorithm defining permissive and non-permissive HLA-DPB1 mismatches 
was developed based on cross-reactive T-cell reactivity patterns. It was suggested that 
permissive mismatches would not result in T-cell responses, whereas strong T-cell 
responses were expected to be generated against non-permissive mismatches.3;4 Clinical 
analysis of different patient cohorts indeed showed a significant higher risk of mortality in 
the non-permissive mismatched group compared to the permissive mismatched group. 
However, the risk of GVHD and relapse did not significantly differ between these groups, 
implying that the effect on overall survival may not have directly resulted from differences 
in alloreactivity.3;5;6 
To analyze whether permissive HLA-DPB1 specific immune responses occur in vivo, we 
analyzed immune responses in two patients responding to donor lymphocyte infusion (DLI) 
following HLA-A,-B,-C,-DRB1,-DQB1 matched, HLA-DPB1 mismatched SCT. The patients 
received a permissive or non-permissive HLA-DPB1 mismatched SCT, respectively. CD4+ 
T-cells were isolated from peripheral blood obtained during the clinical immune response 
to DLI, and stimulated with HLA-class II negative HeLa cells transduced with the specific 
HLA-DP molecules derived from patient or donor. In both patients, HLA-DPB1 specific 
CD4+ T-cells were demonstrated by CD137 upregulation in response to stimulation with 
HeLa cells transduced with patient and not donor HLA-DP molecules (Figure 1A). CD137 
expressing CD4+ T-cells were clonally isolated and specific recognition of patient HLA-
DPB1 molecules was confirmed for 58-78% of the T-cell clones (Figure 1B). T-cell receptor-
Vβ analysis showed a polyclonal origin of these HLA-DPB1 specific CD4+ T-cell responses.
To demonstrate the generation of HLA-DPB1 specific immune responses directed 
against permissive and non-permissive HLA-DPB1 mismatches in different individuals, we 
developed a model to generate allo-HLA-DP responses in vitro. Purified CD4+ T-cells of 4 
different responders were stimulated with HeLa cells transduced with permissive (n=2) or 
non-permissive (n=2) HLA-DPB1 molecules. 14 days after stimulation, CD4+ T-cells were 
restimulated with HeLa cells transduced with HLA-DP molecules used for stimulation and 
HeLa cells transduced with responder HLA-DP molecules. Both stimulation with permissive 
and non-permissive mismatched HLA-DPB1 molecules resulted in the generation of HLA-
DPB1 specific CD4+ T-cells as measured by specific IFN-γ production in response to the 
HLA-DPB1 molecules used for stimulation (Figure 1C). 
In conclusion, we demonstrated that in vivo both permissive and non-permissive 
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HLA-DPB1 mismatches resulted in strong polyclonal immune responses. Furthermore, 
we demonstrated in vitro for 4 additional individuals that permissive and non-permissive 
HLA-DPB1 responses were equally effectively generated. These data show immunogenicity 
of permissive mismatched HLA-DPB1 alleles. We suggest that the difference in overall 
survival between patients transplanted with permissive and non-permissive HLA-DPB1 
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Figure 1.  Permissive and non-permissive HLA-DPB1 mismatches induced HLA-DPB1 specific 
immune responses in vivo and in vitro
Two patients transplanted with an HLA-A,-B,-C,-DRB1,-DQB1 matched, HLA-DPB1 mismatched SCT 
were analyzed for the presence of HLA-DPB1 specific CD4+ T-cells following DLI. Patient 1 (HLA-
DPB1*02:01,03:01) was transplanted for a chronic B cell leukemia with a non-permissive HLA-DPB1 
mismatched donor (HLA-DPB1*04:02,05:01). Patient 2 (HLA-DPB1*04:01) was transplanted for Multiple 
Myeloma with a permissive HLA-DPB1 mismatched donor (HLA-DPB1*03:01,04:02) in the GvH direction. 
(A) Purified CD4+ T-cells obtained during the clinical immune response to DLI were stimulated with 
HLA-class II negative HeLa cells transduced with either donor or patient HLA-DP molecules. After 48 
hours, CD137 expression on CD4+ T-cells was determined using flowcytometry. Percentages of CD137 
positive CD4+ T-cells in response to stimulation with different HLA-DPB1 molecules are shown. (B) 
CD137 expressing CD4+ T-cells shown in figure 1A were clonally isolated and tested for recognition of 
different target cells. IFN-γ production (pg/ml) was determined in 50 µl supernatant. Mean results ± SD 
of a selection of 11 HLA-DPB1*02:01 specific CD4+ T-cell clones, 15 HLA-DPB1*03:01 specific CD4+ 
T-cell clones and 15 HLA-DPB1*04:01 specific CD4+ T-cell clones are shown. (C) Purified CD4+ T-cells 
derived from 4 different healthy individuals were stimulated with HeLa cells transduced with permissive 
mismatched HLA-DPB1 molecules (n=2) or non-permissive mismatched HLA-DPB1 molecules (n=2). At 
day 14, 25,000 CD4+ T-cells from each cell line were restimulated with 50,000 HLA-DP transduced HeLa 
cells used for stimulation (■) or HeLa cells transduced with control donor HLA-DP molecules (□). IFN-γ 
release (pg/ml) measured in 50µl supernatant upon restimulation is shown.
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Clinical studies have indicated that HLA-DP functions as a classical transplantation antigen 
in allogeneic stem cell transplantation. Mismatching for HLA-DPB1 was associated with 
an increased risk of graft versus host disease (GVHD) but also a decreased risk of disease 
relapse. However, specific HLA-DPB1 mismatches were associated with poor clinical 
outcome. It was suggested that this unfavorable effect was caused by a difference in 
immunogenicity between HLA-DPB1 alleles. To analyze whether immunogenicity of HLA-
DPB1 mismatches could be predicted based on the presence or absence of specific 
amino acid sequences we developed a model to generate allo-HLA-DP responses in vitro. 
We tested in total 48 different stimulator/responder combinations by stimulating CD4+ 
T-cells from 5 HLA-DPB1 homozygous individuals with the same antigen presenting cells 
transduced with different allo-HLA-DP molecules. HLA-DPB1 molecules used for stimulation 
comprised 76-99% of HLA-DPB1 molecules present in different ethnic populations. We 
show that all HLA-DPB1 mismatches as defined by allele typing resulted in high frequency 
immune responses. Furthermore, we show that cross-recognition of different HLA-DPB1 
molecules is a broadly observed phenomenon. We confirm previous described patterns 
in cross-recognition, and demonstrate that a high degree in similarity between HLA-DPB1 




Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment 
for a variety of hematological malignancies.1 A significant part of the therapeutic effect 
of allo-SCT can be attributed to donor derived T-cells recognizing antigens on residual 
malignant cells thereby inducing a graft versus leukemia (GVL) effect.2 When such antigens 
are not only present on hematopoietic cells but also on non-hematopoietic cells, donor 
derived T-cells can also mediate detrimental graft versus host disease (GVHD).3,4 Since 
allo-reactive T-cells recognizing HLA-mismatched alleles are present in high frequencies in 
peripheral blood (PB)5, HLA-mismatched SCT may result in strong allo-immunity. To reduce 
the risk of GVHD and allograft rejection, patient and donor are preferably matched for the 
HLA class I molecules HLA-A, -B, -C and the HLA class II molecules HLA-DRB1 and HLA-
DQB1 (10/10 match).6-8 
However, a perfectly matched donor is not always available. Several studies have 
demonstrated the importance of functional matching in order to select the best available 
donor. It has been suggested that mismatches at some loci may be better tolerated than 
others.9-11 Minimal mismatches resulting in single amino acid substitutions have been 
associated with a significant increased risk of GVHD and transplant related mortality 
(TRM).12,13 In contrast, highly diverged HLA class I mismatches with more than 5 amino acid 
substitutions in both the α-helix and β-sheet of an HLA class I molecule in combination with 
a negative cytotoxic T-lymphocyte precursor test have been shown to be better tolerated 
than less diverged mismatches.14 These studies indicated that the number of amino acid 
substitutions between mismatched HLA-alleles was not predictable for the outcome of 
alloreactivity.
HLA-DPB1 is often not taken into consideration in donor selection. Recent large 
clinical studies showed that HLA-DP did function as a classical transplantation antigen 
since HLA-DPB1 mismatching was associated with both GVHD and GVL-reactivity.6,15 The 
overall mortality of patients who received an HLA-DPB1 matched or mismatched SCT did 
not statistically differ, possibly due to a balanced effect of increased GVHD and reduced 
relapse rate. Remarkably, specific HLA-DPB1 mismatches have been associated with poor 
clinical outcome.16-21  It was suggested that matching at an epitope level may be clinically 
more relevant in terms of transplant outcome than matching at allele level. An algorithm 
was developed in which permissive and non-permissive mismatches were defined.19 HLA-
DPB1 molecules were classified in 3 different immunogenicity groups according to their 
recognition by HLA-DPB1*09 specific CD4+ T-cell clones. Recently, the classification was 
modified introducing a fourth category in the algorithm.21 Individuals were not supposed 
to elicit strong anti-HLA-DP responses to HLA-DPB1 molecules classified within the same 
immunogenicity group, based on the hypothesis that T-cells should not respond to 
foreign HLA-DPB1 molecules sharing specific amino acids with the ‘self’-HLA-DPB1 allele. 
These mismatches were assigned to be permissive mismatches. In contrast, strong T-cell 
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responses were expected only to be generated against HLA-DPB1 molecules classified in 
higher immunogenic groups representing non-permissive mismatches.19
Recently, we demonstrated the in vivo occurrence of polyclonal HLA-DPB1 specific 
immune responses following both permissive and non-permissive HLA-DPB1 mismatched 
SCT and donor lymphocyte infusion (DLI).22 In the present study we tested these CD4+ 
T-cells with different HLA-DPB1 specificity for cross-recognition of other HLA-DPB1 
molecules and confirmed previously described patterns in cross-recognition.19,20 In addition, 
cross-recognition of other HLA-DPB1 molecules was found which did not correspond to 
the previously proposed algorithm. To analyze whether immunogenicity of HLA-DPB1 
mismatches could be predicted based on the presence or absence of specific amino acid 
sequences in the HLA-DPB1 molecule we developed a model to generate allo-HLA-DP 
responses vitro. Using this model we tested 48 different combinations. Responders were 
selected by homozygous expression of one of the four most common HLA-DPB1 alleles 
in northern European population. HLA-DPB1 molecules used for stimulation comprised 
76-99% of the HLA-DPB1 alleles present in different ethnic populations.15,23 We show that 
all HLA-DPB1 mismatches as defined by allele typing resulted in high frequency immune 
responses, also between individuals expressing HLA-DPB1 molecules that were frequently 
cross-recognized. Together, these data demonstrate that a high degree of similarity in 
amino acid sequence between HLA-DPB1 molecules is predictive for cross-recognition but 
not for immunogenicity and illustrate that T-cell recognition patterns may not predict allo-
reactivity.
Materials and methods
Cell collection and preparation
Peripheral blood (PB) samples were obtained from healthy donors after approval by the 
LUMC institutional review board and informed consent according to the Declaration 
of Helsinki. Mononuclear cells (MNC) were isolated by Ficoll-Isopaque separation and 
cryopreserved. Stable EBV-transformed B cell lines (EBV-LCL) were generated using 
standard procedures. EBV-LCL and HeLa cells were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM, BioWhittaker, Verviers, Belgium) supplemented with 10% bovine fetal 
serum (FBS, BioWhittaker).
Flowcytometry
The monoclonal antibodies (moAb) anti-CD4 fluorescein isothiocyanate (FITC), anti-CD14 
phycoerythrin (PE), anti-Nerve Growth Factor Receptor (NGFR)-PE, anti-CD3 Peridinin 
Chlorophyll Protein (PerCP), anti-CD19 allophycocyanin (APC) and anti-interferon-γ (IFN-γ)-
APC were obtained from Becton Dickinson (BD, San Jose, CA, USA). Anti-CD56-APC and anti-
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CD154-PE were obtained from Beckman Coulter (Fullerton, CA, USA). Anti-CD8-APC moAbs 
ware purchased from Caltag Laboratories (Burlingame, CA, USA) and anti-HLA-DP-PE 
moAbs were obtained from Leinco Technologies (St. Louis, Missouri, USA). Flowcytometric 
analysis was performed on a BD flowcytometer using CellquestPro software, and cell 
sorting was performed using a BD FACSAria cell-sorting system. 
Transduction of HeLa cells with different retroviral constructs
HLA class II negative HeLa cells were retrovirally transduced with 12 different combinations 
of HLA-DPB1 and HLA-DPA1 molecules as described in table 1. In order to allow appropriate 
co-stimulation and processing of the HLA-DP molecules HeLa cells were first transduced 
with CD80, Invariant chain (Ii) and HLA-DM. HLA-DMA, HLA-DMB and CD80-Ii were cloned 
into separate pLZRS retroviral vectors. HLA-DMA was combined with the marker gene 
ΔNGF-R and HLA-DMB with enhanced green fluorescence protein (eGFP). HLA-DPA1 and 
HLA-DPB1 molecules were cloned into separate MP71-IRES retroviral vectors containing 
the marker genes eGFP or ΔNGF-R respectively. The identity of all constructs was verified 
by sequencing. Retroviral supernatants were generated using packaging Φ-NX-A cells 
as previously described24,25 and used for transduction of HeLa cells or EBV-LCL using 
recombinant human fibronectin fragments CH-296 (BioWhittaker, Verviers, Belgium)25,26 
HLA-DM and CD80-Ii transduced HeLa (HeLa-II) cells were purified by flowcytometric 
cell sorting based on expression of both marker genes and CD80 staining. Selected 
cells were subsequently transduced with HLA-DPA1 and HLA-DPB1 constructs. HLA-DP 
transduced HeLa-II cells were selected based on positive staining for anti-HLA-DP-PE. 
EBV-LCL expressing the specifically transduced HLA-DPA1 and HLA-DPB1 molecules were 
isolated by selecting for eGFP and ΔNGF-R double positive cells.
Characterization of CD4+ T-cell clones
To analyze cross-recognition of different HLA-DPB1 molecules by our previously isolated 
HLA-DPB1 specific CD4+ T-cell clones22, IFN -γ production in response to HeLa-II cell 
lines transduced with different HLA-DPB1 molecules and HLA-DP negative HeLa-II cells 
was determined. To determine IFN-γ production, 5 000 T-cells were co-cultured with 
0.03*106 stimulator cells in culture medium consisting of IMDM supplemented with 5% 
human serum and 5% FBS supplemented with 10 IU Interleukine-2 per ml (IL-2, Chiron, 
Amsterdam, The Netherlands). After overnight incubation, supernatants were harvested, 
and IFN-γ production was measured by enzyme-linked immunosorbent assay (ELISA; 
Centraal Laboratorium voor Bloedtransfusiedienst, CLB, Amsterdam, The Netherlands).
To identify HLA-DPB1 specific CD4+ T-cell clones with the same specificity but derived 
from different clonal origin, T-cell receptor (TCR)-Vβ-chain analysis was performed by 
flowcytometric analysis. CD4+ T-cell clones were stained with specific antibodies for 
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different TCR-Vβ chains using a TCR-Vβ repertoire kit (Beckman Coulter) and analyzed by 
flowcytometry.
Generation of HLA-DPB1 specific CD4+ T-cell lines 
To study immunogenicity of HLA-DPB1 in different stimulator/responder combinations we 
developed a model to generated allo-HLA-DP responses in vitro. Twelve different HLA-
DP transduced HeLa-II cell lines were used to stimulate purified CD4+ T-cells derived 
from different HLA-DPB1 homozygous responders. Responder cells were typed HLA-
DPB1*02:01, *03:01, *04:01 and *04:02. CD4+ T-cells were first purified from PB-MNC 
using magnetic untouched CD4+ T-cell isolation beads (Miltenyi Biotec, GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer’s instructions. Next, negative fractions 
were stained with anti-CD4-FITC, anti-CD14-PE and anti-CD8-APC, anti-CD56-APC and anti-
CD19-APC. CD4+, CD14-/CD8-/CD56-/CD19- cells were selected using flow-cytometric cell 
sorting. 1*106 purified CD4+ T-cells were stimulated with 0.1*106 irradiated (30Gy) HLA-DP 
transduced HeLa-II cells in culture medium supplemented with 50 IU IL-2/ml. At day 14, 
CD4+ T-cell lines were analyzed for specific recognition of various cell lines. 
Characterization of CD4+ T-cell lines
To analyze specificity of the CD4+ T-cell lines stimulated with different HLA-DPB1 
molecules, IFN-γ production in response to HeLa-II cells transduced with 12 different HLA-
DPB1 alleles (including the autologous control) and HLA-DP negative HeLa-II cells was 
determined. To further confirm specificity for allo-HLA-DPB1, IFN- γ production in response 
to autologous responder EBV-LCL transduced with the relevant HLA-DPB1 molecules 
used for stimulation was determined. IFN-γ production was determined in harvested 
supernatants or by intracellular cytokine staining. 
To determine IFN -γ release in supernatants 25 000 , 10 000 or 2 000 CD4+ T-cells 
were co-cultured with 0.05*106 stimulator cells in a final volume of 150μl culture medium. 
Supernatants were harvested following overnight incubation, and IFN-γ production was 
measured by ELISA.   
For intracellular IFN-γ staining 0.05*106 CD4+ T-cells were restimulated with 0.05*106 
stimulator cells in culture medium supplemented with 10μg/ml Brefeldin-A (Sigma-Aldrich, 
St Louis, MO, USA). After 4 hours incubation, CD4+ T-cells were surface stained with CD4-
FITC and CD3-PerCP-labeled MoAbs. Cells were washed, fixed and permeabilised using 
0.1% Saponin (Sigma-Aldrich) for 20 min at 4°C. Next, cells were stained intracellularly with 
CD154-PE and IFN-γ-APC-labeled MoAbs, and analyzed by flowcytometry.  
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Generation of HLA-DPB1 specific CD4+ T-cell clones
To analyze the diversity of HLA-DPB1*14:01 specific CD4+ T-cell responses, HLA-DPB1*14 
specific CD4+ T-cells were clonally isolated from a T-cell line generated as described above. 
At day 14 restimulation was performed, and after 4 hours of incubation, activated IFN-γ 
producing CD4+ T-cells were stained using the IFN-γ capture assay (Miltenyi Biotec GmbH) 
according to the manufacturer’s instructions. PE labeled IFN-γ producing CD4+ T-cells were 
stained with anti-CD4-APC conjugated moAbs and counterstained with propidium iodide 
(PI, Sigma) immediately prior to cell sorting to exclude dead cells. Viable (PI-negative), 
CD4 positive IFN-γ secreting lymphocytes were sorted single cell per well into U-bottom 
microtiter plates (Greiner Bio-One, the Netherlands) containing 100μl feeder mixture 
consisting of culture medium supplemented with IL2 (120 IU/ml), phytohemagglutinin 
(PHA, 0.8μg/ml, Murex Biotec Limited, Dartford, UK), and 50 Gy-irradiated allogeneic 
third-party PB-MNC (0.05x106/ml). Proliferating T-cell clones were selected and further 
expanded using non-specific stimulation and third party feeder cells. 
Results
HLA-DP transduced HeLa-II cells as antigen presenting cells
To study recognition of HLA-DP molecules we used HLA class II negative HeLa cells 
transduced with different HLA-DP molecules as antigen presenting cells (APC). By using 
the same APC in all experiments, the variability between different stimulations was limited 
to the expression of different HLA-DP molecules. Since HeLa cells do not endogenously 
express HLA class II molecules we first transduced CD80, Ii and HLA-DM into the HeLa cells 
(HeLa-II) in order to allow appropriate co-stimulation and processing of transduced HLA-
DP molecules. Next, HeLa-II cells were transduced with different combinations of HLA-
DPA1 and HLA-DPB1 molecules. HLA-DPB1 molecules were co-transduced with HLA-DPA1 
molecules found in positive linkage disequilibrium in different populations.23 (table 1) 
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Cross-recognition of HLA-DPB1 molecules by different HLA-DPB1 specific CD4+ T-cell 
clones
To analyze whether CD4+ T-cell clones with different HLA-DPB1 specificities showed similar 
cross-recognition patterns as previous demonstrated19,20 we tested HLA-DPB1*02:01, HLA-
DPB1*03:01 or HLA-DPB1*04:01 specific CD4+ T-cell clones expressing different TCR-Vβ 
for recognition of 12 different HLA-DPB1 molecules. HLA-DPB1 specific CD4+ T-cells have 
previously been isolated from 2 patients during clinical immune responses following HLA-
DPB1 mismatched SCT and DLI.22 In figure 1 cross-recognition patterns of the different 
Table 1. HLA-DP constructs used for transduction










01:01 01:01 02:01 3,6 4
02:01 02:01 01:03  10,9 3
03:01 03:01 01:03 12,6 2
04:01 04:01 01:03 40,9 4
04:02 04:02 01:03 13 4
05:01 05:01 02:02 3,2 4
06:01 06:01 01:03 2,4 4
09:01 09:01 02:01 1,2 1
11:01 11:01 02:01 2,4 4
13:01 13:01 02:01 1,2 4
14:01 14:01 02:01 1,6 2
17:01 17:01 02:01 2,4 1
1 Construct names for combination of HLA-DPB1 and HLA-DPA1 molecules used for transduction into 
HeLa-II cells or EBV-LCL. 
2 Frequencies of HLA-DPB1 molecule in northern European po pulation according to Begovich et al.23 
3 HLA-DPB1 molecules were previously classified in 4 immunogenicity groups: highly immunogenic 
(group 1), intermediate immunogenic (group 2 and 3) or low immunogenic (group 4)21
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24-a 20 - 337 - - 726 - - - - - - - 
24-b 7.1 - - - - 764 - - - - - - - 
24-c 12 - - - - 632 - - - - - - - 
24-d 9 - 346 - - 834 - - - - - - - 
24-e ? - - - - 733 - - - - - - - 
25-a 13.1 - - 930 446 - - - - - - - - 
25-b 12 - - 871 - - - - - - - - - 
25-c 17 - - 869 - - 163 - - - - 437 - 
25-d 7.1 - - 950 840 - - - - - 914 919 - 
25-e 9 - - 867 500 - - - - - - - - 
25-f ? - - 857 610 - - - - - - - - 
A.                 
HLA-DPB1*02:01  
Specific CD4+  
T cell clones      
B.                
HLA-DPB1*03:01  
Specific CD4+  
T cell clones      
C.                
HLA-DPB1*04:01  
Specific CD4+  
T cell clones      
28-a 12 - - - - - - 437 - - - - - 
28-b 17 - - - - - 181 651 - - - - - 
28-c 13.2 - - - - - - 484 - - - - - 
28-d 21.3 - - - - - 868 679 - - - - - 
28-e ? - - - - - - 915 633 - - - 749 
Clone   TCR-Vβ 
Group 1 Group 2 Group 3 Group 4 
09:01 17:01 03:01 14:01 02:01 01:01 04:01 04:02 05:01 06:01 11:01 13:01 
Figure 1. Differential cross-recognition of HLA-DPB1 molecules by CD4+ T-cell clones with 
the same HLA-DPB1 specificity.  Different HLA-DPB1*02:01 (n=5), *03:01 (n=6) or *04:01 (n=5) 
specific CD4+ T-cell clones, identified by different TCR-Vβ expression, were tested for recognition of 12 
different HLA-DP transduced HeLa-II cell lines. Each row represents recognition of the 12 different HLA-
DPB1 molecules by one CD4+ T-cell clone. Overnight IFN-γ production measured in 50µl supernatant 
is shown (pg/ml). “- “ indicates less than 100 pg/ml IFN-γ measured. (A) HLA-DPB1*02:01 specific CD4+ 
T-cell clones were isolated during the clinical immune response to DLI from an HLA-DPB1*04:02, 05:01 
typed donor. (B) HLA-DPB1*03:01 specific CD4+ T-cell clones were isolated during the clinical immune 
response to DLI from an HLA-DPB1*04:02, 05:01 typed donor. (C) HLA-DPB1*04:01 specific CD4+ T-cell 
clones were isolated during the clinical immune response to DLI from an HLA-DPB1*03:01,04:02 typed 
donor. 
CD4+ T-cell clones is shown. Individual CD4+ T-cell clones directed against the same HLA-
DPB1 allele exhibited different patterns in cross-recognition demonstrating that the CD4+ 
T-cell clones were specific for different epitopes. Interestingly, in accordance to previous 
reports19,27,28, most HLA-DPB1*03 specific CD4+ T-cell clones showed cross-recognition of 
HLA-DPB1*14:01, illustrating the similarity of these two HLA-DPB1 molecules. In addition, 
HLA-DPB1*02:01 and HLA-DPB1*03:01 specific CD4+ T-cell clones showed cross-




Generation of HLA-DPB1 specific CD4+ T-cell responses in vitro
To analyze whether frequently observed cross-reactivity between specific HLA-DPB1 
molecules influenced mutual immunogenicity, we developed a model to generate allo-
HLA-DP responses in vitro. In this model we stimulated purified CD4+ T-cells form healthy 
individuals with HeLa-II cells transduced with different HLA-DPB1 molecules and analyzed 
their specificity at day 14 after stimulation.
First, we analyzed the capacity of HLA-DP transduced HeLa-II cells to induce HLA-DPB1 
specific CD4+ T-cell responses in vitro. We purified CD4+ T-cells from a cryopreserved 
fraction of DLI stored for one of the patients described above22,29, and stimulated 
these donor derived CD4+ T-cells with HLA-DPB1*03 transduced HeLa-II cells. 14 days 
after stimulation CD4+ T-cells were tested for specific recognition of the cell line used 
for stimulation by intracellular IFN-γ measurement as well as IFN-γ ELISA. Specific IFN-γ 
production was observed by 8-12% of CD4+ T-cells in response to restimulation with HLA-
DPB1*03 transduced HeLa-II cells and not in response to HeLa-II cells transduced with 
control HLA-DPB1 molecules or HLA-DP negative HeLa-II cells, illustrating a high frequency 
of HLA-DPB1 specific CD4+ T-cells (data not shown). Similarly, in IFN-γ ELISA specific 
recognition of HLA-DPB1*03 transduced HeLa-II cells and not HeLa-II cells transduced 
with control HLA-DPB1 molecules or HLA-DP negative HeLa-II cells was shown. Specificity 
for allo-HLA-DPB1*03 of the CD4+ T-cell line was further confirmed by specific recognition 
of HLA-DPB1*03 transduced autologous responder EBV-LCL (Figure 2A). 
To confirm specific recognition of HLA-DPB1*03 transduced HeLa-II cells and HLA-
DPB1*03 transduced responder EBV-LCL by a single CD4+ T-cell, HLA-DPB1*03 specific 
CD4+ T-cells were clonally isolated from this CD4+ T-cell line using the IFN-γ capture assay. 
In total 24 CD4+ T-cell clones using at least 8 different TCR-Vβ chains were expanded 
and tested for specific recognition of HLA-DPB1*03 (Figure 2B). The data showed that 
19 CD4+ T-cell clones specifically recognized both HLA-DPB1*03 transduced HeLa-II cells 
and HLA-DPB1*03 transduced autologous responder EBV-LCL. Five CD4+ T-cell clones 
only recognized HLA-DPB1*03 transduced HeLa-II cells probably representing recognition 
of polymorphic peptides or monomorphic cell type specific peptides presented in the 
transduced HLA-DP molecules. These results showed that HeLa-II cells transduced with 
HLA-DP molecules can be used as stimulator cells for in vitro induction of polyclonal HLA-
DPB1 specific CD4+ T-cell responses.     
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Figure 2. In vitro generation of an HLA-DPB1*03 specific CD4+ T-cell line. (A) CD4+ T-cells 
purified from an HLA-DPB1*04:02,05:01 typed responder were stimulated with HeLa-II cells transduced 
with HLA-DPB1*03:01. At day 14, CD4+ T-cells were tested for recognition of untransduced HeLa-II 
cells or responder EBV-LCL and HeLa-II cells or responder EBV-LCL transduced with HLA-DPB1*03 
or random control HLA-DPB1*02. IFN-γ release (pg/ml) in 50µl supernatant is shown after overnight 
incubation with different stimulator cells. (B) IFN-γ production from 24 HLA-DPB1*03 specific CD4+ 
T-cell clones in response to different stimulators was determined in 50µl supernatant. Recognition 
pattern shown in black bars was observed for 19 CD4+ T-cell clones whereas the recognition pattern 
shown by the white bars was observed for 5 CD4+ T-cell clones. 
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Strong and diverse HLA-DPB1 specific immune responses were generated between 
individuals expressing frequently cross-recognized HLA-DPB1 alleles.
To analyze whether frequently observed cross-reactivity between HLA-DPB1*03:01 and 
HLA-DPB1*14:01 resulted in low mutual immunogenicity we generated an HLA-DPB1*14:01 
specific immune response from an HLA-DPB1*03:01 typed responder using our model. 
We generated HLA-DPB1*17:01, HLA-DPB1*02:01 and HLA-DPB1*04:01 specific immune 
response from the same individual as a comparison. HLA-DPB1 molecules were selected 
based on their classification in different immunogenicity groups.21 Purified CD4+ T-cells 
were stimulated with HeLa-II cells transduced with the one of these 4 different HLA-DPB1 
molecules. 14 days after stimulation CD4+ T-cells were tested for specific recognition 
of the relevant HLA-DPB1 molecules used for stimulation. The generation of these four 
HLA-DPB1 specific immune responses was demonstrated by specific IFN-γ production 
in response to restimulation with the HLA-DPB1 molecule used for stimulation and not 
in response to responder HLA-DPB1 molecules (Figure 3A). Specificity for allo-HLA-DPB1 
of the CD4+ T-cell lines was confirmed by specific recognition of autologous responder 
EBV-LCL transduced with the relevant HLA-DPB1 molecules used for stimulation (data not 
shown).
To analyze whether there was a difference in frequencies of HLA-DPB1 specific CD4+ 
T-cells generated against the different HLA-DPB1 molecules, the number of responder 
cells used for restimulation were titrated in IFN-γ ELISA (Figure 3B). All 4 HLA-DPB1 
specific CD4+ T-cell lines showed significant IFN-γ release using 2 000 responder cells 
demonstrating a high frequency of HLA-DPB1 specific CD4+ T-cells in all these cell lines. 
To determine the diversity of this HLA-DPB1*14:01 specific immune response, CD4+ 
T-cells were clonally isolated. Twelve HLA-DPB1*14 specific CD4+ T-cell clones using 4 
different TCR-Vβ chains were tested for cross-reactive recognition of other HLA-DPB1 
molecules. Only one HLA-DPB1*14:01 specific CD4+ T-cell clone showed cross-recognition 
of HLA-DPB1*09:01, whereas 11 CD4+ T-cell clones showed no cross-recognition of other 
HLA-DPB1 molecules (data not shown). 
Next, we analyzed whether the HLA-DPA1 molecule contributed to the specificity of this 
allo-HLA-DP response. We analyzed whether recognition of allo-HLA-DPB1*14 depended 
on expression of the HLA-DPA1*02:01 molecule used for stimulation. Seven CD4+ T-cell 
clones were tested for recognition of HeLa-II cells tranduced with HLA-DPB1*14:01/
DPA1*02:01 and HeLa-II cells transduced with HLA-DPB1*14:01/HLA-DPA1*01:03. Similar 
membrane expression of the different HLA-DP constructs was confirmed by flowcytometry 
(data not shown). For 4 CD4+ T-cell clones recognition depended on the presence of HLA-
DPA1*02:01 used for stimulation since no IFN-γ production was observed in response 
to HeLa-II cells transduced with HLA-DPB1*14:01/DPA1*01:03 (Figure 3c). For 3 HLA-
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Figure 3. Comparable HLA-DPB1 specific immune response generated against HLA-DPB1 
molecules classified in 4 different groups.  (A) Purified CD4+ T-cells derived from a healthy HLA-
DPB1*03:01 typed individual were stimulated with HeLa-II cells transduced with HLA-DPB1*17:01, 
*14:01, *02:01 or *04:01. At day 14, 25 000 CD4+ T-cells from each cell line were restimulated with 
50 000 HLA-DPB1 transduced HeLa-II cells used for stimulation (■) or HeLa-II cells transduced with 
control responder HLA-DPB1*03:01 molecules (□). IFN-γ release (pg/ml) measured in 50µl supernatant 
upon restimulation is shown. (B) IFN-γ production of the 4 different HLA-DPB1 specific CD4+ T-cell 
lines in response to HLA-DPB1 transduced HeLa-II cells used for stimulation is shown using different 
numbers of responder cells. IFN-γ release was determined in 50μl supernatant following overnight 
incubation using 25 000, 10 000 or 2 000 responder cells. Immune responses generated against 
different HLA-DPB1 molecules are depicted using different symbols and lines. (C) Recognition of two 
representative HLA-DPB1*14:01 specific CD4+ T-cell clones in response to HeLa-II cells transduced with 
HLA-DPB1*14:01 combined with different HLA-DPA1 molecules. Specificity for HLA-DPB1*14 of the 
CD4+ T-cell clones is shown by recognition of responder EBV-LCL transduced with HLA-DPB1*14. IFN-γ 
production in 50μl supernatant was determined by ELISA. 
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cells transduced with a different HLA-DPα chain was preserved. CD4+ T-cell clones with 
the same TCR-Vβ as identified by antibody staining showed different recognition patterns 
further demonstrating the diversity of this immune response.
These data demonstrate that minor differences between HLA-DPB1 molecules 
expressed by stimulator and responder cells resulted in a high-frequency polyclonal CD4+ 
T-cell response.
HLA-DPB1 specific immune responses were generated from all HLA-DPB1 mismatch 
combinations
To determine immunogenicity of HLA-DPB1 molecules in multiple different stimulator/
responder combinations, CD4+ T-cells purified from 4 healthy individuals were stimulated 
with HeLa-II cells transduced with 11 different allo-HLA-DPB1 molecules. Responders were 
selected based on homozygous expression of HLA-DPB1*02:01, HLA-DPB1*03:01, HLA-
DPB1*04:01 or HLA-DPB1*04:02. In total 44 different stimulator/responder combinations 
were analyzed for the generation of allo-HLA-DPB1 specific immune responses. At day 14 
after stimulation, CD4+ T-cells were tested for specific recognition of the relevant HLA-DPB1 
molecules used for stimulation. HLA-DPB1 specific immune response were generated in 
42 out of 44 stimulations as demonstrated by specific IFN-γ production in response to 
restimulation with the HLA-DPB1 transduced HeLa-II cell lines used for stimulation and 
not in response to HeLa-II cells transduced with responder HLA-DPB1 molecules or HLA-
DP negative HeLa-II cells (Figure 4). Some CD4+ T-cell lines showed minor IFN-γ release in 
response to HeLa-II cells transduced with responder HLA-DPB1 molecules and HLA-DP 
negative HeLa-II cells which may be explained by non-HLA-DP restricted recognition of 
HeLa-II cells. 
As shown in figure 4, CD4+ T-cells were also stimulated with HeLa-II cells transduced 
with the autologous responder HLA-DPB1 molecule. IFN-γ production observed in response 
to HeLa-II cells transduced with the autologous HLA-DPB1 molecule illustrated that CD4+ 
T-cell responses could also be generated against polymorphic minor histocompatibility 
antigens30, 31 or cell-type specific peptides presented in ‘self’- HLA-DP.
These data demonstrate that HLA-DPB1 specific CD4+ T-cell responses can result 
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Figure 4. HLA-DPB1 specific immune responses can be generated from all HLA-DPB1 
mismatch combinations. Purified CD4+ T-cells derived from 4 different responders were stimulated 
with HeLa-II cells transduced with 12 different HLA-DPB1 molecules. At day 14, 25 000 CD4+ T-cells from 
each cell line were restimulated with 50 000 HLA-DPB1 transduced HeLa-II cells used for stimulation 
(■), HeLa-II cells transduced with autologous responder HLA-DPB1 (■) or HeLa-II cells without HLA-DP 
expression (□). IFN-γ release (pg/ml) measured in 50µl supernatant upon restimulation is shown.
Cross-recognition of HLA-DPB1 molecules by HLA-DPB1 specific CD4+ T-cells
To investigate whether we could identify additional patterns in cross-reactivity of HLA-
DPB1 molecules by HLA-DPB1 specific CD4+ T-cells, all HLA-DPB1 specific CD4+ T-cell lines 
shown in figure 4 were analyzed for cross-recognition of 12 different HLA-DPB1 molecules. 
Complete data sets of experiments from two representative responders are shown in 
figure 5. In figure 5A, cross-recognition of different HLA-DPB1 molecules by 12 HLA-DPB1 
specific CD4+ T-cell lines generated from an HLA-DPB1*03:01 typed responder (group 2)21 




A broad diversity in cross-reactivity between different HLA-DPB1 specific CD4+ 
T-cell lines was observed (Figure 5). CD4+ T-cell lines with the same HLA-DPB1 specificity 
generated from different responders showed cross-recognition of different HLA-DPB1 
molecules. This phenomenon is likely to be caused by a different TCR-repertoire present 
in each responder. 
Figure 5. Cross-recognition of 12 different HLA-DPB1 molecules by HLA-DPB1 specific CD4+ 
T-cells.  12 CD4+ T-cell lines specific for 12 different HLA-DPB1 alleles were tested for recognition 
of HeLa-II cells transduced with 12 different HLA-DPB1 molecules. Each row in one figure represents 
recognition of the 12 different HLA-DPB1 molecules by one CD4+ T-cell line. Gray boxes represent 
recognition of the specific HLA-DPB1 molecule used for stimulation for each CD4+ T-cell line. ‘++’ 
indicates more than 100pg/ml IFN-γ production in 50µl supernatant by 10 000 CD4+ T-cells upon 
restimulation with a specific HLA-DPB1 transduced HeLa-II cell line. ‘+’ indicates more than 100pg/
ml IFN-γ production in 50µl supernatant by 25 000 CD4+ T-cells upon restimulation with a specific 
HLA-DPB1 transduced HeLa-II cell line. (A) Results of 12 different HLA-DPB1 specific CD4+ T-cell lines 
generated from an HLA-DPB1*03:01 typed responder. (B) Results of 12 different HLA-DPB1 specific 
CD4+ T-cell lines generated from an HLA-DPB1*04:01 typed responder. 
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In total, 33 out of 42 HLA-DPB1 specific CD4+ T-cell lines showed cross-recognition 
of at least one other HLA-DPB1 molecule and a broad variety in cross-recognition of the 
different HLA-DPB1 specific CD4+ T-cell lines was observed. However, consistent patterns 
in cross-recognition reported in previous studies were observed. All HLA-DPB1*09 specific 
CD4+ T-cell lines (n=4) recognized HLA-DPB1*17 and vice versa. Furthermore, all HLA-
DPB1*03 specific CD4+ T-cell lines (n=3), generated from responders who did not express 
HLA-DPB1*03, showed cross-recognition with HLA-DPB1*14 and vice versa. Finally, 
HLA-DPB1*04:01 and HLA-DPB1*04:02 specific CD4+ T-cell lines generated from HLA-
DPB1*02:01 or HLA-DPB1*03:01 typed responders (n=2) showed cross-reactivity with 
each other. These cross-recognized HLA-DPB1 molecules were previously classified in 
different groups.19,21 Furthermore, we did not find additional patterns in cross-recognition. 
These data showed that the previously reported classification of HLA-DPB1 molecules 
in different immunogenicity groups was predictive for cross-recognition by HLA-DPB1 
specific CD4+ T-cells. 
Discussion
In this study we showed that all HLA-DPB1 mismatch combinations as defined by allele 
typing resulted in high-frequency polyclonal immune responses. As reported previously, 
cross-recognition of different HLA-DPB1 molecules by HLA-DPB1 specific CD4+ T-cell 
clones was a common observation. However, we demonstrated that frequently observed 
cross-reactivity between specific HLA-DPB1 molecules did not preclude the capacity to 
generate HLA-DPB1 specific immune responses between individuals expressing these 
HLA-DP molecules. These data illustrate that an algorithm defining permissive and non-
permissive mismatches for HLA-DPB1 alloreactivity can not be developed merely based 
on T-cell recognition patterns. 
We demonstrated that a single stimulation with a cell population expressing HLA-DP 
molecules in combination with relevant molecules involved in the HLA class II processing 
pathway resulted in high-frequency of HLA-DPB1 specific CD4+ T-cells in more than 95% 
of the different stimulator/responder combinations analyzed. Responder cells expressed 
one of the four most common HLA-DPB1 molecules present in northern-European 
population23 and 97% of SCT donors in our center expressed at least one of these HLA-
DPB1 molecules. HLA-DPB1 molecules used for stimulation comprised 76-99% of HLA-
DPB1 molecules present in different ethnic populations.23 We demonstrated that all HLA-
DPB1 mismatches as defined by allele typing were immunogenic. 
Our data confirmed previously described patterns in cross-recognition of HLA-DPB1 
molecules19,27,32, illustrating that the proposed classification of HLA-DPB1 molecules in 
different immunogenicity groups19, 21 was predictive for cross-recognition. The high degree 
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in similarity of amino acid sequences in the hypervariable region of HLA-DPB1 molecules 
classified within group 1 (HLA-DPB1*09 and HLA-DPB1*17) and group 2 (HLA-DPB1*03 
and HLA-DPB1*14) is likely to explain the frequently observed cross-reactivity between 
HLA-DPB1 molecules classified within these groups. In addition, we demonstrated a 
broad diversity of cross-recognition patterns by several other HLA-DPB1 specific CD4+ 
T-cell lines. We demonstrated that allo-HLA-DPB1 specific immune responses comprised 
a variety of T-cell clones apparently generated against different immunogenic epitopes. 
Cross-recognition patterns of these T-cell clones could often not simply be explained by 
the presence or absence of specific shared amino acid sequences in the hypervariable 
region of HLA-DPB1 (data not shown), illustrating the complexity of the three-dimensional 
structure of an HLA-DP-peptide complex for T-cell recognition. 
In this study we demonstrated a redundancy of epitopes against which allo-reactive 
T-cells can be generated. Not only differences in the HLA-DPB1 molecule but also the 
HLA-DPA1 molecule contributed to the specificity of allo-HLA-DP responses. Furthermore, 
previous reports have shown that substitutions of single amino acids in the HLA-DPB1 
molecule influenced T-cell recognition either by direct contact with the TCR or indirectly 
by changing the conformation of peptides presented in the groove.33 We demonstrated 
by generating immune responses against HeLa-II cells transduced with ‘self’-HLA-DPB1 
molecules that polymorphic peptides presented in ‘self’-HLA-DP were also capable of 
stimulating allo-responses. Although the magnitude of these immune responses was 
lower than allo-HLA-DP responses, it is known from HLA-matched donor recipient pairs 
that allo-immune responses directed against mHags presented in HLA class I or HLA class 
II are capable of inducing clinically significant allo-responses.34-37 In conclusion, although 
individuals expressing highly similar HLA-DPB1 molecules may clonally delete T-cells 
specific for shared epitopes, our data demonstrate that sufficient differences between the 
HLA-DPB1 molecules remain to mount strong allo-HLA-DPB1 specific immune responses. 
Although we demonstrated immunogenicity of all HLA-DPB1 mismatches, clinical 
studies showed a significant decrease in overall survival and higher risk for transplant 
related mortality for specific HLA-DPB1 mismatches.18,21,38 However, the studies also 
showed that these specific mismatches did not enhance GVHD or GVL-reactivity. Since 
both the risk of disease relapse and the risk of aGVHD did not significantly differ, the 
observed effect on overall survival may have resulted from mechanisms other than 
merely differences in alloreactivity between the HLA-DPB1 molecules. Specific HLA-DPB1 
molecules have been associated with an increased susceptibility to particular diseases.39-41 
The observed adverse effect on overall survival of some HLA-DPB1 mismatches may 
therefore be the result of indirect (immunologic) factors. For example the presence of 
a single nucleotide polymorphisms within the innate immunity receptor NOD2/CARD15 
between recipient and donor has been associated with a significant reduction in overall 
survival.42-44 Although the exact mechanisms by which these data can be explained are 
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not yet resolved, the observed effects are likely to be caused by indirect influences on the 
immune system as well.
In conclusion, we show that all HLA-DPB1 mismatches as defined by allele typing 
resulted in high frequency CD4+ T-cell responses. Furthermore, we show that cross-
recognition of HLA-DPB1 molecules is a broadly observed phenomenon and confirm 
previously described patterns in cross-reactivity. We demonstrate that frequently observed 
cross-reactivity between specific HLA-DPB1 molecules did not preclude allo-HLA-DPB1 
responses between individuals expressing these HLA-DPB1 molecules. Together these 
data demonstrate that a high degree in similarity between HLA-DPB1 alleles is predictive 
for cross-reactivity but not for immunogenicity and illustrate that T-cell recognition patterns 
may not predict allo-reactivity.
Acknowledgments
The authors thank M. van den Hoorn en G. de Roo for technical assistance with flow 
cytometric isolations. This work has been supported by a grant from the Dutch Cancer 
Society (grant number 05-3267) and by a grant from the European Union 6th Framework 




1. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 
2003;54:491-512.
2. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008 
Dec 1;112(12):4371-83.
3. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in 
human stem cell transplantation. Exp Hematol 2003 Sep;31(9):743-51.
4. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after 
allogeneic hematopoietic stem cell transplantation. Blood Rev 2003 Sep;17(3):153-62.
5. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 
1993;11:385-402.
6. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to 
the success of unrelated donor marrow transplantation. Blood 2007 Dec 15;110(13):4576-83.
7. Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation 
outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated 
with overall survival. Biol Blood Marrow Transplant 2007 Aug;13(8):965-74.
8. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution 
matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching 
is associated with a strong adverse effect on transplantation outcome. Blood 2004 Oct 
1;104(7):1923-30.
9. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible 
for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 
2007 Oct 1;110(7):2235-41.
10. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) 
allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, 
and HLA-DR matched unrelated donors. Blood 2002 Jun 1;99(11):4200-6.
11. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic 
cell transplantation. Blood 2004 Nov 1;104(9):2976-80.
12. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated 
donors: the impact of mismatches with substitutions at position 116 of the human leukocyte 
antigen class I heavy chain. Blood 2001 Nov 15;98(10):3150-5.
13. Macdonald WA, Purcell AW, Mifsud NA, et al. A naturally selected dimorphism within the HLA-B44 
supertype alters class I structure, peptide repertoire, and T-cell recognition. J Exp Med 2003 Sep 
1;198(5):679-91.
14. Heemskerk MB, Cornelissen JJ, Roelen DL, et al. Highly diverged MHC class I mismatches are 
acceptable for haematopoietic stem cell transplantation. Bone Marrow Transplant 2007 
Aug;40(3):193-200.
15. Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor 
hematopoietic cell transplantation. Blood 2007 Dec 15;110(13):4560-6.
Immunogenicity of HLA-DPB1
73
16. Cesbron A, Moreau P, Cheneau ML, et al. Crucial role of the third and fourth hypervariable regions 
of HLA-DPB1 allelic sequences in primary mixed-lymphocyte reaction: application in allogeneic 
bone marrow transplantation. Transplant Proc 1993 Feb;25(1 Pt 2):1232-3.
17. Kawase T, Matsuo K, Kashiwase K, et al. HLA mismatch combinations associated with decreased 
risk of relapse: implications for the molecular mechanism. Blood 2009 Mar 19;113(12):2851-8.
18. Ludajic K, Balavarca Y, Bickeboller H, et al. Impact of HLA-DPB1 allelic and single amino acid 
mismatches on HSCT. Br J Haematol 2008 Jul;142(3):436-43.
19. Zino E, Frumento G, Marktel S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles 
determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 2004 
Feb 15;103(4):1417-24.
20. Zino E, Vago L, Di TS, et al. Frequency and targeted detection of HLA-DPB1 T-cell epitope 
disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow 
Transplant 2007 Sep;13(9):1031-40.
21. Crocchiolo R, Zino E, Vago L, et al. Non-permissive HLA-DPB1 disparity is a significant independent 
risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood. 2009 Aug 
13;114(7):1437-44.
22. Rutten CE, Luxemburg-Heijs SA, van der Meijden E.D., Griffioen M., Oudshoorn M, Willemze R, et 
al. Both permissive and non-permissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 
specific immune responses in vivo and in vitro. Blood. 2010 Jan 7;115(1):151-3
23. Begovich AB, Moonsamy PV, Mack SJ, et al. Genetic variability and linkage disequilibrium within 
the HLA-DP region: analysis of 15 different populations. Tissue Antigens 2001 May;57(5):424-39.
24. Griffioen M, van Egmond HM, Barnby-Porritt H, et al. Genetic engineering of virus-specific T-cells 
with T-cell receptors recognizing minor histocompatibility antigens for clinical application. 
Haematologica 2008 Oct;93(10):1535-43.
25. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of 
peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific 
T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003 Nov 
15;102(10):3530-40.
26. Heemskerk MH, Blom B, Nolan G, et al. Inhibition of T-cell and promotion of natural killer 
cell development by the dominant negative helix loop helix factor Id3. J Exp Med 1997 Nov 
3;186(9):1597-602.
27. de Koster HS, Kenter MJ, D’Amaro J, et al. Positive correlation between oligonucleotide typing and 
T-cell recognition of HLA-DP molecules. Immunogenetics 1991;34(1):12-22.




29. Rutten CE, van Luxemburg-Heijs SA, Griffioen M, et al. HLA-DP as specific target for cellular 
immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia 2008 Jul;22(7):1387-94.,
30. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, et al. A class II-restricted cytotoxic T-cell 
clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. 
Br J Haematol 2005 Jan;128(1):73-81.
31. Matsushita M, Yamazaki R, Ikeda H, et al. Possible involvement of allogeneic antigens recognised 
by donor-derived CD4 cytotoxic T-cells in selective GVL-effects after stem cell transplantation of 
patients with haematological malignancy. Br J Haematol 2006 Jan;132(1):56-65.
32. Naruse TK, Nose Y, Kagiya M, et al. Cloned primed lymphocyte test cells recognize the fourth, 
fifth, and sixth hypervariable regions at amino acid positions 65-87 of the DPB1 molecule. Hum 
Immunol 1995 Feb;42(2):123-30.
33. Diaz G, Amicosante M, Jaraquemada D, et al. Functional analysis of HLA-DP polymorphism: a 
crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T-cell allorecognition and 
peptide binding. Int Immunol 2003 May;15(5):565-76.
34. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase 
type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci 
U S A 2008 Mar 11;105(10):3837-42.
35. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor 
histocompatibility antigens HA-1- or HA-2-specific T-cells can induce complete remissions of 
relapsed leukemia. Proc Natl Acad Sci U S A 2003 Mar 4;100(5):2742-7.
36. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. 
Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic 
targets in antitumor immunity. Blood 2009 Oct 22;114(17):3684-92.
37. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-
restricted human male-specific minor histocompatibility antigen involved in graft-versus-host 
disease. Blood 2002 Apr 15;99(8):3027-32.
38. Shaw BE, Fleischhauer K, Zino E, et al. Significant differences in outcome following unrelated 
donor HCT can be better predicted using an algorithm incorporating both allele and epitope level 
matching for HLA-DPB1. Bone Marrow Transplant. 43 (Supp 1S), 78. 2009. Abstract 416.
39. Begovich AB, Bugawan TL, Nepom BS, Klitz W, Nepom GT, Erlich HA. A specific HLA-DP beta allele 
is associated with pauciarticular juvenile rheumatoid arthritis but not adult rheumatoid arthritis. 
Proc Natl Acad Sci U S A 1989 Dec;86(23):9489-93.
40. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants 
in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009 May;41(5):591-
5.
41. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. 
Science 1993 Oct 8;262(5131):242-4.
42. Madrigal A, Shaw BE. Immunogenetic factors in donors and patients that affect the outcome of 
hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008 Jan;40(1):40-3.
43. Holler E, Rogler G, Brenmoehl J, et al. The role of genetic variants of NOD2/CARD15, a receptor 
of the innate immune system, in GvHD and complications following related and unrelated donor 
haematopoietic stem cell transplantation. Int J Immunogenet 2008 Aug;35(4-5):381-4.
Immunogenicity of HLA-DPB1
75
44. Mayor NP, Shaw BE, Hughes DA, et al. Single nucleotide polymorphisms in the NOD2/CARD15 
gene are associated with an increased risk of relapse and death for patients with acute leukemia 
after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007 Sep 
20;25(27):4262-9.

5 Patient HLA-DP specific CD4+ T-cells from HLA-DPB1 mismatched donor lymphocyte infusion can induce GVL-reactivity in the presence or absence of GVHD
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Clinical studies have demonstrated that HLA-DPB1 mismatched stem cell transplantation 
(SCT) is associated with a decreased risk of disease relapse and an increased risk of graft 
versus host disease (GVHD) compared to HLA-DPB1 matched SCT. In T-cell depleted SCT, 
mismatching of HLA-DPB1 was not associated with an increased risk of severe GVHD, 
whereas a significant decreased risk of disease relapse was still observed. To investigate 
whether patient HLA-DP specific CD4+ T-cell responses were frequently induced after T-cell 
depleted HLA-DPB1 mismatched SCT and donor lymphocyte infusion (DLI), we developed 
a method to screen for the presence of HLA-DP specific CD4+ T-cells using CD137 as 
activation marker and analyzed 24 patient-donor combinations. Patients suffered from 
various B-cell malignancies, multiple myeloma and myeloid leukemias. In 13 out of 18 
patients with a clinical response to DLI, patient HLA-DP specific CD4+ T-cells were detected 
after DLI, whereas these CD4+ T-cells were found in only 1 out of 6 patients without clinical 
responses to DLI. Eight patients developed significant GVHD. These data show that patient 
HLA-DP specific CD4+ T-cells frequently occur following HLA-DPB1 mismatched T-cell 
depleted SCT and DLI, and are associated with graft versus leukemia reactivity both in the 
presence and absence of GVHD.
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Introduction
Following allogeneic hematopoietic stem cell transplantation (SCT), donor derived T-cells 
recognizing mismatched antigens on residual malignant cells can induce strong graft 
versus leukemia (GVL) reactions. Treatment of patients with relapsed leukemia, lymphoma 
or multiple myeloma with allogeneic hematopoietic SCT followed by donor lymphocyte 
infusion (DLI) can result in long lasting complete remissions.1-6 Unfortunately, the beneficial 
GVL-effects of DLI are often accompanied by graft versus host disease (GVHD). To reduce 
the risk of GVHD, patient and donor are preferably matched for HLA-A, -B and -C, -DRB1 or 
also HLA-DQB1 (8/8 or 10/10 match).7-9  
HLA-DPB1 is often not taken into consideration in donor selection since the overall 
mortality of patients who underwent HLA-DPB1 matched or mismatched SCT did not 
statistically differ. However, HLA-DPB1 matching status did have an impact on GVL-
reactivity and GVHD.8;10-13 In T-cell depleted SCT, mismatching for HLA-DPB1 has been 
associated with a significant decreased risk of disease relapse without an increased risk 
of severe GVHD.11 The role of HLA-DP as transplantation antigen was confirmed by the 
isolation of polyclonal HLA-DP specific CD4+ T-cells from skin biopsies of patients with 
GVHD following HLA-DPB1 mismatched SCT.14;15 We previously demonstrated a profound 
GVL-effect with only minimal skin GVHD caused by polyclonal HLA-DP specific CD4+ T-cells 
in a patient responding to HLA-DPB1 mismatched DLI for a refractory chronic B-cell 
leukemia, suggesting that HLA-DP specific CD4+ T-cells can be involved in GVHD, but also 
in selective GVL-reactivity.5
The beneficial effect of mismatching for HLA-DPB1 in T-cell depleted SCT on disease 
relapse has been reported to be more pronounced in acute lymphoblastic leukemia (ALL) 
compared to myeloid leukemias16. High expression of HLA-class-II molecules including 
HLA-DP is found on most B-ALL and B-chronic lymphocytic leukemia (CLL) cells, whereas 
myeloid leukemic cells show more variable expression of HLA-DP. However, HLA-DP 
expressing myeloid leukemic cells have been demonstrated to be recognized and lysed 
by HLA-DP specific CD4+ T-cells.5;17 Both B-cell and myeloid hematological malignancies 
with sufficient HLA-DP expression may therefore be susceptible to an HLA-DP mediated 
GVL-effect.
The aim of this study was to investigate whether HLA-DP specific CD4+ T-cell 
responses frequently occur after HLA-DPB1 mismatched allo-SCT and DLI, and whether 
the development of patient HLA-DP specific CD4+ T-cell responses was associated with 
beneficial clinical responses (GVL-effect) or GVHD. We therefore analyzed HLA-DP specific 
immune responses and clinical responses in 24 patients after 10/10 matched, HLA-DPB1 
mismatched T-cell depleted SCT who were treated with DLI. 
To analyze the emergence of an allo-HLA-DP specific immune response after 
administration of DLI, we developed an assay to screen for allo-HLA-DP specific CD4+ 
T-cells. In this assay we used HLA-class-II negative HeLa-cells transduced with all molecules 
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relevant for HLA-class-II processing as stimulator cells and transduced patient or donor 
specific HLA-DP molecules into these cells to measure the emergence of patient HLA-DP 
specific CD4+ T-cells in peripheral blood (PB). Using these HLA-DP transduced HeLa-cells 
we introduced patient and donor HLA-DPB1 molecules as single variables to detect HLA-
DP specific immune responses. Patient HLA-DP specific CD4+ T-cells were found in 72% of 
the patients in whom a clinical response was observed following DLI, but only in  one out 
of six patients (17%) without a clinical response to DLI. Patient HLA-DP specific CD4+ T-cells 
were found in patients with GVHD and in patients with selective GVL-reactivity without 
GVHD. HLA-DP specific CD4+ T-cell responses were observed in patients suffering from 
B-cell malignancies, multiple myeloma and myeloid leukemias. 
Materials and Methods
Cell collection and preparation
PB samples were obtained from patients and healthy stem cell donors after approval by 
the LUMC institutional review board and informed consent according to the Declaration 
of Helsinki. Samples were collected during standard follow-up following SCT and DLI 
(ie 6 weeks, 3 months and 6 months after DLI). In some individuals additional samples 
were available. Mononuclear cells (MNC) were isolated by Ficoll-Isopaque separation and 
cryopreserved. Stable Epstein-Barr virus (EBV)-transformed B cell lines were generated 
using standard procedures. EBV-LCL and HeLa-cells were cultured in Iscove’s modified 
Dulbecco’s Medium (IMDM, BioWhittaker, Verviers, Belgium) supplemented with 10% fetal 
bovine serum (FBS, BioWhittaker). 
Patient selection and characteristics
In total 24 patients who received a 10/10 matched, HLA-DPB1 mismatched T-cell depleted 
SCT followed by DLI between 2000 and 2008 were included in this study (Table 1). 
Patients suffered from multiple myeloma (n=8), B-cell malignancies (n=7) and myeloid 
leukemias (n=9). 15 patients received a single DLI and 9 patients received two or more 
DLIs. Indications for DLI included mixed chimerism, persistent or progressive disease and 
EBV-post-transplant-lymphoproliferative disorder. Leukocyte chimerism as determined by 
short tandem repeats was determined in bone marrow. In the absence of relapse or GVHD 
the level of mixed chimerism was stable in the first months after SCT. DLI was administered 
as intention to treat according to standard protocol. The first DLI was given between 4 
months and 26 months after SCT. At 4 months 0.15*10e6 CD3+ T-cells were administered. 
At 6 months 1.5*10e6 CD3+ T-cells were given for mixed chimerism or persistent disease 
and 2.5*10e6 CD3+ T-cells for progressive disease. At 9 months 2.5*10e6 CD3+ T-cells 
were administered. Dose escalation to a maximum of 5*10e7 CD3+ T-cells was used in 
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patients receiving subsequent DLIs. The first DLI was freshly harvested and for subsequent 
DLIs cryopreserved material was used.
Flowcytometry
The monoclonal antibodies (moAb) anti-CD3 fluorescein isothiocyanate (FITC), anti-
Nerve Growth Factor Receptor (NGFR)-phycoerythrin (PE), anti-CD4 Peridinin Chlorophyll 
Protein (PerCP), anti-CD137 allophycocyanin (APC) and anti-interferon-γ (IFN-γ)-APC were 
obtained from Becton Dickinson (BD, San Jose , CA, USA). Anti-CD154-PE was obtained 
from Beckman Coulter (Fullerton, CA, USA). Anti-HLA-DP-PE moAbs were purchased from 
Leinco Technologies (St. Louis, MO, USA). Flowcytometric analysis was performed on a BD 
flowcytometer. Cell sorting was performed using a BD FACSAria cell-sorting system. 
Transduction with different HLA-DP constructs
HeLa-cells and EBV-LCL were transduced with different HLA-DPA1 and HLA-DPB1 
molecules as described previously.18 Briefly, HeLa-cells were transduced with CD80, HLA-
DM and Invariant chain (HeLa-II cells) to allow appropriate costimulation and processing 
of HLA-DP molecules. Purified HeLa-II cells were subsequently transduced with different 
combinations of HLA-DPA1 and HLA-DPB1 molecules and selected based on positive 
staining with anti-HLA-DP-PE antibodies. HLA-DP transduced EBV-LCL were selected 
based on marker gene expression.
Characterization of HLA-DP specific CD4+ T-cells in PBMNC
To validate the use of HLA-DP transduced HeLa-II cells as stimulator cells to detect HLA-
DP specific CD4+ T-cells in PB, we used PBMNC from a patient in whom we previously 
demonstrated a profound HLA-DPB1*03:01 specific immune response. To determine the 
optimal method to detect HLA-DP specific CD4+ T-cells, percentages of activated CD4+ 
T-cells using different activation markers after various incubation periods were compared. 
Cryopreserved PBMNC were thawed, and CD4+ T-cells were positively selected using 
magnetic CD4-beads (Miltenyi Biotec GmBH, Bergisch Gladbach, Germany) according 
to the manufacturer’s instructions. 0.1x10e6 purified CD4+ T-cells were stimulated with 
0.03x10e6 control HeLa-II cells or cells transduced with patient HLA-DPB1*03:01 or donor 
HLA-DPB1*04:02 for 6 to 44 hrs in 150μl culture medium supplemented with 10% human 
serum and 10 IU/ml IL-2 (Chiron, Amsterdam, the Netherlands). 
For intracellular IFN-γ and CD154 staining, cells were incubated in the presence of 
10μg/ml Brefeldin-A (Sigma-Aldrich, St Louis, MO, USA), harvested after 6, 10 or 18 hrs 
of incubation, surface stained with CD4-FITC and CD3-PerCP-labeled MoAbs, fixed with 
1% paraformaldehyde and permeabilised using 0.1% Saponin (Sigma-Aldrich). Next, cells 




























1 Multiple myeloma 9 Persistent disease 0.30 Yes Grade III (2) No Systemic Thalidomide Deceased 2 months after 
DLI due to GVHD          
2 Multiple myeloma 9 Mixed chimerism 0.29 Yes Grade I (9) Extensive 4 Systemic
3 Multiple myeloma 2 EBV-PTLD 0.17 Yes Grade IV (5) Extensive 4 Systemic R-CHOP for PTLD Measured during 
prednisone treatment 
for PTLD
4 Multiple myeloma 9 Persistent disease 0.43 Yes Grade I (13) Extensive 4 Systemic
5  MCL 4 Mixed chimerism 0.16 / 0.25 Yes Grade II (13) No Systemic
6 CLL 10 Progressive disease 4.50 N.I 1 Grade IV (5) No Systemic  R-CHOP and
 Radiotherapy
Deceased 2 months after 
DLI due to pulmonary 
distress possibly GVHD/
BOOP













8 AML 8 Mixed chimerism 0.15 No Grade I (12) Extensive  4 Systemic
9 CML 10 Molecular relapse 0.31 Yes No No
10 AML 4 Mixed chimersm 0.21 Yes No No
11 WM 7 Persistent disease 3.08 / 0.92 Yes Grade I (11) No Local
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20 B-ALL 6 Mixed chimerism No No No Limited (6) Local


























24 NHL 8 Progressive disease 0.36 No No Limited (3) Local Rituximab Deceased 4 months after 
DLI due to progressive 
disease
GVM indicates graft versus myeloma; WM Waldenstrom macroglobulinemia; MCL Mantle cell lymphoma; 
CLL, Chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic 
leukemia; MDS, myelodysplastic syndrome; EBV-PTLD, Ebstein-Barr virus-induced posttransplantation 
lymphoproliferative disease; R-CHOP, Rituximab-Cyclophosphamide Doxorubicin Vincristine 
Prednisolone; BOOP, Bronchiolitis obliterans with organizing pneumonia; and AIHA, Auto Immune 
Hemolytic Anemia.
1 N.I. indicates Not Interpretable; patient died due to multi organ failure before follow-up analysis was 
performed
2 Late indicates response observed > 6 months after DLI 
3 IFN-α indicates IFN-α given at time of DLI to enhance immune response
4 acute GVHD followed by chronic GVHD
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To determine the expression of surface CD154 and CD137, cells were harvested after 
16, 22 or 44 hrs of incubation, washed, surface stained with CD4-FITC, CD3-PerCP, CD154-
PE and CD137-APC-labeled MoAbs and analyzed. 
To confirm specificity of CD137 expressing CD4+ T-cells, 0.75x10e6 purified CD4+ 
T-cells were stimulated with 0.15x10e6 HLA-DPB1*03:01 transduced HeLa-II cells and 
after 44 hrs of incubation, CD137 expressing CD4+ T-cells were sorted single cell per well 
into U-bottom microtiter plates (Greiner Bio-One, the Netherlands). Proliferating CD4+ 
T-cell clones were expanded using nonspecific stimulation and third-party feeder cells. 
IFN-γ production in response to HLA-DPB1*03:01 or HLA-DPB1*04:02 transduced HeLa-II 
cells, donor EBV-LCL or HLA-DPB1*03:01 expressing EBV-LCL was tested. To determine 
IFN-γ production, 5 000 CD4+ T-cells were cocultured with 30 000 stimulator cells in 150μl 
medium. After overnight incubation, supernatants were harvested and IFN-γ production 
was measured by enzyme-linked immunosorbent assay (ELISA; CLB, Amsterdam, the 
Netherlands). 
Analysis of HLA-DP specific CD4+ T-cells after allo-SCT and DLI in 24 patients
To quantify the presence of HLA-DP specific CD4+ T-cells in PBMNC, CD4+ T-cells 
derived from donors and from patients after SCT before and after DLI were analyzed 
for the expression of CD137 in response to stimulation with patient or donor HLA-DPB1 
molecules. Samples obtained 6 weeks to 6 months after DLI were analyzed according to 
availability and moment of clinical response. CD4+ T-cells were positively selected from 
PBMNC using magnetic CD4-beads (Miltenyi Biotec) according to the manufacturer’s 
instructions. 0.15x10e6 CD4+ T-cells were stimulated with 0.03x10e6 HeLa-II cells, HeLa-II 
cells transduced with donor or shared HLA-DPB1 molecules or HeLa-II cells transduced 
with patient specific HLA-DPB1 molecules in 150μl IMDM supplemented with 10% human 
serum and 10 IU/ml IL-2. After 44 hrs of incubation, CD137 expression on CD3+/CD4+ 
T-cells was analyzed using flowcytometry.
Clinical responses following HLA-DPB1 mismatched T-cell depleted allo-SCT and DLI
Clinical responses to DLI were defined as beneficial clinical responses or GVHD. Beneficial 
clinical responses were defined as a sustained increase in donor chimerism to  ≥ 99% 
donor cells, or a decrease of malignant cells or disease marker resulting in either 
complete disappearance or a reduction of more than 90%. Clinically important GVHD was 
considered present in case of acute GVHD (aGVHD) grade 2 or more or extensive chronic 
GVHD (cGVHD). aGVHD was graded according to Glucksberg criteria and cGVHD according 
to Shulman criteria. Lesions of the mouth matching criteria for cGVHD in the absence of 
other signs of cGVHD were classified as limited cGVHD. Clinical data were analyzed by a 
hematologist who was not informed of the presence or absence of HLA-DP specific CD4+ 
T-cells. 
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Statistical analysis
To determine whether there was a significant association between the presence of patient 
HLA-DP specific CD4+ T-cells and clinical responses two tailed Fisher’s exact test was used. 
To determine whether there was a statistically significant difference in magnitude between 
T-cell responses directed against permissive compared tot non-permissive mismatches, 
Student’s T-test after logarithmic transformation was used.
Results
Detection and isolation of HLA-DP specific T-cells 
To allow quantitative analysis of patient specific allo-HLA-DP responses in patients treated 
with HLA-DPB1 mismatched T-cell depleted allo-SCT and DLI, we developed a method to 
screen for patient HLA-DP specific CD4+ T-cells in PB using HLA-class-II negative HeLa-cells 
transduced with all molecules relevant for HLA-class-II processing and different HLA-DP 
molecules as stimulator cells. Transduction of the same stimulator cells with patient or 
donor specific HLA-DP molecules as single variables allowed detailed analysis of patient 
HLA-DP specific CD4+ T-cell responses. 
To  validate the use of HLA-DP transduced HeLa-II cells as stimulator cells to detect 
HLA-DP specific CD4+ T-cells in PB, we used PBMNC from a patient in whom we previously 
demonstrated a profound HLA-DPB1*03:01 specific CD4+ T-cell response. This patient 
was transplanted with a 10/10 matched, HLA-DPB1 mismatched SCT followed by DLI 
for relapsed chronic B-cell leukemia.5 Purified CD4+ T-cells isolated from PBMNC from 
the peak of the immune response 14 weeks after DLI were stimulated with HeLa-II cells 
transduced with patient HLA-DPB1*03:01 or donor HLA-DPB1*04:02. We compared the 
percentages of activated CD4+ T-cells using different markers after various incubation 
periods. Specific activation of CD4+ T-cells was found after stimulation with HeLa-II cells 
transduced with patient HLA-DPB1*03:01, but not with donor HLA-DPB1*04:02, indicating 
that HLA-DP transduced HeLa-II cells can be used as stimulator cells to detect allo-HLA-DP 
specific CD4+ T-cells (Figure 1). Upon stimulation with patient HLA-DPB1*03:01, maximum 
intracellular IFN-γ and CD154 staining was found after overnight incubation showing 
0.84% and 1.28% activated CD4+ T-cells, respectively. Stimulation with donor specific HLA-
DPB1*04:02 did not result in activated CD4+ T-cells as compared to background staining 
(0.12% for both IFN-γ and CD154 expression) (Figure 1A). After stimulation with patient 
HLA-DPB1*03:01, maximum surface CD137 or CD154 expression was found after 44 hrs 
of incubation, resulting in 4.36% and 3.92% activated CD4+ T-cells respectively. Stimulation 
with donor HLA-DPB1*04:02 resulted again in only background CD137 (0.07%) and CD154 
(0.20%) expression (Figure 1B). 
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Analysis of CD137 expression after different incubation times was repeated in 
independent experiments with similar results (Figure 1C). Based on these results and 
favorable kinetics of CD137 expression on CD4+ T-cells shown by us and others19-21, CD137 
was selected as activation marker to perform further experiments.
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Figure 1.  Kinetics of different activation markers to detect patient HLA-DP specific CD4+ 
T-cells directly ex vivo. PBMNC from a patient (HLA-DPB1*02:01,03:01) transplanted for a chronic 
B cell leukemia with an HLA-DPB1 mismatched donor (HLA-DPB1*04:02,05:01) were analyzed for the 
presence of HLA-DPB1*03:01 specific CD4+ T-cells. Purified CD4+ T-cells obtained during the clinical 
response to DLI were stimulated with HeLa-II cells transduced with donor or patient specific HLA-
DPB1 molecules. (A) After 6 - 18 hrs of incubation, intacellular IFN-γ (upper panel) or CD154 (lower 
panel) staining was determined by flowcytometry. (B) After 16 – 44 hrs of incubation, surface CD137 
(upper panel) and CD154 (lower panel) expression was determined by flowcytometry. (C) Percentages 
of CD137 expressing CD4+ T-cells after incubation with either patient HLA-DPB1*03:01 (■), donor HLA-
DPB1*04:02 (■) or medium alone (□) was determined at different time points. Mean results ± SD of 2-4 
individual experiments are shown
To confirm the specificity of CD137 expressing CD4+ T-cells for patient HLA-
DPB1*03:01, we clonally isolated CD137+/CD4+ T-cells by flowcytometry, and tested 
growing T-cell clones for specific recognition of HLA-DPB1*03:01. A total number of 46 
CD4+ T-cell clones were expanded, and 41 (89%) of these CD4+ T-cell clones showed 
specific recognition of both HeLa-II cells transduced with HLA-DPB1*03:01 as well as EBV-
LCL with endogenous HLA-DPB1*03:01 expression, whereas HeLa-II cells transduced 
with donor HLA-DPB1*04:02 and EBV-LCL with endogenous HLA-DPB1*04:02 were not 
recognized. These results confirmed specificity of CD137 expressing CD4+ T-cells for the 
allo-HLA-DPB1*03:01 molecule, and confirmed that this method can be used to measure 
HLA-DP specific CD4+ T-cells directly ex vivo.
Patient HLA-DP specific CD4+ T-cells are frequently detected following T-cell depleted 
HLA-DPB1 mismatched SCT and DLI
To analyze the presence of HLA-DP-specific CD4+ T-cell responses after HLA-DPB1 
mismatched allo-SCT and DLI, we analyzed immune responses in 24 patients. All patients 
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received a T-cell depleted HLA-A, -B, -C, -DRB1, -DQB1 matched, HLA-DPB1 mismatched allo-
SCT. Patients received DLI for various indications, including mixed chimerism, persistent or 
progressive disease (Table 1). CD4+ T-cells were obtained from donors, and from patients 
after SCT, before and after DLI. For each patient-donor combination, purified CD4+ T-cells 
were stimulated with control HeLa-II cells, and with HeLa-II cells transduced with donor 
specific, shared or patient specific HLA-DPB1 molecules. After 44 hrs of incubation CD137 
expression on CD4+ T-cells was determined.
Figure 2 shows a representative example of the analysis of HLA-DP specific CD4+ 
T-cells in a patient with a clinical response to DLI. This patient with multiple myeloma 
was typed HLA-DPB1*01:01,04:01 and the donor was typed HLA-DPB1*04:01,05:01. The 
patient received a single dose of 2.5x10e6 CD3+ T-cells for mixed chimerism 9 months 
after SCT resulting in conversion to 100% donor chimerism 3 month later (Figure 2A). 
Stimulation of donor derived CD4+ T-cells or CD4+ T-cells derived from the patient after 
SCT before DLI with HeLa-II cells transduced with donor HLA-DPB1*05:01, shared HLA-
DPB1*04:01 or patient specific HLA-DPB1*01:01 molecules did not result in significant 
CD137 expression (0.01%-0.07%). CD4+ T-cells obtained 6 weeks after DLI, however, 
showed 0.3% CD137+/CD4+ T-cells upon stimulation with patient HLA-DPB1*01:01, 
whereas no increase in CD137+/CD4+ T-cells was found in response to shared or donor 
specific HLA-DPB1 molecules (Figure 2B). These results illustrate the emergence of HLA-
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Figure 2. Emergence of patient HLA-DP specific CD4+ T-cells following HLA-DPB1 mismatched 
allo-SCT and DLI. (A) Percentage of donor chimerism in bone marrow after SCT. Arrow indicated DLI. 
Conversion to 100% donor chimerism was observed 3 months after DLI. (B) CD4+ T-cells purified from 
donor PBMNC, patient PBMNC obtained after SCT before DLI, and 6 weeks after DLI were stimulated 
with HeLa-II cells, HeLa-II cells transduced with donor HLA-DPB1*05:01 or shared HLA-DPB1*04:01, 
HeLa-II cells transduced with patient HLA-DPB1*01:01 or left unstimulated. Percentages of CD137 
expressing CD4+ T-cells are shown after 44 hrs of incubation. 
Using this method, we screened the 24 patients for the presence of patient HLA-
DP specific CD4+ T-cell responses. HLA-DP specific immune responses were defined as 
detection of >0.15% CD137+/CD4+ T-cells after stimulation with HeLa-II cells transduced 
with patient specific HLA-DPB1 molecules but not in response to donor or shared HLA-
DPB1 molecules. The cutoff of 0.15% was defined as a positive response based on 
background CD137 expression in response to HeLa-II cells or HeLa-II cells transduced with 
donor HLA-DPB1 molecules of less than 0.10% in all cases. Of the 24 patients, 9 individuals 
exhibited 2 patient specific HLA-DPB1 alleles different from the donor and 15 patients had 
only one patient specific HLA-DPB1 allele. In figure 3, percentages of CD137+/CD4+ T-cells 
for these 24 patients in response to stimulation with the 33 patient specific HLA-DPB1 
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Figure 3. HLA-DP specific CD137+/CD4+ T-cells observed after HLA-DPB1 mismatched allo-SCT 
and DLI in 24 individuals. A total number of 24 patient-donor combinations were analyzed for the 
presence of patient HLA-DP specific CD4+ T-cells. In total, percentages of CD137+/CD4+ T-cells in 
response to 39 donor or shared HLA-DPB1 molecules and 33 patient specific HLA-DPB1 molecules 
are shown. For each patient-donor combination, CD4+ T-cells purified from donor PBMNC and patient 
PBMNC obtained after SCT before DLI and after DLI were stimulated with HeLa-II cells transduced 
with donor or shared HLA-DPB1 molecules (○) or HeLa-II cells transduced with patient specific HLA-
DPB1 molecules (●). Percentages of CD137+/CD4+ T-cells are shown after 44 hrs of co-incubation with 
HeLa-II cells. Results were corrected for background CD137 expression on unstimulated CD4+ T-cells. 
For each patient-donor combination, representative results obtained after only one DLI are shown. 
HLA-DP specific immune responses were defined as detection of >0.15% CD137+/CD4+ T-cells after 
stimulation with HeLa-II cells transduced with patient specific HLA-DPB1 molecules based on <0.10% 
CD137+/CD4+ T-cells in response to donor specific or shared HLA-DPB1 molecules. Line represents the 
threshold of 0.15% for positive results. Results post-DLI represent the first DLI except for patients 14, 
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In 14 individuals, patient HLA-DP specific CD4+ T-cells were detected after DLI. Specific 
CD137+/CD4+ T-cells varying between 0.15% and 4.5% were measured after stimulation 
with HeLa-II cells transduced with patient HLA-DPB1 molecules but not in response to 
donor HLA-DPB1, including shared HLA-DPB1 molecules (0 – 0.07%). Patient HLA-DP 
specific CD4+ T-cells were determined in 9 of the 15 patients with a single HLA-DPB1 
mismatch, and in 5 of the 9 individuals with two HLA-DPB1 mismatches. Of the latter 5 
patients, 3 patients showed CD4+ T-cell responses to both mismatched HLA-DPB1 alleles. 
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In 12 of the 14 patients with detectable HLA-DP specific CD4+ T-cells, patient HLA-DP 
specific immune responses were likely to be induced by DLI, since CD137+/CD4+ T-cells 
were not found before DLI (0% - 0.09%). In the remaining 2 patients (patient 8 and 9), low 
percentages of HLA-DP specific CD4+ T-cells were also measured after SCT before DLI 
(0.16 and 0.25%). 
In summary, in 14 out of 24 (58%) patient-donor combinations analyzed patient HLA-
DP specific CD4+/CD137+ T-cells were found, indicating that HLA-DP specific CD4+ T-cell 
responses frequently occurred after HLA-DPB1 mismatched allo-SCT and DLI. 
Clinical responses following HLA-DPB1 mismatched T-cell depleted allo-SCT and DLI
We evaluated whether the presence of patient HLA-DP specific CD4+ T-cells following 
HLA-DPB1 mismatched T-cell depleted allo-SCT and DLI was related to clinical outcome. 
Clinical responses to DLI were defined as beneficial clinical responses or GVHD. In 18 of 24 
patients (75%), clinical responses to at least one of the DLIs were observed. In 5 patients 
(Table 1: patients 1-5) both a beneficial clinical response and GVHD were observed. 
3 patients (patients 6-8) developed GVHD without a beneficial clinical response. In 10 
patients (patients 9-18) selective beneficial responses without GVHD were observed. The 6 
remaining patients (patients 19-24) did not show any clinical response to DLI.
In figure 4A, percentages of patient HLA-DP specific CD137+/CD4+ T-cells are shown 
for patients with and without clinical responses after DLI. Patient HLA-DP specific CD4+ 
T-cells were observed in 13 out of 18 patients (72%) with clinical responses after DLI, and 
in only one of 6 patients (17%) without clinical responses following DLI. The latter patient 
(patient 24) suffered from lymphoma and died due to progressive disease 4 months after 
DLI. These results illustrate that the presence of patient HLA-DP specific CD4+ T-cells was 
associated with development of clinical responses after DLI (p=0.05).
In figure 4B, percentages of patient HLA-DP specific CD137+/CD4+ T-cells are shown 
for patients with GVHD after DLI and for patients who developed selective beneficial 
clinical responses. CD137+/CD4+ T-cells were detected in all patients with GVHD (patients 
1-8), and in 5 out of 10 patients with selective beneficial clinical responses (patients 9-13). 
These data illustrate an association between the presence of patient HLA-DP specific CD4+ 
T-cells and development of clinical significant GVHD (p=0.036). However, patient HLA-DP 













































Figure 4. HLA-DP specific CD137+/CD4+ T-cells in patients with and without clinical responses 
to DLI. Percentage of CD137+/CD4+ T-cells in response to stimulation with HeLa-II cells transduced 
with patient HLA-DPB1 molecules obtained after allo-SCT and DLI are shown. Results were corrected 
for background CD137 expression on unstimulated CD4+ T-cells. For 9 patients who were screened 
for CD4+ T-cells specific for 2 different patient specific HLA-DPB1 molecules, results for only one HLA-
DPB1 molecule with the highest percentage of CD137+/CD4+ T-cells are depicted. (A) Patient HLA-DP 
specific CD4+ T-cells were found in 13 out of 18 patients with clinical responses to DLI, and in one out 
of six patients without clinical response to DLI. (B) CD137+/CD4+ T-cells were found in all 8 patients 
with GvHD (in presence or absence of GVL), in 5 out of 10 patients who developed beneficial clinical 
responses without GVHD (selective GVL-reactivity). CD137+/CD4+ T-cells were detected in only one 
patient without clinical response to DLI.
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Figure 5. HLA-DP specific CD137+/CD4+ T-cells in response to permissive and non-permissive 
mismatches Percentage of CD137+/CD4+ T-cells in response to stimulation with HeLa-II cells 
transduced with patient HLA-DPB1 molecules obtained after allo-SCT and DLI are shown. Results 
were corrected for background CD137 expression on unstimulated CD4+ T-cells. CD137+/CD4+ T-cell 
responses to each HLA-DPB1 allele are depicted separately. The modified algorithm classifying HLA-
DPB1 alleles in 4 categories was used.19 Results of non-permissive and permissive HLA-DPB1 mismatch 



















Permissive and non-permissive HLA-DPB1 mismatches
To determine whether patient HLA-DP specific CD4+ T-cells were preferentially found in non-
permissive mismatch combinations compared to permissive mismatch combinations19;22, 
we analyzed the percentages of CD137+/CD4+ T-cells found after SCT and DLI in these 
two different groups. In 9 patients two mismatch HLA-DPB1 alleles were present in GVH 
direction. Each mismatched HLA-DPB1 allele was analyzed separately. (Supplemental 
Table S1)
In total, 19 permissive HLA-DPB1 mismatches and 14 non-permissive HLA-DPB1 
mismatches were present. Figure 5 shows the percentages of CD137+/CD4+ T-cells for 
each category. Patient HLA-DP specific CD4+ T-cells were found in both permissive and 
non-permissive mismatched combinations, showing a slightly higher median percentage 

















In this study, we developed an assay to screen patients for HLA-DP specific immune 
responses following HLA-DPB1 mismatched T-cell depleted SCT and DLI. Using HeLa-cells 
transduced with various genes encoding relevant molecules for appropriate HLA-class-II 
processing in conjunction with different HLA-DP molecules as stimulator cells, we were able 
to measure the emergence of patient HLA-DP specific CD4+ T-cells in PB in a simple and 
effective manner. Patient HLA-DP specific CD4+ T-cell responses were frequently found 
following HLA-DPB1 mismatched DLI (58%). The presence of HLA-DP specific CD4+ T-cells 
correlated with clinical responses to DLI, since patient HLA-DP specific CD4+ T-cells were 
measured in 13 (72%) out of 18 patients with clinical responses to DLI, and in only one 
(17%) out of 6 patients without clinical responses (p=0.05). HLA-DP specific CD4+ T-cells 
were most dominantly found in patients who developed GVHD, but patient HLA-DP specific 
CD4+ T-cells were also found in a significant number of patients who developed beneficial 
clinical responses without GVHD after DLI. HLA-DP specific CD4+ T-cell responses were 
induced in patients suffering from a variety of hematological malignancies, including 
multiple myeloma, B-cell malignancies and myeloid leukemias. 
Since alloreactive T-cells recognizing mismatched HLA-alleles are present in relatively 
high frequencies in PB23, HLA-mismatched SCT is likely to frequently induce alloimmune 
responses. Our study indeed demonstrates that mismatching for HLA-DPB1 frequently 
resulted in the generation of patient HLA-DP specific immune responses. In the majority of 
patients, HLA-DP specific CD4+ T-cells were not found in patient PBMNC obtained prior to 
DLI, indicating de novo induction of HLA-DP specific T-cell responses by DLI. Moreover, the 
high frequencies of patient HLA-DP specific T-cells after DLI reflected in vivo development 
and expansion of an anti-HLA-DP response in the patients, since in only two cases low 
frequencies of patient HLA-DP specific CD4+ T-cells could directly be detected in donor 
PBMNC. 
In this study, GVHD was associated with the presence of patient HLA-DP specific CD4+ 
T-cells. In the majority of patients, GVHD coincided with a beneficial clinical response. 
Patient HLA-DP specific CD4+ T-cells were, however, also found in patients with selective 
GVL-reactivity without GVHD, illustrating that HLA-DP specific CD4+ T-cells may induce 
GVL-responses in the presence or absence of GVHD.
HLA-DPB1 mismatched SCT may induce selective GVL-reactivity without GVHD since 
constitutive expression of HLA-class-II molecules is mainly restricted to hematopoietic 
cells. However, HLA-class-II expression on various tissues can be upregulated after 
exposure to pro-inflammatory cytokines. An HLA-DP specific immune response may 
result in GVHD if HLA-class-II molecules on non-hematopoietic tissues are upregulated 
as a consequence of conditioning regimens, infections or ongoing immune responses. 
In some patients with GVHD in this study, a pro-inflammatory environment may have 
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been induced by chemotherapy or radiotherapy administered prior to DLI. Alternatively, a 
profound HLA-DP specific GVL-response may induce pro-inflammatory cytokines, resulting 
in upregulation of HLA-class-II molecules on non-hematopoietic cells, thereby inducing 
GVHD. Furthermore, both GVHD and GVL-reactivity may have been mediated by the 
simultaneous development of immune responses directed against other molecules than 
HLA-DP. An inflammatory environment induced by minor histocompatibility antigen (MiHA) 
specific CD4+ or CD8+ T-cell responses4;6;24-27 may have provoked or enhanced HLA-DP 
specific immune responses. Since HLA-DP specific CD4+ T-cells were found both in the 
presence and absence of GVHD, it is likely that the development of GVHD is not solely 
determined by the induction of an HLA-DP specific immune response, but also by other 
immune responses and factors influencing HLA-class-II expression on non-hematopoietic 
cells.
Antigen presenting cells (APC) are required for efficient induction of anti-tumor immunity 
in vivo. In this study, HLA-DP specific CD4+ T-cells were found in patients with relapsed or 
persistent disease as well as in patients who received DLI for mixed chimerism. In patients 
with relapsed or persistent disease, malignant cells with sufficient HLA-DP expression may 
have served as APC to induce HLA-DP specific immune responses. Alternatively, crosstalk 
between CD4+ T-cells and leukemic cells may have induced an APC phenotype on leukemic 
cells, thereby amplifying HLA-class-II specific immune responses.28 In other patients, 
residual patient derived hematopoietic cells may have served as APC to induce HLA-DP 
specific CD4+ T-cell responses. Previous in vitro studies have demonstrated that HLA-
DP specific CD4+ T-cells were capable of recognizing and lysing multiple myeloma cells, 
B-cell malignancies and myeloid leukemic cells with sufficient HLA-DP expression.5;17;29;30 
Based on these in vitro experiments, HLA-DP specific CD4+ T-cells are expected to induce 
anti-tumor reactivity against a variety of hematological malignancies in-vivo. Indeed, 
in our study beneficial clinical responses after HLA-DPB1 mismatched alloSCT and DLI 
were found in patients suffering from multiple myeloma, various B-cell malignancies, and 
myeloid leukemia. 
In this study, 6 patients did not respond to DLI. Two patients had progressive disease 
at the time of DLI. In one of these patients HLA-DP specific CD4+ T-cells were found, but 
this patient died too early to benefit from the treatment. The other patient suffered from 
AML and immunotolerizing effects may have hampered the induction of an immune 
response. In 3 patients, DLI was administered at 99% donor chimerism. It is likely that in 
these patients numbers of patient derived HLA-class-II expressing APC were insufficient to 
induce an HLA-DP specific immune response. Accordingly, levels of patient chimerism did 
not change in time, reflecting a stable clinical situation in these patients. In the last patient 
mixed chimerism did not convert to 100% donor chimerism within 6 months after DLI. 
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 In 5 patients with a selective beneficial response to DLI, no HLA-DP specific CD4+ 
T-cells were found in samples available for analysis. Two patients (patients 14-15) received 
other treatments in the period that DLI was given. One patient received several drugs 
for multiple myeloma in combination with multiple DLIs, finally resulting in a sustained 
complete remission. The other patient received Rituximab and prednisone for repeated 
episodes of autoimmune hemolytic anemia and thrombocytopenia. In both patients the 
specific contribution of each drug or treatment to the clinical response could not be 
identified and the other treatments are likely to have hampered the analysis of HLA-DP 
specific CD4+ T-cells.
The other 3 individuals (patients 16-18) were treated with DLI for minimal residual 
disease as illustrated by molecular or cytogenetic but no hematological relapse. By clonal 
isolation of activated CD4+ T-cells we could demonstrate low numbers of patient HLA-
DP specific CD4+ T-cells in all 3 patients. (4%-20% of expanded CD4+ T-cell clones, data 
not shown). In these patients overall percentages of patient HLA-DP specific CD4+ T-cells 
were below the threshold of sensitivity of our screening method (0.10%). Since we could 
not unequivocally demonstrate that these HLA-DP specific CD4+ T-cells contributed to 
clinical responses we did not score them as positive results. However, even considering 
these responses as negative, statistical analysis revealed a significant correlation between 
the presence of HLA-DP specific CD4+ T-cells and development of clinical responses. 
Alternatively, we may have missed a significant response if PBMC were not collected at the 
optimal moment during immune responses. For MiHA specific CD8+ T-cells, we previously 
demonstrated that peak responses may not last more than 2 weeks.4;6;31;32 Kinetics of CD4+ 
T-cells are more difficult to study due to lack of HLA-class-II tetramers, but several studies 
showed long term persistence of alloreactive CD4+ T-cells.5;27;33 Alternatively, in some 
patients there may have been immune responses directed towards other mismatched 
antigens, including MiHAs. In two of these patients, we indeed successfully isolated low 
frequencies of MiHA specific CD8+ T-cell clones after DLI (data not shown). 
 In conclusion, in this study we show that HLA-DP specific CD4+ T-cells were frequently 
present in patients treated with T-cell depleted HLA-DPB1 mismatched allo-SCT and DLI for 
various hematological malignancies. HLA-DP specific CD4+ T-cells were found in patients 
with beneficial clinical responses both in the presence and absence of GVHD. It is likely 
that local environmental circumstances and induction of other immune responses may 
determine the balance between GVHD and GVL-reactivity in each individual. To investigate 
more specifically the effect of HLA-class-II mediated immune responses on GVL-reactivity 
and GVHD, a randomized clinical study is presently ongoing in our center to analyze the 
effect of purified CD4+ DLI early after transplantation on donor-chimerism, disease relapse 
and GVHD. 
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Following allogeneic hematopoietic stem cell transplantation (SCT), donor derived T-cells 
recognizing mismatched antigens on residual malignant cells can induce strong graft 
versus leukemia (GVL) reactions. Treatment of patients with relapsed leukemia, lymphoma 
or multiple myeloma with allogeneic hematopoietic SCT followed by donor lymphocyte 
infusion (DLI) can result in long lasting complete remissions.1-4 Unfortunately, the beneficial 
GVL-effects of DLI are often accompanied by graft versus host disease (GVHD). To reduce 
the risk of GVHD, patient and donor are preferably matched for HLA-A, -B and -C, -DRB1 or 
also HLA-DQB1 (8/8 or 10/10 match).5-7 
HLA-DPB1 is not taken into consideration in donor selection, since mismatching for 
HLA-DPB1 is not associated with decreased survival. HLA-DPB1 mismatched allo-SCT is 
however associated with an increased risk of graft versus host disease and a decreased 
risk of disease relapse compared to HLA-DPB1 matched SCT.6;8 In T-cell depleted allo-
SCT, mismatching of HLA-DPB1 was not associated with an increased risk of severe GVHD, 
whereas a significant decreased risk of disease relapse was still observed, suggesting a 
selective GVL-effect.9  In this thesis we investigated whether HLA-DP could be used as a 
relatively specific target for anti-leukemia reactivity following HLA-DPB1 mismatched T-cell 
depleted allo-SCT.
To investigate whether HLA-DP specific T-cells could mediate GVL-reactivity following 
HLA-DPB1 mismatched URD-SCT and DLI we analyzed in chapter 2 the immune response 
in a patient with a refractory chronic B cell leukemia responding to DLI after HLA-DPB1 
mismatched SCT. Patient and donor were fully matched for HLA-A, -B, -C, -DRB1 and –DQB1. 
The patient was typed HLA-DPB1*02:01,03:01 and the donor HLA-DPB1*04:02,05:01. We 
observed a profound GVL-effect with minimal skin GVHD resulting in a persistent complete 
remission of the disease. By ELISPOT analysis we identified the antileukemic CD4+ T-cell 
response starting 6 weeks after DLI. Following clonal isolation of these leukemia reactive 
CD4+ T-cells, blocking studies, panel studies and retroviral transduction experiments of 
the mismatched HLA-DPB1 alleles, identified both mismatched HLA-DPB1*02:01 and HLA-
DPB1*03:01 as the targets of this immune response. The GVL-effect was caused by a 
polyclonal immune response comprising both T-helper and cytotoxic CD4+ T-cells. Since 
the emergence and kinetics of the leukemia-reactive CD4+ T-cells corresponded to the 
disappearance of the malignant cells, these HLA-DP specific CD4+ T-cells were likely to 
have mediated the anti-leukemic effect. Furthermore, the isolated HLA-DP specific CD4+ 
T-cells were capable of recognizing and lysing several HLA-DP-expressing myeloid and 
lymphoid hematological malignant cells. Recognition of non-hematopoietic cells was 
analyzed by testing for recognition of fibroblasts, renal cell carcinoma cell lines or breast 
cell carcinoma cell lines. Expression of HLA-DP was absent on most of these resting non-
hematopoietic cells. Incubation with IFN-γ resulted in upregulated expression of HLA-DP 
and specific HLA-DP restricted recognition. These results illustrated that HLA-DP may 
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represent a relatively specific target for GVL-reactivity and that HLA-DPB1 mismatched allo-
SCT may be preferable over a fully matched SCT for HLA-class II expressing hematological 
malignancies, making use of HLA-DP as a target for immunotherapy.
Some studies showed, in mostly T-cell repleted transplant regimens, that specific HLA-
DPB1 mismatches were associated with poor clinical outcome.10-14 It was suggested that 
this unfavorable effect was caused by a difference in immunogenicity between various HLA-
DPB1 alleles. An algorithm defining permissive and non-permissive HLA-DPB1 mismatches 
was developed based on cross-reactive T-cell recognition patterns. It was suggested 
that permissive mismatches would not result in T-cell responses, whereas strong T-cell 
responses were expected to be generated against non-permissive mismatches.10;13 
To analyze whether permissive HLA-DPB1 specific immune responses occur in vivo, we 
analyzed in chapter 3 immune responses in 2 patients responding to donor lymphocyte 
infusion (DLI) after HLA-A, -B, -C, -DRB1, -DQB1 matched, HLA-DPB1 mismatched SCT. One 
of the patients received a permissive HLA-DPB1 mismatched SCT, the other patient a non-
permissive HLA-DPB1 mismatched SCT. CD4+ T-cells were isolated from peripheral blood 
obtained during the clinical immune response to DLI, and stimulated with HLA-class II 
negative HeLa cells transduced with the specific HLA-DP molecules derived from patient 
or donor. In both patients, HLA-DP specific CD4+ T-cells were demonstrated by CD137 up-
regulation in response to stimulation with HeLa cells transduced with patient and not donor 
HLA-DP molecules. Clonal isolation of these CD4+ T-cells confirmed specific recognition 
of the mismatched patient HLA-DPB1 molecules. Furthermore, we demonstrated in vitro 
for 4 additional individuals that permissive and non-permissive HLA-DPB1 responses 
were equally effective generated, illustrating immunogenicity of both permissive and non-
permissive mismatches.
In chapter 4 we further analyzed whether immunogenicity of HLA-DPB1 mismatches 
could be predicted based on the presence or absence of specific amino acid sequences. 
We developed a model to generate allo-HLA-DP responses in vitro and tested in total 
48 different stimulator/responder combinations by stimulating CD4+ T-cells from 5 HLA-
DPB1 homozygous individuals with the same antigen presenting cells transduced with 
different allo-HLA-DP molecules. HLA-DPB1 molecules used for stimulation comprised 
76-99% of HLA-DPB1 molecules present in different ethnic populations. We showed that 
all HLA-DPB1 mismatches as defined by allele typing resulted in high frequency immune 
responses. Furthermore, we demonstrated that cross-recognition of different HLA-DPB1 
molecules by HLA-DP specific CD4+ T-cell clones was a common observation. Individual 
CD4+ T-cell clones directed against the same HLA-DPB1 molecule exhibited different 
patterns in cross-recognition demonstrating that these CD4+ T-cell clones were specific for 
different epitopes. We confirmed previously described patterns in cross-recognition but 
also demonstrated cross-recognition patterns which did not correspond to the proposed 
algorithm. Overall, the data illustrated that frequently observed cross-recognition patterns 
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between specific HLA-DPB1 molecules did not preclude allo-HLA-DP responses between 
individuals expressing these HLA-DPB1 molecules. Together the data demonstrate that 
a high degree in similarity between HLA-DPB1 alleles is predictive for cross-reactivity but 
not for immunogenicity and illustrate that T-cell recognition patterns may not predict allo-
reactivity. 
To investigate whether patient HLA-DP specific immune responses were frequently 
induced following T-cell depleted HLA-DPB1 mismatched allo-SCT and DLI, we developed 
in chapter 5 a method to screen for the presence of HLA-DP specific CD4+ T-cells. Using 
HeLa cells transduced with various genes encoding relevant molecules for appropriate 
HLA-class II processing in conjunction with different HLA-DP molecules as stimulator 
cells, we were able to measure the emergence of patient HLA-DP specific CD4+ T-cells in 
peripheral blood in a simple and effective manner. We demonstrated that patient HLA-DP 
specific CD4+ T-cell responses were frequently found following T-cell depleted HLA-DPB1 
mismatched SCT and DLI (14 of 24 patients: 58%). The presence of HLA-DP specific CD4+ 
T-cells seemed to correlate with clinical responses to DLI, since patient HLA-DP specific 
CD4+ T-cells were measured in 13 (72%) out of 18 patients with clinical responses to DLI, 
and in only one (17%) out of 6 patients without clinical responses. HLA-DP specific CD4+ 
T-cells were most dominantly found in patients who developed GVHD following HLA-DPB1 
mismatched T-cell depleted SCT and DLI. However, patient HLA-DP specific CD4+ T-cells 
were also found in a significant number of patients who developed beneficial clinical 
responses after DLI without GVHD. HLA-DP specific CD4+ T-cell responses were induced 
in patients suffering from a variety of hematological malignancies, including multiple 
myeloma, B-cell malignancies and myeloid leukemias. 
In summary, HLA-DPB1 mismatched allo-SCT followed by DLI late after transplantation 
can result in selective GVL-reactivity. Furthermore, all HLA-DPB1 mismatches as defined by 
allele typing are immunogenic and resulted in vitro in high frequency immune responses. 
In a cohort of 24 patients transplanted for various hematological malignancies with a 10 
out 10 matched HLA-DPB1 mismatched SCT followed by DLI, HLA-DP specific immune 
responses were frequently found. The presence of HLA-DP specific CD4+ T-cells correlated 
with clinical immune responses including both selective GVL-reactivity and GVHD. It is likely 
that in each individual local environmental circumstances possibly in combination with the 
induction of other immune responses may finally determine the balance between GVHD 
and GVL-reactivity.
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General Discussion 
In this thesis we demonstrated that HLA-DPB1 mismatched SCT followed by DLI late after 
transplantation can result in selective GVL-reactivity. Furthermore, we showed that all HLA-
DPB1 mismatches are immunogenic and that HLA-DPB1 mismatched SCT followed by 
DLI frequently resulted in an HLA-DP specific immune response. The presence of patient 
HLA-DP specific CD4+ T-cells correlated with clinical immune responses. However, in the 
analyzed patient cohort not only selective GVL-reactivity was observed but a significant 
number of patients also developed GVHD.
Of the 24 patients analyzed, 8 patients developed clinical significant GVHD. This 
included both patients who received DLI early after SCT and patients who received DLI later 
after SCT. GVHD was observed in patients receiving DLI for various indications including 
both persistent- and progressive disease and mixed chimerism. Furthermore, patients 
who developed GVHD suffered from various diseases, including multiple myeloma, B-cell 
malignancies and myeloid leukemia. Although this patient cohort was rather diverse en 
small, no clear correlation between clinical circumstances and development of GVHD was 
found. The results indicated that it is not easily predictable in which patients GVHD can be 
expected to develop. 
Balance between GVL-reactivity and GVHD in HLA-class II restricted immune 
responses
In a fully HLA-matched setting, it has been shown that in patients with selective GVL-
reactivity relatively limited immune responses directed against a few MiHAs were found. 
In contrast, in patients with GVHD, higher frequencies of multiple different MiHA specific 
T-cells have been found.15;16 These data suggest that the development of a broader immune 
response may be correlated with the development of GVHD. In an HLA-matched setting, 
MiHA specific T-cells recognize non-self polymorphic peptides in the context of self-HLA 
molecules. During thymic development, T-cells are positively selected for recognition of 
self-HLA-molecules, followed by deletion of T-cells specific for a self-peptide in a self-HLA-
molecule. This selection process results in a T-cell repertoire recognizing only non-self-
peptides in self-HLA.17 In allo-HLA-reactivity, T-cells recognize a peptide in the context of 
non-self HLA molecules. Allo-HLA-reactivity is therefore due to cross-reactivity of T-cells 
educated in the thymus to recognize a non-self peptide in the context of self-HLA. Any 
T-cell may by chance be cross-reactive with a peptide presented in a non-self HLA-
molecule. Since there is no thymic selection for non-self HLA-molecules, no selection for 
cross-recognition of allo-HLA molecules occurs. The frequencies of T-cells directed against 
allo-HLA molecules can therefore be expected to be much higher than the frequencies of 
allo-reactive T-cells in a HLA-matched setting. Frequencies of allo-reactive T-cells in an HLA-
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mismatched setting have been demonstrated to be a 1000 fold higher than the frequencies 
of allo-reactive T-cells in HLA-identical setting.18;19 Following HLA-mismatched allo-SCT and 
DLI a broad immune response is therefore likely to develop, possibly increasing the risk 
for GVHD. Furthermore, in adult donors the T-cell compartment consists of both naïve 
and memory T-cells. Since any T-cell can exhibit reactivity against a peptide in the context 
of non-self HLA, allo-HLA-reactive T-cells may reside both in the naïve and in the memory 
repertoire.18 An allo-HLA-DP specific CD4+ T-cell in the naïve T-cell repertoire requires 
professional antigen presenting cells (APC) for priming and has a relatively high threshold 
of activation.20 In contrast, memory T-cells have a low threshold of activation and do not 
require professional APCs for priming of the immune response.21 If by chance, T-cells 
specific for a peptide/allo-HLA-DP-molecule are present in the memory compartment of 
the donor, a vigorous immune response may be expected to be generated following HLA-
DPB1 mismatched allo-SCT, whereas an allo-HLA-DP specific CD4+ T-cell from the naïve 
repertoire may result in a more limited immune responses.
T-cell responses directed against ubiquitously expressed antigens may be involved 
in both GVL-reactivity and GVHD, whereas T-cell responses directed against antigens 
specifically expressed on hematopoietic cells, including malignant cells may induce 
GVL-reactivity without severe GVHD. Immune responses directed against HLA-class II 
restricted MiHAs may also result in selective GVL-reactivity since expression of HLA-class II 
molecules is relatively restricted to hematopoietic cells. Indeed, T-cell responses directed 
against several HLA-class II restricted MiHAs encoded by broadly expressed genes have 
been identified in patients with GVL-reactivity accompanied by only mild GVHD.22;23 This 
is further supported by the observation from clinical studies showing that CD8+ T-cell 
depletion reduces the incidence of GVHD associated with DLI without adversely affecting 
conversion to donor hematopoiesis.24;25 However, HLA-class II expression can be induced 
on non-hematopoietic cells by pro-inflammatory cytokines.26;27 HLA-class II restricted CD4+ 
T-cell responses may therefore contribute to development of GVHD when high levels of 
pro-inflammatory cytokines are released as a consequence of conditioning regimens or 
high pathogenic loads early after transplantation. High frequencies of MiHA-specific CD4+ 
T-cells have indeed been shown in several studies to precede and closely correlate with 
the onset of clinical GVHD.28;29 Furthermore, allo-HLA-DP specific CD4+ T-cells have been 
isolated from skin biopsies of patients suffering from GVHD.30-32 These data suggest that 
when a broad HLA-class II specific immune response is generated local circumstances at 
the time of DLI may influence the balance between GVL-reactivity and GVHD.
HLA-class II expression on non-hematopoietic tissues
We hypothesized that mismatched HLA-class II molecules may be used as a relatively 
specific target for cellular immunotherapy since most leukemic cells are expected to 
express HLA-class II molecules. In chapter 2 we demonstrated the expression of HLA-DP 
Summary and General Discussion
113
on various leukemic cells. B-ALL and CLL cells showed high expression of HLA-DP whereas 
more variable expression of HLA-DP was found on myeloid leukemic cells. Furthermore, 
we demonstrated that various leukemic cells were recognized and lysed by HLA-DP specific 
CD4+ T-cell clones. Under normal conditions HLA-class II expression on non-hematopoietic 
tissues is anticipated to be restricted to antigen presenting cells. However, upon exposure 
to pro-inflammatory cytokines HLA-class II expression on non-hematopoietic cells may be 
upregulated26;27 and thereby become a target for GVHD. We demonstrated that HLA-DP 
expression was not found on resting non-hematopoietic cells including fibroblasts and 
renal- or breast-cell carcinoma cell-lines, and showed that co-incubation with IFN-γ can 
result in upregulation of HLA-DP and specific recognition by HLA-DP specific CD4+ T-cell 
clones. 
HLA-class II expression on non-hematopoietic tissues following conditioning regimens 
or in the presence of immune responses against pathogens has been described to result 
from a local release of cytokines which induce upregulation of co-stimulatory molecules 
and HLA-class II molecules on APC. These APC then induce activation and proliferation of 
T-cells, resulting in a further release of pro-inflammatory cytokines and more upregulation 
of HLA-class II molecules. In the end this cascade may result in cell damage or tissue 
destruction.33;34
 To further support the hypothesis that mismatched HLA-class II molecules might 
be used as a relatively specific target for cellular immunotherapy in hematological 
malignancies we analyzed the expression of HLA-class II molecules on non-hematopoietic 
tissues at various moments during the course of SCT. Skin biopsies were collected after 
conditioning regimen at the time of SCT and during GVHD and stained for HLA-class II 
expression. In normal skin biopsies, HLA-class II expression was only found on dendritic 
cells in the epidermis. In the dermis clumps of HLA-class II expressing cells, possibly close 
to vessel structures were found. No upregulation of HLA-class II compared to normal 
skin biopsies was found following conditioning regimens at time of SCT. However, three 
months after SCT upregulation of HLA-class II molecules was found. In patients with GVHD 
also increased expression of HLA-class II molecules was demonstrated in the dermis. 
We did not find increased expression of HLA-class II molecules on keratinocytes in the 
epidermis. The results may indicate that not the conditioning regimen itself but possibly 
repair mechanisms or lymphopenia-induced homeostatic proliferation of donor T-cells 
induced upregulation of HLA-class II molecules on non-hematopoietic tissues found prior 
to the development of GVHD. Possibly the inflammatory status in the patient at time of DLI 
infusion greatly influences the outcome of GVHD. (unpublished data)
CD4+ DLI resulting in selective GVL-reactivity or GVHD
In allo-SCT, T-cell depletion of the graft has shown to reduce the risk of severe GVHD. 
However, in these protocols post-transplantation anti-viral and anti-tumor immunity is 
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also significantly impaired. To accelerate immune reconstitution for viral antigens and 
prevent relapse of malignancies, after T-cell depleted allo-SCT, prophylactic DLI can be 
administered. However, early intervention is associated with a risk of GVHD. CD8+ T-cells 
are known to be potent effector cells in both anti-tumor and anti-viral immunity, but they 
also play an essential role in GVHD. Although CD4+ T-cells are generally regarded as helper 
cells in induction and maintenance of CD8+ T-cell immunity, direct cytolytic activity in anti-
tumor and viral responses has been shown. Administration of CD4+ DLI may reduce the 
risk of severe GVHD while preserving anti-tumor and antiviral activity.24;25 
At this moment in our center a phase II open label single center randomized clinical 
study is ongoing in which immunologic effects of prophylactic infusion of purified donor 
CD4+ T-cells early after T-cell depleted allo-SCT for various hematological malignancies are 
evaluated. In patients receiving DLI from a matched related donor, no increase in GVHD was 
observed. Three patients received prophylactic CD4+ DLI from a 10/10 matched unrelated 
donor. Two of these patients suffered from AML and received a graft from a fully HLA-A, 
-B, -C, -DRB1 and -DQB1 matched, HLA-DPB1 mismatched donor. Three months after 
SCT, both patients received CD4+ DLI for mixed chimerism. This resulted in an increase in 
donor chimerism, which coincided with initially limited acute GVHD of the skin requiring 
only topical corticosteroid treatment. Subsequently, three to 8 weeks later, both patients 
developed grade 3/4 acute GVHD of the colon that was successfully treated with systemic 
immune suppression. At 15 months after alloSCT, both patients were still in CR. The clinical 
course and specificity of the T-cell immune response was analyzed in detail in these 
patients. Both patients experienced an episode of cytomegalovirus (CMV) reactivation 
early after alloSCT and were shown to contain significant numbers of patient-derived CMV 
specific T-cells with an activated phenotype as reflected by expression of HLA-class II at 
the time of prophylactic CD4+ DLI. A profound polyclonal CD4+ T-cell immune responses 
directed against mismatched HLA-DPB1 alleles in both patients was found. Allo-reactive 
HLA-DP specific CD4+ T-cells were shown to recognize HLA-class II expressing patient 
hematopoietic cells as well as skin-derived fibroblasts of the patients cultured with pro-
inflammatory cytokines. In addition, colonic biopsies of both patients at the time of GVHD 
showed predominant infiltration with CD4+ T-cells and colonic epithelial cells displayed 
expression of HLA-class II. CMV specific T-cells may have contributed to the upregulation 
of HLA-class II expression on patient hematopoietic as well as non-hematopoietic cells. 
As a consequence, HLA-class II expressing residual patient-derived T-cells and non-
hematopoietic tissues became targets for allo-reactive HLA-DP specific CD4+ T-cells. HLA-
class II expression may have been particularly upregulated on non-hematopoietic cells 
in CMV-infected tissues due to a strong local inflammatory response mediated by CMV 
specific T-cells and activated inflammatory cells. The subsequent recognition of HLA-class 
II expressing non-hematopoietic cells by HLA-DP specific CD4+ T-cells may have resulted in 
local exacerbation of GVHD. These data support the hypothesis that active viral infection at 
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the time of HLA-DPB1 mismatched T-cell infusion may trigger HLA-DP specific CD4+ T-cells 
to mediate both a beneficial GVL-reactivity and detrimental GVHD.35 
CD4+ T-cells as helper cells in GVL-reactivity
CD4+ T-cells are known as helper cells for the induction and maintenance of CD8+ T-cell 
immune responses. Naïve CD8+ T-cells require priming by activated APCs to proliferate and 
differentiate in effector cells. APCs can be activated by inflammatory signals derived from 
pathogens. Alternatively, in the absence of inflammatory signals, CD4+ T-cells can activate 
APCs by CD40-CD40Ligand interaction and cytokine production.36-38 In patients successfully 
treated with DLI for relapsed hematological malignancies after allo-SCT, both MiHA specific 
CD4+ T-cells and CD8+ T-cells have been isolated suggesting that the MiHA specific CD4+ 
T-cells may have provided help for the induction of CD8+ T-cell responses.22;23;39 Animal 
models have shown that in the absence of tissue damage or infection, CD8+ T-cell mediated 
GVL-reactivity following DLI administration required priming of CD4+ T helper cells by host 
APCs.40 
It has been suggested that efficacy of DLI to induce an anti-tumor response may 
depend on the capacity of leukemic cells to become APC in vivo. Recently it was shown that 
cross-talk between CD4+ T-cells and leukemic cells in vivo can change leukemic cells into 
an APC phenotype. In this study, leukemic cells in mice treated with DLI acquired an APC 
phenotype in vivo, whereas leukemic cells from non-treated mice remained unchanged. 
In vitro experiments confirmed that co-culture of primary leukemic cells with leukemia-
reactive CD4+ T-cells induced an APC-phenotype on leukemic cells, whereas this was not 
observed from non-specific CD4+ T-cells. In this study allo-reactive CD4+ T-cells fulfilled a 
dual role in the anti-tumor response. First, as effector cells by directly eliminating leukemic 
cells, and secondly, as helper cells by producing cytokines with induced an APC-phenotype 
on leukemic cells. This cross-talk between leukemic cells and leukemia specific CD4+ T-cells 
may have had a significant role in the overall magnitude of the antitumor response.41 
CD4+ T-cells as effector cells
Although CD4+ T-cells have mostly been studied in their role as helper cells for CD8+ T-cell 
immunity, in several studies CD4+ T-cells with direct cytolytic activity have been isolated 
from patients with GVL-responses after allo-SCT.22;23;42;43 These CD4+ T-cells have been 
suggested to be involved in mediating direct anti-tumor responses as effector cells. This 
is supported by both murine and human studies showing that CD4+ DLI mediated GVL-
reactivity.25;44 Direct evidence that CD4+ T-cells can mediate an anti-tumor response in 
a mouse model was provided by Stevanovic et al. Anti-tumor effect of CD4+ T-cells was 
investigated by administering highly purified CD4+ DLI, obtained after positive isolation 
of CD4+CD8- T-cells by flowcytometry. The CD4+ DLI did not contain contaminating CD8+ 
T-cells and in vivo no expansion of CD8+ T-cells was observed. Since the emergence 
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and kinetics of activated CD4+ T-cells corresponded to the disappearance of leukemic 
cells, conclusive evidence was provided that CD4+ T-cells are capable of mediating GVL-
reactivity.41 In chapter 2, we demonstrated using ex vivo ELISOT analysis the presence 
of only CD4+ and not CD8+ leukemia reactive T-cells in both peripheral blood and bone 
marrow indicating that CD4+ T-cells can elicit a profound anti-leukemia response in the 
absence of leukemia-reactive CD8+ T-cells. In these studies both CD4+ T-cells producing 
high levels of IFN-γ without cytolytic activity and CD4+ T-cells which were capable of direct 
lysis of leukemic cells were found. The results demonstrated that CD4+ T helper cells and 
CD4+ cytotoxic CD4+ T-cells are sufficient for direct effector function in GVL-reactivity in 
patients.  
In conclusion
In chapter 5, it was shown that following HLA-DPB1 mismatched allo-SCT and DLI a variety 
of responses can occur. In a few patients no response was observed, whereas in other 
patients GVL-reactivity in the presence or absence of GVHD was observed. From these 
data it could not be easily predicted in which patient population a selective GVL-effect 
may be expected. We demonstrated in chapter 3 that allo-HLA-DP specific immune 
responses can be generated from all HLA-DPB1 mismatch combinations. Therefore, we 
hypothesize that not only the T-cell repertoire of the donor, but possibly more importantly 
local circumstances in the host determines the balance between GVL-reactivity and GVHD. 
Expression of HLA-class II in different target tissues influenced by inflammatory conditions 
may determine the magnitude and diversity of immune responses. To further support 
this hypothesis research analyzing local circumstances in the host like expression of HLA-
class II molecules, adhesion and co-stimulatory molecules and their relation to GVHD is 
essential.
As long as it is not possible to predict which patients are especially at risk to develop 
GVHD following HLA-DPB1 mismatched SCT and DLI, it may be preferable to use HLA-DPB1 
matched SCT over HLA-DPB1 mismatched SCT in low-grade disease, in order to reduce the 
risk for GVHD as much as possible. However, in high risk patients, in whom a strong anti-
tumor response is required, an HLA-DPB1 mismatched donor may be favorable over an 
HLA-DPB1 matched donor to provoke a GVL-effect while accepting a risk for concurrent 
GVHD.
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Allogene stamceltransplantatie (SCT) is een succesvolle behandeling voor patiënten met 
allerlei kwaadaardige hematologische ziekten. Voorafgaand aan de SCT krijgen patiënten 
hoge dosis chemotherapie en bestraling om kwaadaardige cellen te vernietigen en om het 
hematopoietische- en dus afweersysteem van de patiënt te onderdrukken om zo plaats te 
maken voor donor stamcellen. Oorspronkelijk was het doel van de SCT het vervangen van 
het lethaal beschadigde hematopoietische systeem van de patiënt. Autologe stamcellen 
of stamcellen van een genetische identieke tweeling werden verondersteld de beste bron 
voor hematologische stamcellen te zijn. Transplantatie met stamcellen van een allogene 
donor bleek namelijk gepaard te gaan met immunologische complicaties zoals afstoting 
of graft versus host ziekte (GVHD). Bij GVHD worden gezonde weefsels van de patient, 
zoals huid, darmen en lever, aangevallen door het afweersysteem van de donor. Deze 
afstotingsreactie kan mild zijn, maar ook een levensbedreigende complicatie vormen. 
Klinische studies toonden echter aan dat het optreden van GVHD ook gepaard ging met 
een verminderde kans op recidief van de ziekte wat resulteerde in een betere uiteindelijke 
overleving. Afweercellen (T cellen) van de donor, die ook in het stamceltransplantaat 
aanwezig zijn, bleken niet alleen verantwoordelijk voor het optreden van GVHD maar zijn ook 
in staat een zogenaamd graft versus leukemie (GVL) effect te bewerkstelligen. Verwijdering 
van T cellen uit het transplantaat verminderde de kans op GVHD, maar vergrootte de kans 
op een recidief van de leukemie. Daarnaast bleek een donor lymfocyten infusie (DLI) bij 
een recidief van de ziekte na SCT, een langdurige remissie van verschillen hematologische 
maligniteiten te kunnen induceren. Het grote voordeel van een SCT met een allogene 
donor boven eigen stamcellen is dus dat het immuunsysteem van de donor gebruikt kan 
worden om resterende kwaadaardige cellen van de patiënt na de transplantatie op te 
ruimen. Echter het grote probleem van immunotherapie door middel van DLI is GVHD. 
Een belangrijk doel in SCT onderzoek is dan ook om strategieën voor immunotherapie 
te ontwikkelen waarbij er minder GVHD optreedt maar met behoud van GVL-reactiviteit. 
GVL-reactiviteit en GVHD bij HLA-identieke SCT
Om het risico op afstoting en GVHD te beperken, wordt voor een SCT bij voorkeur gebruik 
gemaakt van een HLA-identieke donor. HLA-moleculen zijn eiwitten op het celoppervlak 
van cellen, die antigenen aan T cellen presenteren. HLA-klasse I moleculen (HLA-A, -B en 
-C) zitten op vrijwel alle kernhoudende cellen. HLA-klasse II moleculen (HLA-DR, -DQ en 
-DP) komen voornamelijk op hematopoietische cellen tot expressie. Allo-reactieve T cellen 
die vreemde HLA-moleculen herkennen, zijn aanwezig in hoge frequenties in perifeer 
bloed. Een HLA-niet-identieke SCT kan daarom leiden tot sterke allo-reactiviteit met daarbij 
een hoog risico op GVHD. Echter ook na een HLA-identieke SCT of DLI treedt vaak GVHD 
op. Dit wordt veroorzaakt door genetische verschillen tussen patiënt en donor anders dan 
HLA-moleculen, zogenaamde minor histocompatibility antigenen (MiHA). Dit zijn stukjes 
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eiwitten, verschillend tussen patient en donor, die in HLA-moleculen gepresenteerd 
worden. Donor T cellen kunnen MiHA van de patiënt als lichaamsvreemd herkennen en 
een immuunrespons hiertegen ontwikkelen. Verschillende studies hebben aangetoond 
dat MiHA-specifieke T cellen betrokken zijn bij GVHD en GVL-reactiviteit. Kinetiek studies 
hebben laten zien dat het opkomen van deze T cellen gepaard gaat met het verdwijnen 
van kwaadaardige cellen uit het bloed wat het GVL-effect illustreert. In patiënten die 
gerespondeerd hebben op DLI na HLA-identieke SCT zijn polyklonale immuunresponsen 
gevonden gericht tegen verschillende MiHAs. 
T cel responsen gericht tegen MiHA die zowel op hematopoietische cellen als op niet-
hematopoietische cellen tot expressie komen zullen waarschijnlijk leiden tot zowel GVL-
reactiviteit als GVHD. Een immunologische respons van CD8+ T cellen tegen een breed 
tot expressie komend MiHA gepresenteerd in een HLA-klasse I molecuul leidt tot zowel 
GVL-reactiviteit als ook herkenning en dus schade in verschillende organen, resulterend in 
ernstige GVHD. Een CD8+ T cel respons specifiek voor een hematopoiese gerestricteerd 
antigeen leidt tot selectieve GVL-reactiviteit. In tegenstelling tot de HLA-klasse I moleculen 
komen HLA-klasse II moleculen vooral tot expressie op hematopoietische cellen. Bij 
patienten met een HLA-klasse II positieve hematologische maligniteit zou dus een 
immuunrespons tegen een HLA-klasse II gerestricteerd MiHA kunnen leiden tot een 
selectief GVL-effect. Inderdaad zijn deze CD4+ T cel responsen gevonden in patiënten bij 
wie geen GVHD plaats vond. Uitgebreide analyse van immuunresponsen in patiënten met 
en sterk anti-leukemie effect met en zonder GVHD, heeft laten zien dat immuunresponsen 
met een hoge amplitude gericht tegen breed tot expressie komende antigenen leidt 
tot zowel GVL-reactiviteit als GVHD, waar beperkte immuunresponsen gericht tegen 
hematopoiese gerestricteerde antigenen vaker resulteerden in selectieve GVL-reactiviteit. 
Traditioneel worden CD8+ T cellen gezien als primaire effector cellen in GVL-
reactiviteit, en CD4+ T cellen als helper cellen voor het induceren en in stand houden van 
CD8+ T cel immuunresponsen. In patiënten met selectieve GVL-responsen zijn echter ook 
CD4+ T cellen gevonden met een direct cytotoxische activiteit tegen leukemie cellen. Dit 
suggereert dat CD4+ T cellen ook als effector cellen kunnen fungeren in GVL-reactiviteit. 
Omdat de expressie van HLA-klasse II moleculen dus met name gerestricteerd is tot 
hematopoietische cellen zou een CD4+ T cel immuunrespons kunnen leiden tot selectieve 
GVL-reactiviteit. Klinische studies hebben inderdaad laten zien dat het verwijderen van 
CD8+ T cellen van het SCT of van DLI kan leiden  tot minder GVHD met behoud van GVL-
reactiviteit. Echter, expressie van HLA-klasse II moleculen op niet-hematopoietische cellen 
kan worden opgereguleerd bij expositie aan pro-inflammatoire cytokines. Een HLA-klasse 
II gerestricteerde immuunrespons kan dan alsnog resulteren in GVHD. 
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SCT van een onverwante donor
Een allogene SCT wordt bij voorkeur uitgevoerd met een HLA-identieke donor om het 
risico van GVHD en afstoting te beperken. De optimale donor is een HLA-identieke broer 
of zus van de patiënt. Deze is echter niet altijd beschikbaar. Als er geen geschikte familie 
donor is, is een HLA-identieke onverwante donor een goed alternatief. Bij voorkeur 
wordt een volledig identieke donor voor HLA-A,-B,-C, -DRB1 en -DQB1 gebruikt. Grote 
studies hebben laten zien dat een mismatch voor HLA-A, -B, -C en –DRB1 geassocieerd 
is met een slechtere uitkomst. Een mismatch voor alleen HLA-DQB1 resulteerde niet in 
een slechtere overleving, echter in combinatie met een andere mismatch werd een nog 
slechtere uitkomst gezien. Een mismatch voor HLA-DPB1 resulteerde niet in een slechtere 
overleving en daarom wordt er bij de donor selectie niet gekeken naar HLA-DPB1.
De rol van HLA-DPB1 in allogene SCT
HLA-DP is het zesde klassieke HLA-molecuul. Vanwege een recombinatie ‘hotspot’ tussen 
de HLA-DPB1 genen en de overige HLA-genen, wordt HLA-DP niet gelinkt aan de andere 
HLA-genen overgeërfd. Dit resulteert een mismatch kans voor HLA-DPB1 tot 10% bij een 
broer of zus en een mismatch kans tot 90% bij onverwante donoren. Lange tijd is de 
rol van HLA-DPB1 in onverwante SCT niet duidelijk geweest. Studies toonden wisselende 
resultaten in data betreffende een risico op GVHD en overleving. HLA-DPB1 werd daarom 
niet meegenomen in donor selectie. Grote klinische studies uitgevoerd tussen 1999 en 
2008 hebben echter laten zien dat HLA-DP zich gedraagt als een klassiek transplantatie 
antigen. Bij een SCT met T cellen werd bij een HLA-DPB1 niet-identieke donor meer GVHD 
en een lagere recidief kans gezien in vergelijking met een HLA-DPB1 identieke donor. Dit 
resulteerde in een gelijke totale overleving. In T cel gedepleteerde SCT werd geen verhoogd 
risico op GVHD gezien, maar wel een lagere kans op recidief van de ziekte. 
Verder bewijs van een immunologische rol voor HLA-DP werd geleverd door 
verschillende studies waarbij na allogene HLA-DPB1 niet-identieke SCT, CD4+ T cellen 
gericht tegen het niet-identieke HLA-DP molecuul werden gevonden. HLA-DP specifieke 
CD4+ T cellen werden geïsoleerd uit huidbiopten van patiënten die GVHD ontwikkelden en 
uit een patiënt die het SCT afstootte. Er werd gesuggereerd dat HLA-DP specifieke T cellen 
wellicht selectieve GVL-reactiviteit konden induceren bij T cel gedepleteerde SCT. Echter 
direct bewijs hiervoor werd niet geleverd.
Permissive en non-permissive mismatches
Vanwege conflicterende resultaten in verschillende studies over de rol van HLA-DP in allo-
SCT, is gesuggereerd dat er wellicht een verschil in immunogeniciteit tussen verschillende 
HLA-DPB1 mismatches zou zijn. Verschillen in aminozuren in specifieke delen van het HLA-
DP molecuul zouden gunstig of ongunstig zijn. Verschillende onderzoeksgroepen vonden 
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andere specifieke mismatches die geassocieerd zouden zijn met meer GVHD of een 
slechtere overleving. Zino en medewerkers ontwikkelden een algoritme waarbij HLA-DPB1 
mismatches werden ingedeeld in 3 en later 4 verschillende groepen. Dit was gebaseerd 
op het herkenningspatroon van enkele T cel klonen. Een mismatch tussen HLA-DPB1 
moleculen met grote onderlinge gelijkenis werd ‘permissive’ genoemd en een mismatch 
tussen HLA-DPB1 moleculen uit verschillende groepen werd ‘non-permissive’ genoemd. In 
een cohort studie bleek een ‘non-permissive’ mismatch geassocieerd met een slechtere 
overleving. 
Diverse bevindingen van de verschillende onderzoeksgroepen konden echter niet 
bevestigd worden in andere studies. 
Mismatched HLA-DP als een target voor GVL-reactiviteit
Een immuunrespons gericht tegen een hematopoiese gerestricteerd antigen wordt 
verwacht te resulteren in selectieve GVL-reactiviteit, terwijl een immuunrespons tegen een 
breed tot expressie komend antigen kan resulteren in zowel GVL-reactiviteit als GVHD. 
Tegelijkertijd blijken beperkte immuunresponsen met lage frequenties MiHA-specifieke 
T cellen GVL-reactiviteit te induceren, waar bredere immuunresponsen gericht tegen 
meerdere antigenen zowel GVL als GVHD induceren. Omdat allo-reactieve T cellen in hoge 
frequenties aanwezig zijn in perifeer bloed, zou een immuunrespons gericht tegen een niet- 
identiek HLA-DPB1 molecuul kunnen leiden tot een sterke immuunrespons en daarmee 
naast GVL-reactiviteit ook GVHD kunnen induceren. Bij HLA-DPB1 niet-identieke SCT met T 
cellen wordt zowel een hoger risico op GVHD gezien als een lager risico op recidief van de 
ziekte. Bij T cel gedepleteerde SCT wordt wel een lager risico op recidief gezien, maar niet 
een verhoogd risico op GVHD. Deze data wijzen erop, dat bij HLA-DPB1 niet-identieke SCT 
het gebruikte transplantatie regiem in combinatie met individuele omstandigheden in de 
patiënt, de balans tussen GVHD en GVL-reactiviteit zouden kunnen bepalen. 
Dit proefschrift
HLA-DPB1 wordt niet meegenomen in donor selectie voor een hematologische SCT. 
Dit komt omdat een HLA-DPB1 niet-identieke SCT niet geassocieerd is met lagere 
overlevingskansen vergeleken met een HLA-DPB1 identieke SCT. Mismatchen voor HLA-
DPB1 is echter wel geassocieerd met een verhoogd risico op GVHD en een lagere kans op 
recidief van de ziekte. Bij een T cel gedepleteerde HLA-DPB1 niet-identieke SCT werd geen 
verhoogd risico op GVHD gevonden, maar wel een significant lager risico op recidief van 
de ziekte. In dit proefschrift is bestudeerd of HLA-DP gebruikt kan worden als een relatief 
specifiek target voor anti-leukemie reactiviteit na een T cel gedepleteerde HLA-DPB1 
niet-identieke SCT. Verder is er gekeken of er bij alle HLA-DPB1 mismatch combinaties 
verwacht kan worden dat er een immuunrespons optreedt. Daarnaast is bestudeerd of 
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een HLA-DP specifieke immuunrespons ook daadwerkelijk vaak optreedt na HLA-DPB1 
niet-identieke SCT en DLI, en of het optreden van een HLA-DP specifieke immuunrespons 
dan ook geassocieerd is met een anti-leukemie effect of GVHD. 
Om te kijken of HLA-DP specifieke T cellen een anti-leukemie reactie kunnen 
bewerkstelligen na HLA-DPB1 niet-identieke SCT en DLI hebben we in hoofdstuk 2 de 
immuunrespons in een patiënt met een chronische B cel leukemie die goed reageerde op 
DLI na HLA-DPB1 niet-identieke SCT bestudeerd. Patiënt en donor waren volledig identiek 
voor HLA-A, -B, -C, -DRB1 en –DQB1. De patiënt was getypeerd HLA-DPB1*0201;0301 
en de donor HLA-DPB1*0402;0501. Er vond een sterke anti-leukemie respons plaats 
met slechts beperkte GVHD van de huid wat resulteerde in een complete remissie van 
de ziekte. Met behulp van ELISPOT analyse werd een CD4+ T cel respons geïdentificeerd 
die 6 weken na DLI begon. Na isolatie en opgroeien van de leukemie reactieve CD4+ T 
cellen tot T cel klonen, kon met behulp van experimenten met blokkerende antilichamen, 
panel experimenten waarbij herkenning van cellijnen met verschillende HLA-DPB1 
moleculen getest werd, en retrovirale transductie van beide gemismatchte HLA-DPB1 
moleculen, HLA-DPB1*02 en HLA-DPB1*03 geïdentificeerd worden als het doelwit van 
deze immuunrespons. De anti-leukemie respons bleek veroorzaakt door een polyklonale 
T cel respons die zowel uit helper als uit cytotoxische CD4+ T cellen bestond. Omdat het 
ontstaan en de kinetiek van de anti-leukemie specifieke CD4+ T cellen overeen kwam 
met het verdwijnen van de kwaadaardige cellen uit het bloed, lijkt het waarschijnlijk 
dat deze HLA-DP specifieke CD4+ T cellen de antitumor respons veroorzaakt hebben. 
De geïsoleerde HLA-DP specifieke CD4+ T cellen waren ook in staat om myeloide en 
lymfatische maligne hematologische cellen van andere patiënten te herkennen en te 
lyseren. Herkenning van niet-hematologische cellen werd bekeken door herkenning van 
fibroblasten, niercelcarcinoom cellijnen en borstkanker cellijnen te bestuderen. HLA-DP 
kwam niet tot expressie op de meeste van deze cellijnen in rust en deze cellen werden 
dus ook niet herkend door de CD4+ T cellen. Echter, behandeling met IFN-γ om een pro-
inflammatoire situatie na te bootsen, resulteerde in opregulatie van HLA-DP en specifieke 
HLA-DP gerestricteerde herkenning van deze niet hematopoietische cellen. De resultaten 
illustreren dat HLA-DP mogelijk een relatief specifiek doelwit kan zijn voor anti-leukemie 
reactiviteit en dat een HLA-DPB1 gemismatchde SCT de voorkeur zou kunnen krijgen over 
een HLA-DPB1 identieke SCT bij HLA-klasse II positieve hematologische maligniteiten om 
op deze manier gebruik te kunnen maken van HLA-DP als een target voor immunotherapie. 
Het toedienen van donor T cellen na een T cel gedepleteerde HLA-DPB1 niet-identieke SCT 
zou op die manier kunnen resulteren in een sterk anti-leukemie effect zonder een groot 
risico op ernstige GVHD. 
Een aantal studies heeft laten zien dat specifieke HLA-DPB1 mismatches waren 
geassocieerd met een slechtere overleving. Er is gesuggereerd dat dit ongunstige effect 
werd veroorzaakt door een verschil in immunogeniciteit tussen verschillende HLA-
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DP allelen. Op basis hiervan werd een algoritme ontwikkeld waarin permissive en non-
permissive HLA-DPB1 mismatches werden gedefinieerd. Dit algoritme was gebaseerd op 
kruisherkenningspatronen van HLA-DP specifieke CD4+ T cellen. Er werd gesuggereerd 
dat bij permissive mismatches geen T cel responsen geïnduceerd zou worden door hoge 
mate van overeenkomst tussen het HLA-DPB1 molecuul van patient en donor. Bij non-
permissive mismatches zou er juist wel een sterke T cel respons plaatsvinden en daarmee 
een grotere kans op het ontstaan van GVHD.
In hoofdstuk 3 hebben we gekeken of ‘permissive’ HLA-DPB1 specifieke 
immuunresponsen in vivo voorkomen. We hebben de immuunrespons in 2 patiënten 
geanalyseerd die reageerden op DLI bij een HLA-A, -B, -C, -DRB1, -DQB1 identieke, HLA-
DPB1 niet-identieke SCT. De ene patiënt had een ‘permissive’ HLA-DPB1 niet-identieke 
SCT gekregen en de andere een ‘non-permissive’ HLA-DPB1 niet-identieke SCT. CD4+ T 
cellen werden uit het bloed geïsoleerd op het moment van de klinische respons op DLI en 
getest op specifieke herkenning van patiënt HLA-DP moleculen. In beide patiënten werd 
specifieke herkenning van patiënt en niet donor HLA-DP moleculen gevonden. Verder laten 
we voor vier andere individuen zien dat zowel ‘permissive’ als ‘non-permissive’ HLA-DPB1 
specifieke immuunresponsen even effectief gegenereerd kunnen worden. Dit illustreert 
immunogeniciteit van zowel ‘non-permissive’ als ‘permissive’ mismatches. 
In hoofdstuk 4 gaan we hier verder op in. We hebben bestudeerd of immunogeniciteit 
van HLA-DPB1 mismatches voorspeld kan worden gebaseerd op de aan- of afwezigheid 
van specifieke aminozuur sequenties. We hebben een model ontwikkeld waarin we in vitro 
allo-HLA-DP immuunresponsen konden genereren. In totaal hebben we 48 verschillende 
stimulator/responder combinaties getest door CD4+ T cellen van 5 HLA-DPB1 homozygote 
individuen te stimuleren met dezelfde antigen presenterende cellen waarin verschillende 
HLA-DP moleculen getransduceerd waren. We laten zien dat vrijwel alle combinaties 
resulteerden in hoge frequente immuunresponsen. Verder laten we in dit hoofdstuk zien 
dat kruisherkenning van verschillende HLA-DPB1 moleculen door HLA-DP specifieke T 
cellen een veel voorkomende observatie is. Individuele CD4+ T cel klonen met dezelfde 
specificiteit lieten verschillende herkenningspatronen in kruisreactiviteit zien. Dit illustreert 
dat ze specifiek voor een ander epitoop zijn. We bevestigen eerder beschreven patronen 
in kruisherkenning, maar laten ook patronen zien die niet overeenkomen met het 
voorgestelde algoritme. Deze data samen illustreren dat een hoge mate van overeenkomst 
tussen HLA-DPB1 allelen voorspellend is in kruis-reactieve herkenning, maar niet voor 
immunogeniciteit. Ook laten we zien dat T cel herkenningspatronen allo-reactiviteit niet 
kunnen voorspellen. 
Om te kijken of HLA-DP specifieke immuunresponsen vaak voorkomen na T cel 
gedepleteerde HLA-DPB1 niet-identieke SCT en DLI hebben we in hoofdstuk 5 een 
methode ontwikkeld om bloed van patiënten te screenen op de aanwezigheid van HLA-
DP specifieke CD4+ T cellen. Door HeLa cellen getransduceerd met verschillende HLA-
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DP moleculen te gebruiken als stimulator cellen, konden we het opkomen van patiënt 
HLA-DP specifieke T cel responsen op een eenvoudige en effectieve manier meten. We 
laten zien dat patiënt HLA-DP specifieke immuunresponsen vaak gevonden worden na 
T cel gedepleteerde HLA-DPB1 niet-identieke SCT en DLI. (14 van de 24 patiënten: 58%). 
De aanwezigheid van HLA-DP specifieke CD4+T cellen leek te correleren met klinische 
respons op DLI omdat HLA-DP specifieke CD4+ T cellen werden gevonden in 13 (72%) 
van de 18 patiënten met een klinische respons op DLI en slechts in 1 (17%) van de 6 
patiënten waarbij geen klinische respons werd gezien. HLA-DP specifieke T cellen werden 
vooral gevonden in patiënten die ernstige GVHD ontwikkelden, maar ook in een significant 
aantal patiënten dat alleen een GVL-reactie na DLI ontwikkelde zonder GVHD. HLA-DP 
specifieke CD4+ T cellen werden gevonden in patiënten met verschillende hematologische 
maligniteiten, waaronder de ziekte van Kahler, B-cel maligniteiten en myeloide leukemieën.
De resultaten van het onderzoek beschreven in dit proefschrift laten zien dat HLA-
DPB1 niet-identieke SCT gevolgd door DLI laat na de transplantatie kan resulteren in een 
selectief GVL-effect. We hebben laten zien dat alle HLA-DPB1 mismatches immunogeen 
zijn en kunnen resulteren in sterke immuunresponsen. In een cohort van 24 patiënten 
die een SCT gevolgd door DLI ontvingen voor allerlei hematologische ziekten van een HLA-
DPB1 niet-identieke donor, werden zeer frequent HLA-DP specifieke immuunresponsen 
gevonden. Bovendien correspondeerde de aanwezigheid van HLA-DP specifieke T cellen 
met het optreden van een klinische respons, waarbij er zowel selectieve GVL-reacties 
werden gezien als GVHD. Waarschijnlijk wordt de uiteindelijke balans tussen GVHD en 
GVL-reactiviteit na HLA-DPB1 niet-identieke T cel gedepleteerde SCT en DLI in ieder 
individu bepaald door het ontwikkelen van HLA-DP specifieke immuunresponsen, de 
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